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Chapter 1
Obesity and related metabolic disorders
Obesity is characterized by an excessive accumulation of fat mass. According to the 
World Health Organization the prevalence of obesity has reached epidemic propor­
tions worldwide nowadays, with more than 1 billion adults being overweight (1). The 
prevalence of overweight and obesity is assessed by using the body mass index (BMI) 
or waist to hip ratio (WHR), defined as the weight in kilograms divided by the square 
of the height in meters (kg/m2) or maximum waist circumference divided by the maxi­
mum hip circumference, respectively.
Important causes of obesity are sedentary lifestyle habits and easy accessibility to 
high energy-dense foods. When energy intake exceeds energy expenditure, the excess 
amounts of energy will be stored in the adipose tissue. Oppositely, in case of energy 
demand, adipose tissue is able to liberate fatty acids that serve as energy source by 
inducing lipolysis (2). Besides environmental determinants, genetic factors play an 
important role in the predisposition to obesity. It has been shown that variations in 
genes like leptin, peroxisome proliferator- activated receptor (PPAR)-y and fat mass 
and obesity associated gene are more associated with the susceptibility to gain weight 
(3-6). During obesity, adipose tissue is considered as one of the key players in the de­
velopment of a disturbed glucose- and lipid homeostasis (7). In this chapter the physi­
ological and pathophysiological aspects of adipose tissue will be described in relation 
to obesity and associated metabolic disorders.
Adipose tissue composition and distribution
Adipose tissue composition
Adipose tissue is composed of a heterogeneous cell population which can roughly 
be divided into two groups: the mature adipocytes and the stromal vascular fraction 
(SVF) (8). The primary functions of mature adipocytes are to regulate lipogenesis and 
lipolysis (9;10), and to secrete many adipose tissue-derived hormones named adipo- 
kines (11;12). During obesity, adipose tissue mass expansion occurs by both an in­
crease in adipocyte cell size (hypertrophy) and by inducing the number of adipocytes 
(hyperplasia) (13). Metabolic abnormalities like adverse changes in glucose- and lipid 
metabolism which are associated with obesity, have been found to be related to adi­
pocyte hypertrophy rather than to adipocyte hyperplasia (14;15). Adipocyte hypertro­
phy is associated with cellular dysfunction, leading to impaired glucose metabolism, 
insulin resistance and eventually type 2 diabetes mellitus (16;17).
The SVF consists of a variety of cell types including pre-adipocytes, fibroblasts, en­
dothelial cells, yet also accommodates all sorts of immune cells including: monocytes, 
macrophages and lymphocytes (18;19). Pre-adipocytes have the potential to differ­
entiate into new mature adipocytes (20). Impaired differentiation of pre-adipocytes is
8
thesis def 1.indd 8 »  11-7-2011 10:19:03
Chapter 1
accompanied by a diminished lipogenesis of newly formed adipocytes that may result 
in hypertrophy of existing mature adipocytes (21). Furthermore, obesity is associated 
with a change in cellular composition of the SVF in adipose tissue (22). This is char­
acterized by an increased influx of different immune cell populations secreting many 
pro-inflammatory mediators, which contribute to an adverse metabolic profile that 
leads to insulin resistance in the adipose tissue. This process will be described in more 
detail later in this chapter.
Adipose tissue distribution
Recently, magnetic resonance imaging scanning revealed that subjects who have a 
normal body weight can suffer from enormous fat accumulation around the organs 
(23;24). These individuals are described as TOFIs (thin on the outside, fat on the 
inside). Adipose tissue can be stored either subcutaneously (in the buttocks, thighs and 
abdomen) or viscerally (around the omentum, intestines and perirenal areas). It has 
been shown that especially an increase in the visceral adipose tissue (VAT) compart­
ment enhanced the risk of type 2 diabetes mellitus and cardiovascular disease (CVD) 
(25-27), whereas an increase in subcutaneous adipose tissue (SAT) depot exerts no 
risk or even has a protective effect against obesity-induced metabolic disturbances, 
presumably by preventing ectopic accumulation of lipids (28-30). Therefore, not 
solely the amount of fat mass is important, but especially the distribution of fat 
throughout the body determines its harmful effects. Two major assumptions have been 
made that may explain the adverse metabolic consequences of VAT. The first is based 
on the anatomical location of VAT and its capacity to deliver free fatty acids (FFAs) 
and various adipokines into the portal circulation were they can directly affect liver 
metabolism (31). The second assumption considers the intrinsic cellular properties in 
VAT, regarding decreased adipocyte differentiation capacity, and the increased release 
of unfavorable adipokines and pro-inflammatory mediators compared to SAT (32-35).
Adipose tissue as an active endocrine organ
As already briefly mentioned, adipose tissue is an active endocrine organ secreting 
many adipokines that are able to modulate energy homeostasis (energy intake and 
expenditure), glucose- and lipid metabolism. Two of the most well studied adipokines 
are adiponectin and leptin. Adiponectin is exclusively produced by adipocytes and 
high serum levels of this adipokine are associated with increased insulin sensitivity 
(36). Adiponectin circulates in the plasma in various multimeric forms that include the 
low molecular weight (LMW), middle molecular weight (MMW) and the high molec­
ular weight (HMW) isoforms (37). It has been shown that especially the HMW form 
of adiponectin acts as an insulin sensitizer in an autocrine fashion, but also promotes
9
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fatty acid oxidation and glucose uptake of the muscle and liver (38;39). Furthermore, 
adiponectin exhibits anti-inflammatory and anti-atherogenic properties, which is il­
lustrated by the inverse relationship between circulating concentrations of this protein 
and the incidence of CVD (40). Leptin is also mainly produced by adipose tissue 
and plays an important role in controlling food intake and energy expenditure via 
leptin receptors in the neural regions of the hypothalamus (41). Furthermore, leptin 
influences immune functions by regulating T-lymphocyte response (42).
Excessive fat accumulation is associated with a disturbed adipokine secretion pat­
tern. As previously discussed, the increased number of large adipocytes may be 
responsible for this altered production (16;17). The expression level of adiponectin is 
significantly reduced in large adipocytes, whereas leptin levels, and the more harmful 
adipokines resistin and visfatin, are elevated in hypertrophic cells (43-45). Alterations 
in adipokine production that promote adverse metabolic effects are more pronounced 
in expanding VAT compared to SAT (46). All together this implicates that obesity, as­
sociated with an increase in VAT, results in an adverse endocrine secretion profile that 
could lead to metabolic disturbances. Interestingly, most of the adipokines produced 
by the expanded adipose tissue are pro-inflammatory mediators, suggesting that adi­
pose tissue also acts as an immunologically active organ (47).
#  Adipose tissue as an inflammatory organ #
It is now generally accepted that obesity is accompanied by the development of a 
chronic state of low-grade inflammation. Both animal and human studies revealed that 
obesity is associated with elevated circulating levels of pro-inflammatory cytokines 
including tumor necrosis factor (TNF)-a, high sensitive C-reactive protein (hsCRP) 
and interleukin (IL)-6, which have been demonstrated to induce insulin resistance 
(48;49). In fact, weight loss in obese subjects results in a reduction of systemic in­
flammatory cytokine levels and an improvement in insulin sensitivity (50). Together, 
these observations support the close link between inflammation and insulin resistance 
(51-53) and suggest that expanding adipose tissue strongly contributes to the develop­
ment of obesity-induced inflammation. Indeed, adipose tissue has been recognized 
as an important instigator of obesity-induced inflammation (54;55). The inflamma­
tory properties of adipose tissue have been discovered since the revolutionary study 
performed by Spiegelman et al. in 1993, showing that adipose tissue from animals 
with diabetes and obesity is able to secrete TNF-a (56). The concept of adipose tis­
sue as an important source of pro-inflammatory mediators rapidly expanded with the 
identification of IL-6, IL-8, plasminogen activator inhibitor (PAI)-1 and monocyte 
chemo-attractant protein-1 (MCP-1) as drivers of metabolic adipocyte dysfunction 
(57-59). Concerning the different adipose tissue depots, VAT seems to contribute to 
a larger extend to these elevated cytokine levels than SAT (57;60). Currently, less is
10
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known about triggers that instigate the inflammatory response in adipose tissue and 
the possible sensors that detect these triggers, although some progress has been made 
by the identification of elevated levels of glucose and FFAs as inducers of several pro- 
inflammatory adipokines (61-63).
IL-1 family o f cytokines in obesity-induced inflammation
The class of IL-1 family cytokines has been shown to play an important role in 
obesity-induced inflammation that promotes the development of insulin resistance 
and type 2 diabetes mellitus. Plasma levels of the prominent IL-1 family members 
IL-1p and IL-18 are increased during obesity and associated with insulin resistance 
(64-67). IL-ip is a pro-inflammatory cytokine having insulin desensitizing effects in 
liver and adipose tissue and causes pancreatic beta-cell failure (66;68;69). Oppositely, 
IL-18 has been shown to improve insulin sensitivity and control food intake (70;71). 
The adipose tissue is also able to produce IL-1p and IL-18 (64;72), yet the underlying 
mechanism or triggers that control the release of these cytokines from adipose tis­
sue remains unknown. However, in several cell types that are known to produce high 
amounts of cytokines including monocytes, macrophages and dendritic cells, inactive 
pro-IL-1p and pro-IL-18 are cleaved into its mature active form by a cysteine protease 
called caspase-1 (73). This enzyme requires activation by an intracellular multi-pro­
tein complex termed the inflammasome. The most fully characterized inflammasome 
complex consists of caspase-1, the cytoplasmic pattern recognition receptor named 
nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein 3 
(NLRP3), and the adapter protein apoptosis-associated specklike protein (ASC) (74). 
Lately, inflammasome-generated IL-1p secretion has also been ascribed to pancreatic 
beta-cells that mediates the development of insulin resistance, with a crucial role for 
the protein thioredoxin interacting protein (TXNIP) in controlling the release of IL-1p 
(75). This protein, which acts as an inhibitor of the reactive oxygen species (ROS) 
scavenging protein thioredoxin, is expressed in different cell types, including adipo­
cytes, and is elevated in subjects with type 2 diabetes mellitus (76;77). The authors 
have shown that upon induction of ROS, TXNIP is released from thioredoxin and 
can interact with NLRP3 to activate caspase-1, which leads to the release of IL-1p in 
mouse pancreatic beta-cells (75).
11
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Figure 1 A model of NLRP3 inllammasome activation by nutrient-derived signals. The NLRP3 in- 
flammasome is activated by nutrient-derived triggers including high levels of glucose and free fatty acids. 
These signals directly or indirectly activate NLRP3. NLRP3 oligomerizes and provokes the recruitment 
of ASC. This signals the assembly of pro-caspase-1, which is cleaved by a process called auto-cleavage 
into active caspase-1. Active caspase-1 is able to process the pro-forms of IL-ip and IL-18 into their ac­
tive forms, which are secreted from the cell.
Cellular sources o f pro-inflammatory mediators in adipose tissue
Like other inflammatory responses, obesity-induced inflammation leads to infiltra­
tion of a variety of immune cells into the inflamed tissue. In the last ten years, it 
has been clarified that the infiltration of macrophages into adipose tissue plays an 
important role in the onset of obesity-induced inflammation. Increased numbers of 
adipose tissue macrophages (ATMs) are robustly associated with elevated levels of 
pro-inflammatory mediators including TNF-a, MCP-1, IL-6 and IL-8 and the devel­
opment of insulin resistance (22;78). In line with these observations, a reduction in 
ATMs results in a diminished inflammatory response together with an improvement in 
insulin sensitivity (79;80). However, recent evidence suggests that ATMs are not the 
only immune cells responsible for the inflammatory response during obesity. Neutro­
phils represent one of the most prominent components of the innate immune system, 
displaying strong phagocytotic and antimicrobial activity. It has been demonstrated 
that the number of neutrophils and its activation state is higher in severely obese 
subjects (81). Besides immune cells belonging to the innate immune system, involve­
ment of the adaptive immunity has also been linked to adipose tissue inflammation. 
Recently, it has been demonstrated that T-lymphocytes (CD3+ T-cells) accumulate in 
obese adipose tissue due to large numbers of CD8+ T-cells (cytotoxic T-lymphocytes) 
and the pro-inflammatory T helper (Th)-1 cell subset of CD4+ T-cells (82-84). Fur­
thermore, infiltration of cytotoxic T-lymphocytes into the adipose tissue has found 
to precede the accumulation of macrophages, suggesting an essential role of T-cells
12
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in the initiation and maintenance of adipose tissue inflammation (85;86). In contrast, 
numbers of the anti-inflammatory Th-2 cells and regulatory T (Treg)-cells are found to 
be lower in adipose tissue of obese animals (87;88). Influx of immune cells into adi­
pose tissue also appears to be depot specific since macrophage and T-cell infiltration 
is more pronounced in VAT as compared to SAT (85;89;90). Therefore, the influx of 
immune cells in this particular fat depot might also contribute to its pro-inflammatory 
character.
Besides the immune system, pre-adipocytes and adipocytes themselves contribute to 
the obesity-induced inflammation. It has been shown that hypertrophic adipocytes 
have a disturbed secretion pattern of pro- and anti-inflammatory cytokines leading to­
wards a more pro-inflammatory profile (44). Moreover, impaired differentiation from 
pre-adipocytes into mature adipocytes has been associated with a more pro-inflamma­
tory profile and enhanced release of chemokines, which are critical for the recruitment 
of immune cells into the adipose tissue (91). In this way, the enhanced inflammatory 
response associated with dysfunctional adipose tissue could link obesity to metabolic 
disorders characterized by insulin resistance.
Figure 2 Alterations in adipose tissue morphology contributes to obesity-induced inflammation. (A)
In lean subjects, adipose tissue is characterized by small insulin sensitive adipocytes and the presence 
of anti-inflammtory Treg cells and Th2 cells. This is accompanied with elevated levels of adiponectin 
and anti-inflammatory cytokines including IL-10 and IL-1 receptor antagonist that suppresses inflamma­
tion and improves insulin sensitivity (B) In obese subjects, adipose tissue is characterized by adipocyte 
hypertrophy with an increased release of FFAs and pro-inflammatory adipokines including leptin, IL-6, 
IL-8, TNF-a and MCP-1. These mediators are released into the circulation and mediates the infiltration 
of macrophages and pro-inflammatory cytotoxic T-cells and Th1 cells in the adipose tissue. This further 
amplifies the immune response in the adipose tissue eventually resulting in local and systemic insulin 
resistance.
13
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Obesity and related metabolic disorders
Adipose tissue inflammation predisposes to the development of insulin resistance and 
several other metabolic abnormalities including dyslipidemia and hypertension (43).
Insulin resistance is defined as a diminished ability of a cell to respond to insulin that 
will subsequently lead to a reduced uptake of glucose. To compensate, the pancreas 
starts to produce increasing amounts of insulin. Eventually, insulin resistance may 
develop into type 2 diabetes mellitus when insulin-producing pancreatic beta-cells can 
no longer compensate for the decrease in tissue insulin sensitivity. In addition, insulin 
resistance is closely linked to the pathogenesis of chronic diseases such as metabolic 
syndrome, familial combined hyperlipidemia (FCH) and cardiovascular diseases 
(CVD) (92-94).
As discussed above, pro-inflammatory cytokines are key players that link obesity-in­
duced inflammation to insulin resistance and recent studies provided more insight into 
the underlying mechanisms. Elevated cytokine levels could inhibit insulin signaling 
pathways in metabolically active organs, such as liver, pancreas and muscle, by block­
ing Insulin Receptor Substrate-1 phosphorylation (95). Furthermore, inflammatory 
mediators might lead to the down-regulation of certain genes involved in the insulin 
signaling cascade and to the augmentation of lipolysis (96). This results into increased 
levels of circulating FFAs that may promote ectopic fat deposition that further ampli- 
^  fies systemic insulin resistance. The central role for the pro-inflammatory cytokine ^
IL-1P in the pathophysiology of insulin resistance has been supported by results from 
a clinical trial in which patients with type 2 diabetes mellitus receiving treatment with 
IL-1 receptor antagonist display an improvement of glycemic control (97). Another 
class of insulin sensitizing pharmaceutical compounds known as thiazolidinediones 
(TZDs) have been described, which are agonists of PPAR-y. TZDs induce glucose 
uptake transporter (GLUT)-4 expression via PPAR-y activation and restore adipocyte 
lipogenesis and differentiation (98;99). Furthermore, TZDs possess anti-inflammatory 
activities by increasing the PPAR-y target adiponectin and reducing inflammatory 
gene expression (100). These findings indicate that anti-inflammatory therapies are 
valuable to reduce obesity-associated inflammation.
14
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Outline of the thesis
The central aim of this thesis is to further investigate the role of adipose tissue adipo- 
kines and inflammation in the etiology of metabolic disorders associated with insulin 
resistance in both mice and man. In the first two chapters we studied adipose tissue 
dysfunction in two different patient populations. First, we described the pathogenic 
role of adipose tissue in patients suffering from FCH (chapter 2). To analyze adi­
pocyte dysfunction, we studied the adipocyte-specific secretion of the metabolically 
favorable HMW isoform of adiponectin in the circulation of FCH subjects and healthy 
controls. In a second study, we investigated whether the insulin sensitive effects of 
the TZD pioglitazone were related to a more beneficial adipocyte morphology and 
metabolic profile of SAT in patients with congenital adrenal hyperplasia (CAH), who 
are characterized by insulin resistance (chapter 3).
The role of two prominent members of the IL-1 cytokine family: IL-1P and IL-18 and 
their intracellular processor, the inflammasome-mediated caspase-1 were studied in 
chapter four to seven. We determined the role of these components in adipose tissue 
inflammation and controlling insulin sensitivity. Since IL-1P and IL-18 have con­
tradictory effects on insulin sensitivity, we first studied the contribution of IL-18 to 
the development of obesity-induced insulin resistance by feeding both wild-type and 
IL-18-/- animals a high fat-diet (chapter 4). Because IL-1P and IL-18 affect meta- 
^  bolic homeostasis and due to the essential role of caspase-1 in activating these two ^
cytokines, we next studied the possible role of caspase-1 as a potential key player in 
regulating adipose tissue inflammation and insulin sensitivity (chapter 5). In addition, 
we focused on hyperglycemia as a potential trigger of caspase-1 in human adipose 
tissue that may contribute to chronic inflammation and insulin resistance via IL-1P 
(chapter 6). Furthermore, we investigated the involvement TXNIP in hyperglycemia- 
induced IL-P secretion by human adipocytes. Finally, we determined whether the in- 
flammasome components NLRP3, ASC and caspase-1 are more active in human VAT 
compared to SAT, which may partly explain the previously reported differences in the 
pro-inflammatory character between both adipose tissue depots (chapter 7).
15
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Abstract
Introduction: Adiponectin is secreted from adipocytes in different multimers, of 
which the high molecular weight (HMW) form is supposed to mediate favourable 
metabolic and anti-atherogenic effects.
Materials and Method: We determined adiponectin multimers in 29 female and 22 
male patients with familial combined hyperlipidemia (FCH) and 51 age-, gender- and 
BMI-matched controls in relation to cardiovascular disease (CVD).
Results: We observed a clear sexual dimorphism of total adiponectin and its multim­
ers. Female, but not male, FCH patients had significant lower total adiponectin and 
both HMW and low molecular weight (LMW) adiponectin than controls.
Conclusions: The adiponectin sensitivity index (ASI), reflected by HMW/total 
adiponectin, and the LMW/HMW adiponectin ratio did not differ significantly be­
tween FCH females and control females. However, FCH females with CVD exhibited 
significantly lower ASI (34.2 ± 10.1% vs 46.0 ± 7.1%) and higher LMW/HMW ratio 
(1.5 ± 0.8 vs 0.7 ± 0.3) compared to FCH females without CVD, reflecting a more 
atherogenic adiponectin multimer distribution.
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Introduction
Adipose tissue is an active endocrine organ secreting many biologically active sub­
stances (adipokines) (1). Adiponectin is an adipokine which is adipocyte-specific and 
is abundantly present in the circulation (2). After post-translational modifications, adi­
ponectin is secreted into the circulation in three different multimers: a low molecular 
weight (LMW) form, a middle molecular weight (MMW) form and a high molecular 
weight (HMW) form (3;4). Previous studies reported that circulating levels of total 
adiponectin are decreased in disorders associated with obesity, dyslipidemia, insulin 
resistance and inflammation (5-9). In the last years, many studies have also described 
an association of adiponectin deficiency with increased incidence of coronary heart 
disease (10;11). This is in agreement with the observation that high levels of adipo­
nectin are associated with a reduced risk of atherosclerotic plaque formation (12). 
Furthermore, experimental data suggest that adiponectin is involved in prevention of 
foam cell formation, down regulation of adhesion molecules, inhibition of endothelial 
dysfunction, and smooth muscle cell proliferation and migration (13-16). Therefore, 
adiponectin is supposed to be protective against cardiovascular diseases (CVD). 
Recently, we reported that total plasma adiponectin is decreased in patients with fa­
milial combined hyperlipidemia (FCH), even after adjustment for body adiposity and 
degree of insulin resistance (17). FCH is the most common heritable, multifactorial 
lipid disorder with a prevalence of 1-5% in the general population. The disturbed lipid 
profile seen in patients with FCH is characterized by elevated levels of total choles­
terol (TC), triglycerides (1) and apolipoprotein B (apoB). Other characteristic features 
are increased levels of low-density lipoprotein cholesterol (LDLc), decreased levels 
of high-density lipoprotein cholesterol (HDLc) and the presence of small dense LDL 
(sdLDL) (18-20). In addition, FCH patients are often obese and insulin resistant (21).
So, FCH patients are exposed to several cardiovascular risk factors which contribute 
to the 2-5 fold increased risk to develop CVD before the age of 60 years (22;23). The 
pathophysiology of this lipid disorder is still unknown, but the finding of reduced 
plasma adiponectin levels in patients with FCH supports the hypothesis that a dis­
turbed adipose tissue metabolism may contribute to FCH (17).
Recently tools became available to specifically determine LMW, MMW and HMW 
forms of adiponectin, and researchers started to focus on these different multimers 
(3;4;24). In this way it was revealed that the favourable metabolic effects of adipo­
nectin are attributed to the HMW multimer. Plasma levels of the HMW form show 
a higher correlation with glucose tolerance than total level of adiponectin and this 
multimer is selectively suppressed in coronary artery disease (CAD) and elevated dur­
ing weight loss (25-27). Furthermore, Pajvani et al described that the ratio of HMW 
to total adiponectin, also called the Adiponectin Sensitivity Index (ASI), correlates 
stronger with insulin sensitivity than just total adiponectin in patients with diabetes 
type 2 (28).
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At the moment no data are present about the adiponectin multimer distribution in 
patients with FCH. Therefore, the first purpose of this study was to investigate wheth­
er a reduced plasma level of total adiponectin in FCH is associated with an altered 
distribution of the adiponectin multimers. Secondly, we evaluated the associations of 
adiponectin multimers with the presence of CVD in FCH.
Materials and Methods
Study population
In this study 51 patients with FCH and 51 controls were included. The patients with 
FCH were derived from a cohort consisting of 37 FCH families (29). The control 
subjects were obtained from the Nijmegen Biomedical Study (NBS), comprising a 
random sample of the total population surrounding Nijmegen (30). Patients and con­
trols were matched for age, gender and body mass index (BMI).
Diagnosis of FCH was based on plasma levels of total cholesterol, triglycerides and 
apoB using the nomogram recently published by Veerkamp et al (29). CVD was 
defined as presence of peripheral artery disease or history of myocardial infarction, 
angina pectoris, coronary artery bypass or angioplasty, transient ischemic attack or 
stroke.
After withdrawal of lipid-lowering medication for four weeks and an overnight fast, 
blood was drawn by venipuncture. BMI was calculated as body weight (in kilograms) 
divided by the square of height (in meters). The maximum hip circumference and 
waist circumference (at the umbilical level) were measured in the late exhalation 
phase while standing. These two measurements were used to calculate waist-hip ratio 
(WHR). The study protocol is approved by the ethical committee of the Radboud 
University Nijmegen Medical Centre and the procedures followed were in accordance 
with institutional guidelines. All subjects gave written informed consent.
Biochemical analyses
Plasma total cholesterol and total triglycerides were determined by enzymatic, com­
mercially available reagents (catalog number 237574 (Boehringer-Mannheim) and 
catalog number 6639 (Sera Pak), respectively). HDLc was determined by the polyeth­
ylene glycol 6000 method. In the FCH population VLDL was isolated and cholesterol 
of this fraction was determined as above. LDLc was calculated by subtraction of 
VLDLc and HDLc from plasma total cholesterol. In the control population LDLc was 
calculated according to the method of Friedewald. Total plasma apoB concentrations 
were determined by immunonephelometry. Glucose concentrations were measured 
in duplicate using the oxidation method (Beckman®, Glucose Analyser2, Beckman 
Instruments Inc., Fullerton, CA 92634, USA).
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Intima media thickness (IMT) measurement
Carotid IMT was determined using an AU5 Ultrasound machine (Esaote Biomedica,
Genova, Italy) with a 7.5MHz linear-array transducer. Longitudinal images of the 
distal-most 10 millimetres of both the far wall and the near wall of both common ca­
rotid arteries were obtained in the optimal projection (anterolateral, lateral or postero­
lateral). The sonographer performed the actual measurement of the IMT off-line at the 
time of the examination, using semi-automatic edge-detection software (M’Ath®Sdt 
version 2.0, Metris, Argenteuil, France). All measurements were carried out in end­
diastole, using the R-wave of a simultaneously recorded ECG as a reference frame.
From each frame the mean IMT was calculated over at least 7.5mm of the above men­
tioned 10mm segment (yielding a quality index of at least 75%). The outcome vari­
able was defined as the mean IMT of the near and far wall of both common carotid 
arteries (31).
Plasma adiponectin multimer assay
Plasma levels of total, LMW, MMW and HMW adiponectin were determined in du­
plicate using a commercially available enzyme-linked immunosorbent assay (ELISA) 
from ALPCO Diagnostics (catalog number 47-ADPH-9755, New Hampshire, USA).
This assay is able to quantify total adiponectin, HMW + MMW and HMW directly.
The concentrations of LMW and MMW are obtained by subtracting HMW + MMW 
^  from total adiponectin and HMW from HMW + MMW, respectively. The Adiponectin ^
Sensitivity Index (ASI) was calculated as the percentage of HMW from total adi­
ponectin (28). The LMW/HMW ratio was calculated as the ratio of LMW to HMW 
adiponectin. Inter-assay and intra-assay coefficients of variance were 2.7% and 1.3% 
for total adiponectin, 1.5% and 2.1% for HMW adiponectin, and 11.1% and 2.4% for 
HMW + MMW, respectively.
Statistical analysis
Continuous variables are expressed as mean ± SD unless otherwise indicated. Vari­
ables showing skewed distribution were logarithmically transformed before the analy­
ses. Student’s unpaired t-test was used to assess statistical significance of differences 
observed between patients with FCH and controls. Two-tailed P-values less than 0.05 
were considered significant. All statistical analyses were performed with the SPSS
14.0 software package.
Results
Characteristics
The anthropometric and metabolic characteristics of the patients with FCH and 
controls are presented in table 1. Compared to control subjects, patients with FCH
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Characteristics o f  patients with familial combined hyperlidem ia and controls
Characteristics FCH patients Controls
All Men Women All Men Women
N 51 22 (43%) 29 (57%) 51 22 (43%) 29 (57%)
Age (years) 63.9(8.0) 62.5 (7.7) 65 (8.2) 62.8 (6.6) 61.6 (6.9) 63.7 (6.3)
BMI (kg/m2) 28.5 (3.4) 27.9 (3.0) 28.9(3.6) 28.4 (3.3) 27.8 (2.9) 28.9 (3.6)
WHR 0.93 (0.06) 0.98 (0.04)* 0.89 (0.05) 0.90 (0.08) 0.96 (0.07)* 0.85 (0.06)
TC (mmol/L) 7.4 (1.2)* 7.2 (1.2) 7.5 (1.1) 6.3 (1.3) 5.9 (0.9)* 6.6 (1.4)
TG (mmol/L) 3.7 (2.0)* 4.4 (2.5) 3.3 (1.5) 1.7 (0.8) 1.8 (1.0) 1.6 (0.7)
HDL-c (mmol/L) 1.1 (0.3)* 1.1 (0.23)* 1.2 (0.24) 1.4 (0.4) 1.3 (0.3) 1.4 (0.4)
LDL-c (mmol/L) 4.4 (1.2) 3.9 (1.1)* 4.8 (1.2) 4.3 (1.1) 3.9 (0.8)* 4.5 (1.3)
ApoB (mg/L) 1481 (245)* 1421 (176) 1528 (281) 1127 (268) 1105(240) 1151 (301)
Glucose (mmol/L) 5.5 (0.9) 5.7 (1.0) 5.3 (0.8) 5.6 (1.1) 5.7 (1.3) 5.6 (0.9)
IMT 0.86 (0.13) 0.90 (0.14) 0.83 (0.11) 0.86 (0.13) 0.87 (0.14) 0.86 (013)
CVD 22 (43%)* 11 11 9 (18%) 5 4
Data are presented as means ± SD; CVD data is presented as number (%). TG, glucose and IMT data are skewed distributed. *, P-value<0.05, 
compared to controls; t, P-value<0.05, compared to females within the same subgroup. BMI, body mass index; WHR, waist-to-hip ratio; TC, total 
cholesterol; TG, triglyceride; ApoB, apolipoprotein B; IMT, intima media thickness; CVD, cardiovascular disease.
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showed significantly higher levels of TC, TG and apoB. HDLc level was significantly 
decreased in the FCH population.
Mean WHR tended to be somewhat higher in FCH subjects than in controls, but this 
difference was not significant. However, WHR was higher and HDLc and LDLc lower 
in males compared to females, both in patients with FCH and in controls. Plasma glu­
cose was not different between patients with FCH and controls. Mean IMT value was
0.86mm in both groups. The incidence of CVD was higher in patients with FCH than 
in control subjects (43% vs 18%, .P-value<0.05).
Levels o f total adiponectin and the different multimers in FCH
In both FCH and control group, we observed higher levels of adiponectin in females 
compared to males (Table 2). Because of this sexual dimorphism, we analyzed the 
data stratified by gender. Mean total adiponectin levels were lower in FCH patients 
compared to control subjects, but the difference reached statistical significance for 
females only. This decrease in total adiponectin in FCH was associated with reduced 
levels of HMW and LMW adiponectin, again reaching statistical significance in fe­
males only. The level of MMW adiponectin did not differ between patients with FCH 
and controls (Table 2).
Significant correlation was observed with WHR for total adiponectin (controls r= 
-0.49, FCH r= -0.54), HMW (controls r= -0.47, FCH r= -0.54), MMW (controls r= 
-0.38, FCH r= -0.46), and LMW (controls r= -0.39, FCH r= -0.30). Total plasma 
adiponectin, HMW- and MMW adiponectin also significantly correlated with HDLc 
within FCH patients (total adiponectin r= -0.30, HMW r= 0.28, MMW r= 0.35). Simi­
lar correlations of total adiponectin and its multimers with HDLc were found within 
control subjects. Significant correlation of adiponectin levels with plasma glucose was 
seen only in the patients with FCH and only for total adiponectin (r= -0.38), HMW 
(r= -0.36) and MMW (r= -0.36). Total adiponectin and its multimers did not correlate 
with IMT, neither in patients with FCH nor in controls (data not shown).
Besides the gender specificity in total plasma adiponectin level and its multimers, 
adiponectin multimer distribution was also different between males and females (Fig­
ure 1). Male subjects showed lower ASI and higher LMW/HMW adiponectin ratio 
compared to females in both patients with FCH and control subjects, reaching statisti­
cal significance in control subjects only (ASI: 36.7 ± 11.3% and 42.1 ± 9.8% for FCH 
males and females, respectively, and 36.4 ± 11.2% and 45.6 ± 11.0% for control males 
and females, respectively; LMW/HMW adiponectin ratio: 1.3 ± 0.8 and 0.9 ± 0.7 for 
FCH males and females, respectively, and 1.4 ± 0.7 and 0.9 ± 0.7 for control males 
and females, respectively). However, no differences were observed in the adiponectin 
multimer distribution between the patients with FCH and the control subjects (Figure 
1).
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Levels o f  total plasm a adiponectin and its multimers in patients with FCH and controls
FCH patients Controls
All Men Women All Men Women
Total adiponectin (ng/inl) 4.8 (2.3)* 3.3 (1.2)t 5.9 (2.3)* 6.2 (3.1) 4.1 (1.7)t 7.7 (3.0)
HMW (ng/inl) 2.0 (1.2)* 1.2 (0.6)t 2.6 (1.3)* 2.8 (1.9) 1.5 (0.9)t 3.7 (2.0)
MMW (ng/inl) 1.1 (0.7) 0.7 (0.3)t 1.4 (0.7) 1.2 (0.7) 0.8 (0.4)t 1.5 (0.8)
LMW (ng/inl) 1.7 (0.8)* 1.4 (0.7) 1.9 (0.9)* 2.2 (1.0) 1.7 (0.7)t 2.6 (1.0)
Data are presented as means ± SD; Total adiponectin, HMW, MMW and LMW data are skewed distributed. *, P-value<0.05, compared to controls; t, 
P-value<0.05, compared to females within the same subgroup; t P-value<0.05, compared to female controls. HMW, high molecular weight protein; 
MMW, middle molecular weight adiponectin; LMW, low molecular weight adiponectin.
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Figure 1 Adiponectin sensitivity index (ASI), reflected by percentage HMW adiponectin to total 
adiponectin (A) and ratio of LMW and HMW adiponectin in patients with FCH and controls, stratified by 
gender (B). * P-value<0.01, t P-value<0.05, compared to females of the control group.
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Adiponectin multimer distribution and CVD
No difference was observed between mean total plasma adiponectin of patients with 
FCH with or without CVD stratified by gender (Figure 2a). We did not compare 
adiponectin levels of controls with and without CVD, because the number of con­
trol subjects with CVD was too low (5 males and 4 females). However, within the 
FCH population, women with CVD exhibited significantly lower ASI (34.2 ± 10.1% 
vs 46.0 ± 7.1%) and higher LMW/HMW ratio (1.5 ± 0.8 vs 0.7 ± 0.3) compared to 
women without CVD (Figure 2b and 2c). Both these ratios were not different in male 
patients with FCH with and without CVD.
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Figure 2 Plasma levels of total adiponectin (A), adiponectin sensitivity index (ASI), reflected by percent­
age HMW adiponectin to total adiponectin (B) and ratio of LMW and HMW adiponectin in FCH patients 
with and without CVD, stratified by gender (C). * P-value<0.05, compared to FCH females with CVD, i 
P-value<0.05, compared to FCH males with or without CVD.
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Discussion
In this study, we show that patients with FCH have a reduced level of total adiponec- 
tin, but their adiponectin multimer distribution does not differ from age-, gender-, 
and BMI- matched controls. However, FCH females with CVD have a less favorable 
adiponectin multimer distribution with significant lower ASI and higher LMW/HMW 
adiponectin ratio than FCH females without CVD. Consequently, the profile of adi­
ponectin multimers in FCH females with CVD reflects a more atherogenic multimer 
distribution.
Like earlier studies, our study shows a clear sexual dimorphism of adiponectin levels 
in the control population (6). Females have higher total plasma adiponectin than 
males, and this difference is due to elevated levels of all multimers, but HMW mul­
timer in particular (28;32). As a result of these differences, ASI is higher and LMW/
HMW ratio is lower in females compared to males. Gonadal steroids are presumed to 
be involved in the gender-related difference in adiponectin levels. Testosterone was 
previously shown to selectively inhibit the secretion of HMW adiponectin (32), and 
plasma estradiol concentration was shown to negatively correlate with plasma total 
adiponectin concentration in postmenopausal women (6;33). This effect of testoster­
one on HMW adiponectin production was hypothesized to partly explain the higher 
risk of CVD in males. Lara-Castro et al. demonstrated that the HMW adiponectin 
^  multimer exhibits close associations with insulin sensitivity, high concentrations of ^
less atherogenic LDL and more cardioprotective HDL (34). In the present study we 
observed significant correlations of HMW and MMW adiponectin with HDLc and 
with plasma glucose. These features might contribute to the increased CVD risk in 
subjects having decreased relative amounts of the HMW adiponectin multimer. Con­
sistent with this, cross-sectional studies have also demonstrated the selective reduc­
tion of the HMW adiponectin multimer in type 2 diabetes (25), in CVD (27) and in 
the metabolic syndrome (35).
Concurrent with the reduction of the relative amount of the HMW multimer of adipo­
nectin we show that in a subset of FCH females, the protective effect of HMW adipo­
nectin against CVD diminishes and CVD risk may rise. Previously, in cross-sectional 
studies HMW adiponectin has consistently been shown to be a better marker than 
total adiponectin in the prediction of insulin resistance and the metabolic syndrome 
(34), endothelial dysfunction (36), and type 2 diabetes (37). In addition, plasma HMW 
adiponectin was reported to serve as a marker for severity of CAD (38). With respect 
to prediction of future cardiovascular events, reports, however, are rather contradic­
tory. Inoue et al. showed that plasma HMW adiponectin levels may also predict future 
CVD events in patients with CAD (38). In contrast, others (39;40), who measured 
only total adiponectin, reported that high adiponectin level was associated with 
increased total mortality in patients with chronic heart failure and with recurrence of 
cardiovascular events in patients who had a recent clinical manifestation of vascular
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disease. Poor physical condition may have confounded the outcome of the latter two 
studies. Patients with chronic heart failure experience weight loss (wasting) due to 
increased resting energy expenditure and low-grade chronic inflammation precedes 
recurrence of vascular events. The FCH patients included in the present study were in 
good physical condition, suggesting that physical condition may not have confounded 
the analyses.
It has often been shown that visceral adiposity is an independent negative predictor 
of adiponectin. In addition, Lara-Castro et al showed that this close association of 
plasma total adiponectin with reduced abdominal fat, is attributed primarily to the 
HMW adiponectin multimer (34). Therefore, the reduced levels of HMW adiponectin 
found in the present study in a subset of FCH females may be related to increased 
visceral adiposity. An increase in visceral adiposity may be associated with adipocyte 
hypertrophy and lead to less functional adipocytes and altered adipokine production. 
Consistent with this, we did find a significant inverse correlation of HMW adiponectin 
with WHR, which is surrogate marker of visceral adiposity.
A limitation of this study is that the cross-sectional design limits inferences about 
causality. Furthermore, the age of the subjects ranged from 50 to 70 years. As a 
consequence, most females included in the study were postmenopausal and may have 
relatively high adiponectin levels due to reduced estradiol concentration. Moreover, 
due to an impairment in renal function, age is positively associated with plasma adi- 
ponectin levels. Unfortunately, no data on renal function of the present population are 
available. For these reasons our results cannot be generalized to younger subjects.
In conclusion, despite reduced total adiponectin, FCH males show normal adiponectin 
multimer distribution. However, due to a more pronounced reduction of the HMW 
multimer in FCH females with CVD, these females have a more atherogenic adipo- 
nectin multimer distribution with decreased ASI and increased LMW/HMW adipo­
nectin ratio.
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Abstract
Context: Obesity-related insulin resistance is associated with an increase in adipo­
cyte size. In rodent models, treatment with the insulin-sensitizers thiazolidinediones 
(TZDs) leads to the appearance of small, insulin sensitive adipocytes. Whether such 
TZD-dependent morphological changes occur in adipose tissue of insulin resistant 
patients is unclear.
Objective: To study the effects of treatment with the TZD pioglitazone on subcutane­
ous adipose tissue morphology and function in insulin resistant subjects.
Design: Placebo-controlled, randomized cross-over study.
Setting: University Medical Centre.
Patients: Twelve adult patients with congenital adrenal hyperplasia (CAH) character­
ized by insulin resistance were included in this study.
Intervention: After a 4-week run-in phase, patients were treated with pioglitazone 
(45mg/d) followed by placebo, each for 16 weeks or vice versa.
#  ” #  
Main Outcome Measures: After both placebo and pioglitazone treatment, insulin 
sensitivity was determined by hyperinsulinemic euglycemic clamp and abdominal 
subcutaneous adipose tissue was obtained to measure adipocyte cell surface and ex­
pression of genes involved in glucose uptake and inflammation.
Results: Pioglitazone treatment significantly improved the insulin sensitivity index 
(placebo: 0.35 ± 0.16^mol/kg/min/mU/L; pioglitazone 0.53 ± 0.16^mol/kg/min/ 
mU/L, ^-value<0.001) and increased mRNA expression levels of adiponectin and 
GLUT-4 in adipose tissue. The increase in insulin sensitivity was accompanied by a 
significant enlargement of the subcutaneous adipocyte cell surface (placebo: 2323 ± 
725^m2; pioglitazone 2821 ± 885^m2, .P-value=0.03).
Conclusions: In the human situation, treatment of insulin resistant subjects with pio- 
glitazone, improves insulin sensitivity while at the same time subcutaneous adipocyte 
cell surface increases.
40
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Introduction
Obesity is associated with an abnormal secretion pattern of adipocytes and increased 
infiltration of macrophages into adipose tissue (1;2). Recent studies have shown that 
the increased risk for obese subjects to develop insulin resistance and type 2 diabe­
tes mellitus (T2DM) is associated with increased subcutaneous abdominal adipocyte 
surface (3;4). Large adipocytes are relatively insulin-insensitive and have an increased 
basal lipolysis and an altered secretion of adipokines (5;6). In addition, hypertrophic 
adipocytes promote the infiltration of macrophages into adipose tissue leading to en­
hanced production of pro-inflammatory cytokines that contribute to the development 
of insulin insensitivity (7). It has therefore been assumed that the presence of large 
adipocytes may drive the development of insulin resistance.
Thiazolidinediones (TZDs) are an insulin-sensitizing class of pharmacological com­
pounds widely used for treatment of T2DM, which exhibit their insulin-sensitizing 
effects by decreasing visceral fat content, enhancing insulin action and improving 
glucose homeostasis (8). At the same time, TZDs increase the subcutaneous fat depot 
(9). TZDs are ligands for peroxisome proliferator-activated receptor-y (PPAR-y), a 
nuclear transcription factor highly expressed in adipose tissue (10). One of the adi­
pose tissue-specific effects of TZDs, mainly described in rodent studies, is the stimu­
lation of adipocyte differentiation and apoptosis of large adipocytes, resulting in an 
^  increased population of small, more insulin sensitive adipocytes (11). This suggests ^
that improvement in glucose homeostasis by TZD treatment will be accompanied by 
changes in adipocyte size.
In the present study, we investigated the effects of pioglitazone treatment on insulin 
sensitivity, subcutaneous adipocyte surface and expression of genes involved in glu­
cose uptake and inflammation, in insulin resistant subjects.
Materials and Methods
Study population
Twelve patients with genetically-characterized, “classical”, congenital adrenal hyper­
plasia (CAH) on a stable corticosteroid dose were studied in a randomized cross-over 
design. Based on their underlying condition and chronic treatment, this group of pa­
tients is characterized by insulin resistance (12). After a 4 week run-in phase, patients 
were randomized to treatments with placebo and pioglitazone (45mg/d) in a blinded 
fashion for 16 weeks, or vice versa. At the end of each treatment period, subcutane­
ous adipose tissue biopsies were obtained under local anesthesia by needle biopsies 
6-10cm lateral to the umbilicus. Samples were taken after an overnight fast. Fasting 
plasma adiponectin, leptin, insulin and glucose were determined and insulin sensitiv­
ity index (ISI) was assessed. Finally, the percentage of trunk fat was determined.
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The ethical committee of the Radboud University Nijmegen Medical Centre approved 
the study protocol and the procedures followed were in accordance with institutional 
guidelines. All subjects gave written informed consent.
Adipocyte surface
Morphometry of individual fat cells was assessed in a blinded fashion using digital 
image analyses as described recently (13). In short, after biopsy, adipose tissue was 
immediately fixed in paraformaldehyde and embedded in paraffin. Subsequently, par­
affin slides were stained with heamatoxylin-eosin. Inasmuch our method to measure 
adipocyte size requires intact cell membranes, we initially optimized the thickness of 
our sections. Microscopic observation revealed that adipose tissue samples cut into 
sections < 8pm showed ruptured cells. To avoid multilayered cells, we used 10pm 
sections for the analysis. For each subject, surface of all fat cells in 4-7 microscopic 
fields of view were measured. On average, 250 fat cells were measured per specimen 
(range 150-350).
RNA isolation and real time PCR analysis
Total RNA was extracted from subcutaneous adipose tissue using TRIzol reagent (In- 
vitrogen, Carlstad, USA). RNA concentration was determined using the NanoDrop™
(NanoDrop Technologies, Wilmington, USA). cDNA synthesis was performed using 
^  the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). Real-time ^
PCR was performed using Power-SYBR® Green master mix and the 7300 Real-Time 
PCR system (Applied Biosystem, Warrington, UK). Expression of genes was normal­
ized to P2M gene expression levels. Primer sequences are available upon request.
Insulin sensitivity and body fa t distribution
Insulin sensitivity was assessed by a hyperinsulinemic euglycemic clamp and ex­
pressed as glucose disposal rate (Rd) and ISI essentially as described previously (14). 
Total-body Dual-energy X-ray absorptiometry (DEXA) scanning was performed using 
a Hologic QDR 4500 densitometer to determine indirectly the percentage of trunk fat 
mass by dividing the absolute fat mass of the trunk by the total mass of the trunk.
Biochemical analyses
Glucose concentrations were measured using the oxidation method (Beckman®, 
Glucose Analyser2, Beckman Instruments Inc., Fullerton, CA 92634, USA). Plasma 
concentrations of leptin and total adiponectin were determined using enzyme-linked 
immunosorbent assays (R&D Systems, Minneapolis). The inter-assay and intra-assay 
coefficient of variation were 6.5% and 3.5% for total adiponectin and 4.4% and 3.2% 
for leptin.
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Statistical analyses
Variables are expressed as means ± SD. Differences in adipocyte surface after placebo 
and pioglitazone treatment were studied using one-way univariate analysis of vari­
ance. Students’ paired t-test was used to analyze statistical significance of treatment 
differences of other variables. Two-tailed P-values less than 0.05 were considered 
significant. Tukey honestly significant difference post-hoc testing was applied for 
multiple comparison testing. All statistics were performed using SPSS software (SPSS
16.0 Inc, Chicago, Il).
Results
Study population characteristics
A total of 12 patients (five men, seven women; age 36 ± 9yr; BMI 26.9 ± 4.7kg/ 
m2) completed the study. Mean fasting plasma insulin, glucose, triglycerides, and 
total cholesterol levels after placebo were 8.8 ± 5.8mU/L, 5.0 ± 0.2mmol/L, 0.96 ±
0.3mmol/L and 4.53 ± 0.7mmol/L, respectively. The cell surface of subcutaneous 
adipocytes in our study population showed large variation. Whereas the mean subcu­
taneous adipocyte surface was 2323 ± 725 ¡am2, clear inter-individual differences were 
observed (Figure 1A and B).
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Figure 1 Characteristics of subcutaneous adipocytes after placebo. A: Morphometry of fat cells as­
sessed by digital image analysis. B: Heamatoxylin-eosin staining images of subcutaneous adipose tissue 
of two subjects. C: Pearson correlation of mean adipocyte surface with percentage of trunk fat, plasma 
leptin level, insulin sensitivity index, and (D) gene expression levels of Glut-4 and MCP -1.
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Interestingly, adipocyte cell surface was positively correlated with the percentage of 
trunk fat (r=0.73; P-value=0.01) and plasma leptin levels (r=0.70; P-value=0.01) and 
negatively correlated with the ISI (r=-0.60; P-value=0.04) (Figure 1C). In addition, 
adipocyte surface correlated negatively with glucose transporter 4 (Glut-4) mRNA ex­
pression (r= -0.65; P-value=0.03) and positively with the mRNA expression level of 
the inflammatory marker monocyte chemoattractant protein-1 (MCP-1) in the adipose 
tissue (r=0.57; P-value=0.05) (Figure 1D). Noticeably, adjustment for BMI did not 
significantly alter the correlations that were observed between the different variables 
and adipocyte surface.
Effects o f pioglitazone treatment
After 16 weeks of pioglitazone treatment, body weight and BMI had increased (by 2.0 
± 3.3kg and 0.7 ± 1.1kg/m2; P-value=0.06 for both), but no difference was observed 
in mean trunk fat percentage. Insulin sensitivity improved significantly after piogli­
tazone as reflected by ISI (placebo: 0.35 ± 0.16; pioglitazone: 0.53 ± 0.16^mol/kg/ 
min/mU/L); P-value<0.001). The ISI was based on Rd (placebo: 28.5 ± 11.6^mol/ 
kg/min; pioglitazone 38.9 ± 11.0^mol/kg/min, P-value<0.001) and the insulin level 
at 120 minutes (placebo: 87.5 ± 22.9mU/L; pioglitazone 76.3 ± 13.8mU/L; P-val- 
ue=0.03). Subcutaneous adipocyte surface increased significantly (by 497 ± 625^m2; 
P-value=0.03) following pioglitazone treatment: 8 out of 11 patients showed larger 
adipocytes (Figure 2A and B). Pioglitazone had no significant effect on fasting plasma 
insulin (7.9 ± 4.1mU/L after pioglitazone), glucose (5.1 ± 0.5mmol/L after piogli­
tazone), adiponectin (placebo: 5.4 ± 3.9^g/mL; pioglitazone: 6.1 ± 4.7^g/mL) and 
leptin levels (placebo: 23.6 ± 14.9ng/mL; pioglitazone 22.9 ± 16.3ng/mL). qPCR 
analysis revealed increases in expression of adiponectin (P-value<0.01) and GLUT-4 
(P-value=0.10) mRNA in adipose tissue after pioglitazone treatment. MCP-1 mRNA 
expression appeared lower after pioglitazone treatment, but the differences were not 
statistically significant (Figure 2C).
After pioglitazone treatment, the negative correlation between subcutaneous adipocyte 
surface and ISI was slightly weaker (r= -0.58; P-value=0.05), and the negative corre­
lation between GLUT-4 and subcutaneous adipocyte surface was no longer significant 
(r= -0.42; P-value=0.2). Correlations between subcutaneous adipocyte surface and the 
percentage of trunk fat, plasma leptin levels, and MCP-1 gene expression were dra­
matically changed after pioglitazone treatment. In contrast to placebo treatment, the 
percentage trunk fat and plasma leptin levels were no longer positively correlated with 
subcutaneous adipocyte surface. In addition, the positive correlation of MCP-1 gene 
expression levels and adipocyte surface observed after placebo treatment, was lost 
after pioglitazone treatment. Apparently, enlarged adipocyte surface no longer predicts 
metabolic abnormalities and adipose tissue functioning after pioglitazone treatment in 
this study population.
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Figure 2 Characteristics of subcutaneous adipocytes after 16 weeks of pioglitazone treatment. A:
Individual changes of mean subcutaneous adipocyte cell surface following pioglitazone treatment. B: 
Representative heamatoxylin-eosin staining images of subcutaneous adipose tissue after placebo and 
after pioglitazone treatment. C: Individual adipose tissue mRNA expression levels of adiponectin, Glut-4 
and MCP-1 after both treatments. Person 4 is missing since no biopsy was taken after pioglitazone treat­
ment. Black dashes represent mean values.
Discussion
In the present study we describe the effect of pioglitazone on subcutaneous adipose 
tissue morphology, gene expression levels and insulin sensitivity in a group of insu­
lin resistant patients. Although adipocyte hypertrophy was associated with indices of 
insulin resistance, pioglitazone treatment resulted in an enlargement of subcutaneous 
adipocytes in parallel with an improvement of systemic insulin sensitivity.
The positive association between obesity-induced adipocyte hypertrophy and the de­
velopment of insulin resistance and T2DM has been reported before (4). The develop­
ment of hypertrophic adipocytes is partly explained by the impaired ability to differ­
entiate new fat cells, resulting in enlargement of existing adipocytes (15). Enlarged 
adipocytes are characterized by a lower insulin mediated glucose disposal, disturbanc­
es in lipid mobilization, and secretion of higher levels of leptin compared with smaller 
adipocytes (3;16). In line with these detrimental effects of adipocyte hypertrophy, our 
data show that after placebo enlarged subcutaneous adipocyte surface correlates with
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elevated levels of circulating leptin, low insulin sensitivity, and lower GLUT-4 mRNA 
expression, an essential glucose uptake transporter. Adipocyte surface also positively 
correlates with secretion of pro-inflammatory adipokines (17). In our study, the MCP- 
1 pro-inflammatory gene expression positively correlated with subcutaneous adipo­
cyte surface, suggesting that enlarged adipocytes have increased secretion levels of 
MCP-1 (17). Elevated MCP-1 levels might also be indicative for increased accumula­
tion of macrophages in subcutaneous adipose tissue that promote the development of 
insulin resistance. Altogether, our observations suggest that subcutaneous adipocyte 
hypertrophy is indicative for unfavorable metabolic functioning of adipose tissue after 
placebo treatment.
In agreement with previously published studies, treatment with pioglitazone signifi­
cantly improved insulin sensitivity in our study population despite an increase in 
body weight (18). Since PPAR-y efficiently binds TZDs and is abundantly expressed 
in adipose tissue, pioglitazone is thought to primarily target the adipose tissue where 
it promotes the development of small adipocytes characterized by an improvement 
in metabolic function. However, evidence in support of this mechanism of action 
has mainly been obtained from rodent studies (11). The number of studies that have 
investigated subcutaneous adipocyte surface in response to TZD treatment in humans 
is limited and has revealed ambiguous results. So far, studies have reported no change 
or an increase in the number of small adipocytes together with an improvement of in­
sulin sensitivity after TZD treatment (19;20), although a trend towards fat cell volume 
increase was also observed (21). In the present study we observed a clear increase 
in subcutaneous adipocyte surface by pioglitazone together with an improvement of 
whole body insulin sensitivity. These divergent results may be explained by differenc­
es in methodology. Previous studies have measured adipocyte surface using isolated 
adipocytes obtained after collagenase digestion and subsequent centrifugation. This 
treatment usually results in breakage of large cells leading to an unrepresentative 
sample of the original cell population with underestimation of large cells (22). In the 
present study, immediate fixation of adipose tissue biopsies after isolation warranted 
accurate estimation of adipocyte surfaces.
Importantly, positive correlations between adipocyte surface and plasma leptin, per­
centage trunk fat, and MCP-1 gene expression levels, markers indicative for insulin 
resistance and adipose tissue dysfunctioning, disappeared after pioglitazone-induced 
enlargement of adipocytes. These findings suggest that pioglitazone-induced adipo­
cyte surface enlargement has not a detrimental but a beneficial effect on adipose tissue 
metabolism. Hypothetically, the pioglitazone-induced adipocyte hypertrophy might 
result from redistribution of visceral and ectopic fat towards subcutaneous storage 
ultimately leading to smaller visceral adipocytes, though enlarged subcutaneous adi­
pocytes. Since no visceral fat biopsies were taken, no data is available to support this 
hypothesis.
This study was performed in a group of adult patients with CAH on stable corticoste-
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roid treatment. These patients are characterized by insulin resistance (12), and were 
used in this study as a human “model” for obesity-associated insulin resistance. The 
advantage of this approach is that pioglitazone treatment will not lead to changes in 
glucose levels and hence the “pure” -  not confounded by changes in glycemic level 
-  effect of the TZD on fat metabolism can be studied. The improvement of insulin 
sensitivity suggests a normal response to pioglitazone in CAH patients and affirms the 
applicability of the model. However, we cannot exclude that other human models of 
insulin resistance would show different responses.
In conclusion, our data, obtained from human adipose tissue samples, confirm that 
increased subcutaneous adipocyte surface correlates with indices of insulin resistance 
at the whole body and the cellular level. Pioglitazone treatment enlarges adipose tis­
sue and increases adipocyte surface, while at the same time improving the systemic 
insulin sensitivity.
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Abstract
Introduction: In parallel with the development of insulin resistance, obese individu­
als display a chronic low grade inflammation characterized by an increased activity of 
numerous pro-inflammatory cytokines. Cytokines appear to make divergent contribu­
tions since some facilitate and others seemingly inhibit the development of obesity-in­
duced insulin resistance. Although IL-18, member of the IL-1 family of cytokines, has 
been positively correlated with the presence of obesity and insulin resistance, IL-18 
has also been shown to suppress food intake, improve insulin sensitivity and prevent 
the development of obesity. Therefore we hypothesized that IL-18 protects against the 
development of high fat diet-induced insulin resistance.
Materials and Methods: To test our hypothesis, wild-type and IL-18-/- animals were 
fed a low fat diet (LFD) or high fat diet (HFD) for 16 weeks to induce obesity and 
insulin resistance.
Results: Gene expression analysis revealed that IL-18 is highly expressed in liver and 
white adipose tissue. Although a HFD induced weight gain and hepatic steatosis to a 
similar extend in both genotypes, insulin sensitivity tests revealed that IL-18-/- mice 
fed the HFD were more insulin resistant compared to wild-type animals. In parallel, 
^  IL-18-/- animals displayed lower plasma adiponectin levels, elevated plasma VLDL
triglycerides and higher serum ALT levels. Treatment of animals with recombinant IL- 
18 improved hepatic insulin sensitivity as determined by pAKT levels. Surprisingly, 
adipose tissue macrophage influx was lower in HFD fed IL-18-/- animals as compared 
to wild-type controls concurrent with lower adipose tissue levels of the chemokine 
MCP-1. However, gene expression analysis revealed higher levels of IL-6 and lower 
expression levels of IL-1 receptor antagonist in adipose tissue of HFD-fed IL-18-/- 
animals.
Conclusions: IL-18 determines insulin sensitivity independently of the development 
of HFD-induced obesity, hepatic steatosis and influx of macrophages into adipose tis­
sue.
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Introduction
Obesity fuels the development of a chronic low grade inflammation illustrated by 
increased plasma concentrations of pro-inflammatory mediators (1). It is generally 
believed that obesity-induced inflammation originates from expanding adipose tissue 
that secretes a wide variety of proteins named adipokines (2). During the develop­
ment of obesity, adipose tissue undergoes morphological changes including adipocyte 
hypertrophy accompanied by the infiltration of macrophages (3). This leads to a more 
pro-inflammatory secretion profile of adipose tissue from obese individuals compared 
to lean subjects (4). In addition to changes of the adipose tissue, the liver also under­
goes morphological changes during the development of obesity. Fat accumulation in 
liver is a common phenomenon in obese individuals and can eventually result in the 
development of hepatic inflammation, enhanced plasma ALT levels and increased 
production of pro-inflammatory proteins (5).
Although it is well established that obesity leads to a state of chronic low grade in­
flammation and insulin resistance, various cytokines make divergent contributions to 
this process. Whereas several cytokines positively contribute to the development of 
obesity and insulin resistance, others appear to inhibit this pathophysiological process.
Tumor necrosis factor (TNF)-a is able to induce insulin resistance (6) and anti-TNFa 
treatment of insulin resistant individuals improves insulin sensitivity (7;8). Recent 
^  work in IL-18-/- animals revealed an important role of IL-18 in metabolic processes ^
that modulate energy balance and insulin sensitivity (9;10). IL-18, part of the IL-1 
cytokine family, has initially been identified as a potent inducer of interferon gamma 
(IFN)-y secretion participating in inflammatory processes (11). Unlike other members 
of the IL-1 cytokine family that are induced during acute inflammation, IL-18 is con­
stitutively expressed (12). Despite these pro-inflammatory capacities, IL-18 seems to 
protect against the development of obesity and insulin resistance. In contrast, several 
lines of evidence hint at a role for IL-18 in inducing obesity-related complications 
since circulating levels of IL-18 are increased during obesity individuals and have 
been positively correlated to the development of the metabolic syndrome (13;14).
Additionally, weight loss has been shown to reduce circulating levels of IL-18 (15).
However, it can be envisioned that elevated IL-18 plasma concentrations are the result 
of compensatory mechanisms due to a reduced response to IL-18 similar to the devel­
opment of hyperinsulinemia and hyperleptinemia in obese individuals (16).
In this study, we hypothesized that IL-18 is essential for effective insulin signaling 
during high fat diet. To test our hypothesis, both wild-type and IL-18-/- animals were 
fed a high fat diet to induce insulin resistance. Our results show that IL-18 controls 
insulin sensitivity independently of the development of obesity, hepatic steatosis and 
macrophage influx into the adipose tissue.
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Material and methods
Animal studies
IL18-/- mice were generated on a C57B1/6J background as previously described 
(17). Age-matched wild type C57B1/6J mice were used as the control group. Body 
weight of the mice was measured every month. To induce obesity, animals were fed 
a high fat diet containing 45 energy% from fat (D12451, Research diets, New Bruns­
wick, USA). Control animals received a low fat diet containing 10 energy% from fat 
(D12450B, Research diets, New Brunswick, USA).
Insulin tolerance tests
Insulin-tolerance tests were performed as previously described (18). Briefly, the insu- 
lin-tolerance tested animals were fasted overnight. Insulin was given intraperitoneally 
at a dose of 0.75U/kg bodyweight. Blood samples were taken before and 30, 60, 90 or 
120 minutes after insulin administration to determine the plasma glucose levels.
RNA isolation and qPCR analysis
RNA from animal tissues was isolated using Trizol Reagent (Invitrogen) following 
manufacturer’s instructions. RNA concentration and purity was determined using 
a Nanodrop (Thermo Fisher Scientific, USA). 500ng or 1^g of RNA was used for 
reverse transcription using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories BV, 
Veenendaal, The Netherlands). Real-Time PCR was done with a Power Sybr Green 
PCR master mix (Applied Biosystems) using a 7300 Real-Time PCR System (Applied 
Biosystems). Primers sequences are available upon request. Melt curve analysis was 
included to assure a single PCR product was formed. Values were corrected using the 
housekeeping gene 36B4.
Histology/immunohistochemistry
For detection of macrophages, an F4/80+ antibody (Serotec, Oxford, UK) was used. 
Sections were pre-incubated with 20% normal goat serum followed by overnight 
incubation at 4 °C with the primary antibody diluted 1:150 in PBS/ 1% Bovine 
Serum Albumin (BSA). After incubation with the primary antibody, a goat anti rat 
IgG conjugated to horseradish peroxidase (Serotec) was used as secondary antibody. 
Visualization of the complex was done using 3,3’-diaminobenzidene for 5 minutes. 
Haematoxylin and Eosin (HE) staining of sections was done using standard protocols 
to determine white adipose tissue and liver morphometry.
Plasma analysis
Plasma insulin, adiponectin, leptin and adipose tissue MCP-1 levels were measured 
using commercially available ELISA kits following manufacturer’s instructions. The 
insulin ELISA kit was from Linco, adiponectin, leptin and MCP-1 ELISA kits were
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from R&D systems. Plasma glucose, cholesterol and triglyceride levels were de­
termined using commercially available kits from Human. Plasma IL-18 levels were 
measured using an ELISA kit from Invitrogen following manufacturer’s instructions.
Statistical analysis
Statistical significant differences were calculated using a Student’s T-test. The cut-off 
for statistical significance was set at a P-value of 0.05 or below.
Results
IL-18 is mainly expressed in liver and adipose tissue 
To compare the relative contribution of muscle, liver, and fat to express IL-18, 
transcription levels were determined by qPCR. As shown in figure 1A, IL-18 is most 
prominently expressed in liver and adipose tissue. Interestingly, among the IL-1 fam­
ily members, IL-18 displayed the highest basal gene expression levels suggestive of a 
different function as compared to other members within the IL-1 family of cytokines 
(Figure 1B). To identify the cellular source of IL-18, immunohistochemical staining 
and qPCR analysis of specific fractions of the liver and adipose tissue of wild-type 
C57/Bl6 animals were performed. As shown in figure 1C, IL-18 protein is predomi­
nantly expressed in kupffer cells, yet qPCR analysis revealed gene expression of IL-
18 in both hepatocytes and Kupffer cells. Transcriptional and immunohistochemical 
analysis of the adipose tissue revealed that IL-18 is primarily expressed in adipocytes 
compared to the stromal vascular fraction (SVF) (Figure 1D).
IL-18-/- animals fed  a high fa t diet are more prone to the development of 
insulin resistance
We next set out to study the effect of IL-18 during the development diet-induced 
obesity and insulin resistance. Interestingly, plasma concentrations of IL-18 were 
positively correlated with the body mass of mice with varying degrees of adipos­
ity (Figure 2A) suggesting that IL-18 participates in the development of obesity. To 
explore the effects of IL-18 during the development of obesity, wild-type and IL-18- 
/- animals were fed a high fat diet (HFD) or a low fat diet (LFD). The HFD induced 
a comparable weight gain in both IL-18-/- animals and wild-type mice (Figure 2B). 
Plasma insulin analysis revealed a significant 2-fold increase (P-value<0.01) in 
wild-type mice compared to IL-18-/- mice fed the LFD (Figure 2C). Although insulin 
levels tended to be higher in the IL-18-/- fed the HFD compared to their wild-type 
controls (Figure 2C), results were not significantly different. Whereas plasma leptin 
levels were increased due to HFD feeding, no differences between both genotypes 
were observed (Figure 2D). Interestingly, plasma adiponectin levels were significantly 
lower in HFD fed IL-18-/- animals compared to the wild-type controls (Figure 2E).
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Diet-induced changes in plasma glucose (Figure 2F) and cholesterol (Figure 2G) con­
centrations displayed similar profiles in wild-type and IL-18-/- animals. In contrast, 
plasma triglyceride (TG) concentrations were significantly higher in IL-18-/- animals 
independent of the diet interventions (Figure 2G). Detailed analysis of the TG content 
in the different lipoprotein fractions revealed a significant 2-fold increase in very low- 
density lipoprotein (VLDL)-TG concentrations in IL-18-/- animals independently of 
the dietary intervention (Table 1).
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Figure 1 IL-18 expression in white adipose tissue and liver of C57/B16 wild-type animals A. Gene 
expression levels of IL-18 determined in liver, white adipose tissue and muscle (w=l per group). B. Ex­
pression analysis of all IL-1 family-members in liver and white adipose tissue by qPCR (w=l per group). 
C. Immunohistochemical staining in liver and qPCR analysis using hepatocytes or kupffer cells of IL-18. 
The arrows indicated positive staining of cells. Macrophage marker CD68 was used as a positive control 
to discriminate Kupffer cells from hepatocytes (w=10 per group) D. Immunohistochemical staining in 
white adipose tissue and qPCR analysis using adipocytes or stromal vascular cells of IL-18. Adipocyte 
marker leptin was used as a positive control to discriminate adipocytes from stromal vascular cells (w=10 
per group). The arrows indicate positive staining of cells. Data are presented as means ± SEM. **= P- 
value<0.01. nd=not detected.
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Table 1
Plasma TG levels in different plasma lipoprotein fractions
Animals VLDL-TG (mmol/L) HDL-TG (mmol/L) LDL-TG (mmol/L)
Wild-type-LFD 0.37 ±0.16 0.13 ±0.01 0.09 ±0.008
Wild-type-HFD 0.24 ±0.014 0.25 ± 0.029 0.09 ±0.06
IL-18-/- LFD 0.71 ±0.212* 0.14 ±0.02 0.08 ±0.003
IL-18-/- HFD 0.57 ±0.074# 0.20  ±0.01 0.11 ±0.007
Data are presented as means ± SEM. *, P-value<0.05, compared to wild-type animals fed a low fat diet (LFD). P-value<0.05, compared to wild- 
type animals fed a high fat diet (HFD). VLDL, very low density lipoprotein; HDL, high density lipoprotein; LDL, low density lipoprotein. (w=10 per 
group).
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To determine the effect of IL-18 on HFD-induced insulin resistance, an insulin toler­
ance test was performed. Whereas HFD-feeding led to the development of insulin 
resistance in wild-type animals compared to animals fed the LFD (data not shown), 
depletion of IL-18 aggravated the development of insulin resistance after the HFD 
intervention (Figure 2H). To counteract the absence of IL-18, we treated IL-18-/- 
animals with a single dose of PBS or recombinant IL-18 (10^g/ml) 24 hours prior 
to short term exposure to insulin. Interestingly, pre-treatment with IL-18 led to an 
enhancement of insulin-induced hepatic pAKT levels as compared to IL-18-/- ani­
mals pre-treated with PBS only (Figure 2I), which suggest a direct effect of IL-18 on 
hepatic insulin sensitivity.
Figure 2 Absence of IL-18 leads to insulin resistance in animals with diet-induced obesity. A. Plasma 
levels of IL-18 correlates positively with body weight (grams) in wild-type mice. B. Body weight of 
wild-type and IL-18-/- mice fed a high fat diet (HFD) or a low fat diet (LFD) for 16 weeks («=10 per 
group). C. Plasma levels of insulin, leptin (D), adiponectin (E), glucose (F), cholesterol and triglycerides 
(G) in wild-type and IL-18-/- mice fed a HFD or a low fat diet (LFD) for 16 weeks («=10 per group). H. 
Insulin tolerance test in wild-type and IL-18-/- animals fed a HFD («=5 per group).
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I. Western blot analysis of phosphorylated AKT and total AKT levels after insulin (0.0225U/mouse) 
treatment for 10 minutes («=3 per group). Data are presented as means ± SEM. Asterisks represents 
statistically significant differences between both genotypes within the same dietary intervention group. * 
=P-value<0.05, ** = P-value<0.01.
Inasmuch IL-18 has been shown to affect food intake (9;10), we studied gene expres­
sion levels of hypothalamic neuropeptides that regulate feeding behaviour. Interest­
ingly, although food intake levels were higher in LFD-fed IL-18-/- animals, HFD- 
feeding did not result in significant changes in food intake between wild-type and 
IL-18-/- mice (Figure 3A) suggesting that IL-18-/- animals do not overeat the HFD. 
Our results correspond with earlier work (10) and imply that IL-18 is involved in 
determining macronutrient preference. Hypothalamic gene expression levels of the 
orexigenic neuropeptides neuropeptide Y (NPY) and agouti-related peptide (AGRP) 
were significantly increased in HFD-fed IL-18-/- animal (Figure 3B). In contrast, 
hypocretin gene expression levels were 2 times lower in IL-18-/- mice fed a LFD 
compared to wild-type control animals (Figure 3B). Anorexigenic neuropeptides proo­
piomelanocortin (POMC) and cocaine- and amphetamine regulated transcript (CART) 
did not show any differences in gene expression between wild-type and IL-18-/- ani­
mals fed a LFD or HFD (Figure 3C).
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Figure 3 Role of IL-18 in controlling hypothalamic neuropeptide expression levels. A. Food intake 
(kcal/day) of wild-type and IL-18-/- animals fed a HFD or a LFD for 16 weeks (;;=10 per group). B.
Gene expression levels of the orexigenic neuropeptide genes NPY, AGRP and hypocretin in the hypo­
thalamus of wild-type and IL-18-/- animals fed a HFD or a LFD for 16 weeks (;;=10 per group). C. Gene 
expression levels of the anorexigenic neuropeptide genes POMC and CART in the hypothalamus of 
wild-type and IL-18-/- animals fed a HFD or a LFD for 16 weeks (;;=10 per group). Data are presented as 
means ± SEM. Asterisks represents statistically significant differences between both genotypes within the 
same dietary intervention group. * = P-value<0.05, ** = P-value<0.01.
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Liver and adipose tissue-specific effects in IL-18-/- animals fed  a HFD 
Since IL-18 is predominantly expressed in liver and adipose tissue, adipose- and liver- 
specific effects in IL-18-/- animals during the development of high-fat diet induced 
obesity were analyzed. First, we examined changes in hepatic morphology, triglyc­
eride storage and gene expression after the diet intervention in wild-type and IL-18- 
/- animals. Liver morphology, as assessed by HE-staining, revealed a similar degree 
of hepatic steatosis within the same dietary intervention groups (Figure 4A) that was 
confirmed by quantification of the hepatic triglyceride levels in wild-type and IL-18-/- 
mice (Figure 4B). However, plasma alanine transaminase (ALT) showed a significant
2-fold elevation in animals lacking IL-18 fed the HFD compared to the wild-type 
controls (Figure 4C), suggestive of an increase in liver damage. Noticeably, although 
HFD significantly induced gene expression levels of multiple liver injury markers 
including tissue inhibitors of metalloproteinase (TIMP)-1, matrix metalloproteinase 
(MMP)-12 and a-smooth muscle actin (SMA), no differences were observed between 
wild-type and IL-18-/- fed the HFD (data not shown).
Figure 4 Liver specific effects of IL-18 in diet-induced obesity. A. Representative HE staining of liver 
tissue from wild-type and IL-18-/- animals fed a HFD or a LFD for 16 weeks. B. Intra-hepatic triglyc­
eride levels of wild-type and IL-18-/- animals fed a HFD or a LFD for 16 weeks («=10 per group). C. 
Plasma ALT levels in wild-type and IL-18-/- animals fed a HFD or a low fat diet (LFD) for 16 weeks 
(«=10 per group). D. Gene expression levels of the lipogenic genes SCD-1, SPOT14, MOD1 and FAS in 
the liver of wild-type and IL-18-/- animals fed a HFD or a LFD for 16 weeks («=10 per group).Data are 
presented as means ± SEM. Asterisks represents statistically significant differences between both geno­
types within the same dietary intervention group. * = P-value<0.05.
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Since increased levels of hepatic lipogenesis may contribute to the elevated plasma 
VLDL-TG levels observed in IL-18-/- animals (19), we studied gene expression levels 
of several lipogenic markers in liver. As shown in figure 4D, gene expression levels 
of stearoyl-Coenzyme A desaturase (SCD)-1 and mosaic death (MOD)-1 were not 
significantly different between wild-type and IL-18-/- animals fed either the LFD or 
HFD. SPOT14 was 3.5 times higher expressed in IL-18-/- mice fed a LFD as com­
pared to the wild-type controls, whereas after HFD feeding fatty acid synthase (FAS) 
showed a significant decrease in IL-18-/- mice compared to their wild-type control.
The HFD intervention did not resulted in differences in adipose tissue mass (data not 
shown) or adipocyte cell size between wild-type and IL-18-/- animals (Figure 5A).
Inasmuch insulin resistance is partly induced by the development of adipose tissue 
inflammation characterized by the influx of macrophages (20), qPCR and immunohis- 
tochemical analysis of the white adipose tissue was performed. Despite an impairment 
in insulin sensitivity (Figure 2I), analysis of transcriptional macrophage markers (Fig­
ure 5C) and immunohistochemical staining using an antibody against F4/80+ (Figure 
5B), revealed a significant reduction in macrophages present in white adipose tissue of 
HFD-fed IL-18-/- animals. The chemokine monocyte chemoattractant protein (MCP)- 
1 plays an essential role in attracting the macrophages into the tissue. In line with the 
reduction in macrophage influx into the adipose tissue, adipose tissue levels of MCP-1 
were significantly reduced in IL-18-/- animals compared to wild-type animals fed the
0  HFD (Figure 5D). 0
Despite a reduction in macrophage content of the adipose tissue, gene expression lev­
els of TNFa were not lower in adipose tissue of HFD-fed IL-18-/- animals. However, 
interleukin (IL)-6 expression levels were increased and levels of the anti-inflammato­
ry protein IL-1 receptor antagonist (IL-1Ra) were reduced in adipose tissue of IL-18- 
/- animals compared to the wild-type controls after 16 weeks of HFD feeding (Figure 
5E).
Discussion
The main finding of this study is that IL-18 controls insulin sensitivity independently 
of the development of obesity, hepatic steatosis or macrophage influx after 16 weeks 
of HFD feeding. Moreover, IL-18 appears to be required for effective hepatic insulin 
signaling as treatment with recombinant IL-18 improved insulin-induced phosphory­
lation of AKT in vivo.
Our results appear to contradict with previous studies showing that obesity results in 
an elevated state of inflammation characterized by an increased activity of numerous 
inflammatory cytokines including TNFa, IL-6 and IL-18 contributing to the develop­
ment of insulin resistance (21). Our findings support the hypothesis that pro-inflam­
matory cytokines do not unequivocally induce insulin resistance exemplified by the
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Figure 5 White adipose tissue specific effects (if IL-18 in diet-induced obesity. A. Representative HE 
staining of white adipose tissue of wild-type and IL-18-/- mice fed a HFD or a LFD for 16 weeks. B. 
Representative immunohistochemical staining with anti-F4/80+ of white adipose tissue of a wild-type 
and IL-18-/- mouse fed a HFD for 16 weeks. C. Gene expression levels of the macrophage markers 
F4/80+ and CD68 in white adipose tissue of wild-type and IL-18-/- animals fed a HFD or a LFD for 16 
weeks («=10 per group). D. Adipose tissue levels of MCP-1 wild-type and IL-18-/- animals fed a HFD 
or a LFD for 16 weeks («=10 per group). E Gene expression levels of the pro-inflammatory cytokines 
TNF-a and IL-6 and the anti-inflammatory cytokine IL-1Ra in white adipose tissue of wild-type and IL- 
18-/- animals fed a HFD or a LFD for 16 weeks («=10 per group).Data are presented as means ± SEM. 
Asterisks represents statistically significant differences between both genotypes within the same dietary 
intervention group. * = P-value<0.05.
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protective role of IL-18 in the development of high fat diet induced insulin resistance. 
Several pro-inflammatory cytokines, including IL-1p, have been shown to negatively 
interfere with insulin signaling pathways. In vitro, cytokines can inhibit phosphory­
lation of insulin receptor substrates ultimately leading to insulin resistance and the 
development of Type 2 diabetes mellitus (22;23). In vivo, plasma concentrations of 
cytokines are often positively correlating with the severity of obesity or presence of 
insulin resistance (24). Recently published studies have suggested that members of 
the IL-1 family of cytokines including IL-18 contribute to the development of insulin 
resistance (25;26). Our data revealed high steady-state gene expression and protein 
levels of IL-18 in liver and white adipose tissue. In line with its high basal expression 
levels, absence of IL-18 in mice fed a HFD led to disturbances in energy homeostasis 
and reduced insulin sensitivity exemplified by a lower plasma adiponectin concentra­
tion and increased TG levels. Additionally, HFD feeding enhanced plasma ALT liver 
enzymes in the absence of IL-18. Whereas acute IL-18 treatment has been reported to 
induce liver failure and injury (27), other studies have shown a protective function of 
IL-18 (28). Our data provides additional indications for a protective role of IL-18 in 
liver during chronic overfeeding.
In contrast to other members of the IL-1 family of cytokines with low or absent basal 
expression levels, the constitutive expression is suggestive of a more endocrine func­
tion of IL-18. Hypothetically, IL-18 plays an important role in controlling insulin 
{g} signaling pathways supported by the impaired insulin sensitivity observed in IL-18-/-
mice and improvement of insulin sensitivity after treatment with recombinant IL-18. 
The precise mechanisms or signaling pathways by which IL-18 may control insulin 
signaling are currently unknown and deserve further study.
Paradoxically, observations in humans have shown that IL-18 concentrations are 
increased in individuals with type 2 diabetes mellitus and obesity and infusion of 
glucose leads to an acute increase in serum IL-18 concentrations (15;29). Only re­
cently, it has been reported that in vitro cultured adipocytes treated with recombinant 
IL-18 have lower adiponectin secretion as compared to untreated cells (30). These 
results imply that IL-18 induces the development of insulin resistance. However, it 
has also been shown that in-vitro treatment of adipocytes with IL-18 enhances insulin­
dependent glucose uptake (31). It can be envisioned that during the development of 
obesity a reduced sensitivity towards IL-18 is developed similar to insulin or leptin 
resistance. Subsequently, IL-18 resistance is compensated by a higher production of 
IL-18 to overcome the resistance. Additionally, the development of obesity induces 
down regulation of IL-18 receptor complexes (9;16) or may result in up regulation 
of IL-18bp thereby leading to blockage of IL-18 signaling pathways and resulting in 
IL-18 resistance. Although increased levels of IL-18 have been frequently linked to 
the development of obesity and insulin resistance, mechanistic studies to decipher 
the regulation of IL-18 are scarce. Our data suggest that IL-18 protects against the 
development of obesity-induced insulin resistance and contributes to effective hepatic
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insulin signaling. These effects may partially be effectuated by regulating adiponectin 
secretion, since HFD-fed IL-18-/- animals suffer from lower circulating concentra­
tions of this insulin-sensitizing protein (32).
Surprisingly, absence of IL-18 prevented the HFD-induced influx of macrophages 
into the adipose tissue as both immunohistochemical analysis and qPCR revealed a 
reduced number of macrophages present in adipose tissue of IL-18-/- animals fed the 
HFD as compared to wild-type mice. IL-18 has been shown to regulate MCP-1 gene 
expression and protein levels (33) and we observed lower adipose tissue concentra­
tions of MCP-1 in IL-18-/- animals. Inasmuch macrophage influx into the inflam­
matory adipose tissue has been clearly linked to the development of systemic insulin 
resistance, the absence of IL-18 appears to overrule these effects in determining sys­
temic insulin sensitivity. In contrast, the absence of IL-18 led to enhanced expression 
of IL-6 and reduced expression of IL-1Ra in adipose tissue. Therefore, IL-18 may be 
involved in limiting pro-inflammatory activity in adipose tissue during chronic over­
feeding and thereby reduce the development of systemic insulin resistance.
Besides its role in insulin signaling, IL-18 has been shown to control food intake that 
may involve controlling hypothalamic neuropeptides levels, which regulates feeding 
behaviour. Although IL18-/- animals overate the LFD, HFD-fed IL-18-/- mice did not 
display significant differences in food intake compared to wild-type mice. This sug­
gests that IL-18 controls macronutrient-specific food intake other than that of fat. One 
potential candidate neuropeptide to be involved in IL-18-controlled feeding behaviour 
is orexin/hypocretin, as hypothalamic gene expression levels were significantly lower 
in LFD fed IL-18-/- animals. Although acute orexin treatment propagates appetite, 
chronic activation of orexin signaling pathways has been shown to promote energy 
expenditure and reducing consumption (34). By regulating hypothalamic levels of 
orexin, IL-18 may reduce food intake. Overall, the relatively small changes observed 
in hypothalamic neuropeptide levels of NPY and AGRP and unchanged levels of 
POMC and CART between wild-type and IL-18-/- animals do not support a substan­
tial role of IL-18 in controlling neuropeptide gene expression levels.
In contrast to previous reports, the HFD intervention did not lead to changes in 
bodyweight gain in IL-18-/- animals compared to wild-type mice (10). The age of the 
animals at the start of our study (3 months) or differences in diet composition may 
explain the lack of bodyweight differences between both genotypes.
In conclusion, our results suggest an important and direct role of IL-18 in control­
ling insulin sensitivity independently of the development of obesity, liver steatosis 
and macrophage influx into the adipose tissue. Although our results concerning food 
intake and bodyweight development partly differ from earlier studies, our data dem­
onstrates that IL-18 protects against the development of insulin resistance due to HFD 
feeding.
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Abstract
Obesity-induced inflammation originating from expanding adipose tissue interferes 
with insulin sensitivity. Important metabolic effects have been recently attributed to 
IL-ip and IL-18, two members of the IL-1 family of cytokines. Processing of IL-ip 
and IL-18 requires cleavage by caspase-1, a cysteine protease regulated by a protein 
complex called the inflammasome. We demonstrate that the inflammasome/caspase-1 
governs adipocyte differentiation and insulin sensitivity. Caspase-1 is upregulated 
during adipocyte differentiation and directs adipocytes towards a more insulin-resis­
tant phenotype. Treatment of differentiating adipocytes with recombinant IL-ip and 
IL-18, or blocking their effects by inhibitors, reveals that the effects of caspase-1 on 
adipocyte differentiation are largely conveyed by IL-1p. Caspase-1 and IL-1p activ­
ity in adipose tissue is increased both in diet- and genetically-induced obese animal 
models. Conversely, mice deficient in caspase-1 are more insulin sensitive as com­
pared to wild-type animals. In addition, differentiation of pre-adipocytes isolated from 
caspase-1-/- or NLRP3-/- mice resulted in more metabolically active fat cells. In vivo, 
treatment of obese mice with a caspase-1 inhibitor significantly increases their insulin 
sensitivity. Indirect calorimetry analysis revealed higher fat oxidation rates in cas- 
pase-1-/- animals. In conclusion, the inflammasome is an important regulator of adi­
pocyte function and insulin sensitivity, and caspase-1 inhibition may represent a novel 
^  therapeutic target in clinical conditions associated with obesity and insulin resistance. ^
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Introduction
The prevalence of obesity, an important risk factor for type 2 diabetes, hypertension 
and hyperlipidemia, has reached epidemic proportions worldwide (1). Initially viewed 
as a tissue that merely stores energy, recently it has become evident that adipose tissue 
also releases hormone-like mediators named adipokines, and exerts effects reminis­
cent of an endocrine organ (2). During the development of obesity, the morphology 
and functional properties of adipose tissue change dramatically. In addition to adipo­
cyte hypertrophy due to storage of increasing amounts of lipids, adipose tissue turns 
into an inflamed tissue characterized by macrophage infiltration and altered secretion 
of adipokines (3;4). Whereas the secretion of pro-inflammatory cytokines is enhanced, 
the production of insulin-sensitizing adipokines such as adiponectin is reduced. To 
date, many pro-inflammatory cytokines have been linked to the development of insu­
lin resistance and type 2 diabetes including TNFa and IL-6 (3;5). More recently, inter­
est has grown into the role of the IL-1 family of cytokines and its prominent members 
IL-1p and IL-18. IL-ip is a pro-inflammatory cytokine with a role in the pathogenesis 
of type 1 diabetes through its toxic effects on beta-cells of the pancreas (6). It has 
been shown that treatment of type 2 diabetic patients with IL-IRa, an antagonist of 
IL-1 signaling, improves glycemic control and beta-cell function (7). Recent work has 
also revealed an important role of IL-18 in modulation of energy balance and insulin 
sensitivity (8).
In order to be activated, IL-1p and IL-18 have to be processed from inactive pre­
cursors by an intracellular cysteine protease called caspase-1 (9;10). Activation of 
caspase-1 itself takes place by conformational changes in a protein platform called the 
inflammasome, consisting of caspase-1 and proteins of the NACHT-LRR (NLR) fam­
ily including NLRP3 and ASC, leading to the release of the active enzyme (11). The 
inflammasome is activated in response to so-called danger-associated molecular pat­
terns, which can be elicited either by microbial components (e.g. peptidoglycan) or by 
endogenous danger signals (e.g. uric acid, ATP) (9). Because of the metabolic effects 
described for IL-1p and IL-18, and due to the crucial role of caspase-1 for the activa­
tion of these cytokines, we hypothesized that inflammasome-dependent activation of 
caspase-1 plays an important role in the metabolic function of the adipose tissue. This 
hypothesis was tested using a number of in vitro and in vivo approaches.
Methods
Animal studies
IL -1p-/- mice were a gift from J.Mudgett, Merck Research Laboratories, Rah­
way, USA. Caspase-1-/- mice were a kind gift from Prof. Dinarello, Department of 
Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
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NLRP3-/- mice were generated as described previously (12). All mice were back- 
crossed ten generations to C57B1/6 mice, and age-matched wild-type C57B1/6J mice 
were used as controls throughout the different experiments. Db/Db and Ob/Ob mice in 
a C57Bl/6 background were obtained from the Jackson Laboratories.
Diet intervention
Wild-type C57Bl/6J male mice received a low fat diet (LFD) or a high fat diet 
(HFD) for 16 weeks, providing 10 or 45% energy percent in the form of triglycerides 
(D12450B or D12451, Research Diets, New Brunswick, USA). In the last week of 
dietary intervention, some animals were injected intraperitoneally with clodronate 
liposomes. The liposomes were prepared as described previously (13) using phos­
phatidylcholine (Lipoid GmbH, Ludwigshafen,Germany) and cholesterol (Sigma 
Chem.Co. USA). Cl2MDP (or clodronate) was a gift of Roche Diagnostics GmbH,
Mannheim, Germany. Caspase-1-/- and wild-type mice were fed the similar LFD or 
HFD during 10 weeks. Insulin-tolerance tests were performed as previously described 
(14). Briefly, animals were fasted for 4 hours and insulin was given intraperitoneally 
at a dose of 0.75 U/kg bodyweight. Blood samples were taken before and 30, 60, 90 
or 120 minutes after insulin administration. Plasma levels of insulin and adiponectin 
secretion in cell culture medium were measured using ELISA (LINCO Research Inc.,
St. Charles, MO, USA ).
#  #  
Euglycemic hyperinsulinemic clamp analysis
Euglycemic hyperinsulinemic clamps were performed as described earlier (15). Brief­
ly, after an overnight fast, animals were anesthetized with 6.25mg/kg acepromazine 
(Sanofi Santé Nutrition Animale, Libourne Cedex, France), 6.25mg/kg midazolam 
(Roche, Mijdrecht, The Netherlands) and 312.5^g/kg fentanyl (Janssen-Cilag, Til­
burg, The Netherlands) and an infusion needle was placed in the tail vein. A bolus of 
insulin (3mU) was given, and a hyperinsulinemic euglycemic clamp was started with 
a continuous infusion of insulin (5mU/h) and a variable infusion of 12.5% D-glucose 
(in PBS) to maintain blood glucose level at euglycemic levels. Blood samples were 
taken every 5 to 10 minutes from the tip of the tail to monitor plasma glucose levels 
(AccuCheck). 70, 80 and 90 minutes after the start of the clamp, blood samples (70 
^l) were taken for determination of plasma glucose, insulin and FFA concentrations.
Plasma glucose, insulin and FFA levels were determined using commercially available 
kits (Instruchemie, crystal chem. Inc. and Wako Pure Chemical Industries respec­
tively).
Indirect calorimetry
Animals were housed in a controlled environment (23°C, 55% humidity) under a 12h 
light-dark cycle (07:00-19:00). Food and tap water was available ad libitum during 
the whole experiment. Mice were fed normal laboratory chow (RM3, Special Diet
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Services, UK) throughout the experiment. Indirect calorimetry was performed for a 
period of 60 hours (Comprehensive Laboratory Animal Monitoring System, Colum­
bus Instruments, Columbus Ohio, US). An acclimatization period of 24 hours prior 
to the start of the experiment was included. Food intake, oxygen consumption (VO2) 
and carbon dioxide production rates (VCO2) were measured at intervals of 7 min­
utes. Respiratory exchange ratio (RER) was calculated as the ratio between VCO2 
and VO2. Absolute oxidation rates for fat and carbohydrate were calculated accord­
ing to Peronnet and Massicotte (16). Fecal output was determined at the end of the 
experiment. Fat content of the faeces was analyzed using the acid steatocrit method as 
described previously (17).
All the animal studies were approved by the animal experimentation committee of 
Wageningen University, Leiden University Medical Center, Radboud University Ni­
jmegen Medical Centre, the Netherlands, the University of Illinois at Chicago, and St 
Jude Children’s Research Hospital, Memphis, Tennessee, United States of America.
IL-lfi and IL-18 measurements
IL-1P concentrations in white adipose tissue or cell culture medium were determined 
using a specific radioimmunoassay as previously described (18). IL-18 concentra­
tions in white adipose tissue were measured using a commercially available ELISA 
(Invitrogen). Bio-active IL-1 was measured using the murine thymoma cell line EL4/ 
NOB 1 that produces IL-2 in response to bioactive IL-1 (19). IL-2 levels were subse­
quently measured by ELISA (R&D).
Cell culture
Mouse 3T3-L1 cells and human SGBS cells were cultured and differentiated towards 
adipocytes as described previously (20;21). Oil red O staining of cells was performed 
using a standard protocol. Oil red O staining was quantified by using total photo­
graphic images of the staining which were divided in multiple fields and the number 
of positive cells per field were counted. 2 hours before insulin treatment of cells to 
assess insulin sensitivity, cells were cultured in serum-free medium.
Caspase-1 activity assay
Caspase-1 activity was measured in isolated adipocytes and total white adipose tissue 
using a fluorometric assay (Biovision, California, USA) following manufacturer’s in­
structions with slight modifications. Briefly, total adipose tissue or isolated adipocytes 
were homogenized in lysis buffer and caspase-1 activity was measured by the addition 
of the caspase-1 specific peptide YVAD-AFC. Cleavage of the substrate by caspase-1 
releases AFC that can subsequently be quantified using a fluorimeter. By compar­
ing the fluorescence of AFC from an untreated sample with a sample treated with the 
specific caspase-1 inhibitor Pralnacasan, caspase-1 activity can be determined.
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Isolation and culturing o f primary adipocytes and white adipose tissue 
explants
Freshly isolated mouse epididymal adipose tissue was used for the isolation of adipo­
cytes and stromal vascular cells. Minced adipose tissue was digested using collage­
nase (Sigma-Aldrich) at a concentration of 5mg/ml dissolved in Dulbecco’s Modified 
Eagle’s Medium (DMEM). Tissues were incubated for 45 minutes at 37°C and were 
subsequently filtered through a 250^M nylon mesh filter. After centrifugation, the 
floating cells were collected as adipocytes and the pelleted cells as stromal vascu­
lar cells. Stromal vascular cells were cultured and differentiated towards adipocytes 
using standard protocols. A similar protocol was applied for the isolation of human 
adipocytes and stromal vascular cells. For culturing of white adipose tissue explants, 
freshly isolated fat was minced and directly brought into culture using Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% fetal calf serum. Human adipose 
tissue was obtained from patients undergoing reconstructive abdominal surgery after 
written informed consent.
Histology
Morphometry of individual fat cells was assessed using digital image analysis. Micro­
scopic images were digitized in 24 bit RGB (specimen level pixel size 1.28x1.28um2). 
Recognition of fat cells was initially performed by applying a region growing algo­
rithm on manually indicated seed points, and minimum Feret diameter were calculat­
ed. Differences between groups were studied using one-way univariate Anova. Tukey 
HSD post hoc testing was applied for multiple comparison testing.
RNA and DNA isolation and qPCR analysis
RNA from animal tissues was isolated using Trizol Reagent (Invitrogen) following 
manufacturer’s instructions. RNA was reverse transcribed using the iScript cDNA 
Synthesis Kit (Bio-Rad Laboratories BV, Veenendaal, The Netherlands). Real-Time 
PCR was done with a Power Sybr Green PCR master mix (Applied Biosystems) us­
ing a 7300 Real-Time PCR System (Applied Biosystems). Melt curve analysis was 
included to assure a single PCR product was formed. Values were corrected using 
the housekeeping gene 36B4 or beta2-microglobulin (ß2M). DNA was isolated from 
adipose tissue and mitochondrial DNA was quantified using primers to detect mito­
chondrial D-loop. Results were corrected for the total amount of DNA within samples 
using primer sequences to detect LPL. Primer sequences are available upon request.
Immunoblot analysis
Immunoblotting was carried out using an ECL system (Amersham Biosciences. 
Diegem, Belgium). Equal amounts of cell lysates as determined by Bio-Rad Protein 
Assay reagent (Bio-Rad Laboratories BV) were resolved by SDS/PAGE on a 12% 
polyacrylamide gel. Proteins were transferred using the iBLOT system (Invitrogen)
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following manufacturer’s instructions. The pAKT and AKT antibody (R&D Systems), 
caspase-1 antibody (Santa Cruz) and actin antibody (Sigma-Aldrich) were used at a 
dilution of 1:1000 and the membranes were incubated overnight at 4°C. The second­
ary antibodies were used at a dilution of 1:5000. All incubations were performed in 1x 
Tris-buffered saline, pH 7.5, with 0.1% Tween 20 and 5% dry milk. In the final wash­
ings, dry milk was removed from the solution.
Statistical analysis
Statistical significant differences were calculated using a Student’s T-test. The cut-off 
for statistical significance was set at a P-value of 0.05 or below.
Results
Expression and function o f  caspase-1 in adipocytes 
To explore the role of the caspase-1 in adipocyte function, we first assessed the 
expression of caspase-1 during in vitro adipogenesis. Interestingly, differentiation of 
mouse 3T3-L1, human SGBS (Simpson-Golabi-Behmel Syndrome) and human pri­
mary adipocytes was associated with a significant increase in expression of caspase-1 
in parallel with the adipogenic transcription factor PPARy (Figure 1A). IL-1P gene 
expression levels during adipocyte differentiation displayed a more variable pattern 
(Figure 1B).
Caspase-1 protein levels were significantly higher in differentiated cells (Figure 1B) 
and caspase-1 activity levels were increased in fully differentiated adipocytes vs. pre­
adipocytes (Figure 1C). In order to assess whether caspase-1 influences adipocyte dif­
ferentiation, we blocked caspase-1 with the caspase-1 inhibitor Pralnacasan (22). This 
inhibitor more effectively reduced caspase-1 activity compared to the frequently used 
caspase-1 inhibitor Yvad as determined by an in vitro caspase-1 activity assay (supple­
ment Figure 1A). Caspase-1 blockade improved expression levels of adipogenic 
marker genes including PPARy, adiponectin and Glut4 gene expression (Figure 1D). 
Importantly, caspase-1 blockage in human adipose tissue using Pralnacasan reduced 
the secretion of IL-1P (Supplement Figure 1B). In addition to caspase-1 inhibition 
using an inhibitor, caspase-1 function was silenced using siRNA. Treatment of cells 
with siRNA targeted to caspase-1, led to a significant reduction in caspase-1 gene 
expression (relative gene expression levels: 1.00 ± 0.04 vs. 0.16 ± 0.01). In addi­
tion to mRNA levels, caspase-1 protein levels were decreased in cells transected with 
siRNA targeted against caspase-1 (Supplemental Figure 1G). Basal secretion levels 
of bio-active IL-1, as measured by using the murine thymoma cell line EL4/NOB 1 
that produces IL-2 in response to bioactive IL-1, were unchanged in cells depleted of 
caspase-1. Probably, levels of IL-1 produced by the cells under normal conditions are 
relative low and the secreted IL-1 may directly bind to the cell membrane.
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Figure 1 Caspase-1 is activated during adipogenesis in-vitro and is present in adipocytes of mouse 
and human white adipose tissue in-vivo. A, quantitative PCR analysis of differentiating human or 
mouse adipocytes. Representative results are shown of n=3 experiments. B, Western blot analysis of 
caspase-1 protein levels in differentiating mouse 3T3-L1 adipocytes and human SGBS adipocytes. Pro­
tein marker is given in kDalton. C, caspase-1 activity in pre-adipocytes (Pre) and adipocytes at day 8 of 
differentiation (Mature). D, quantitative PCR analysis of SGBS adipocytes differentiated for 12 days in 
the presence of the specific caspase-1 inhibitor Pralnacasan at 100^M. E, quantitative PCR analysis and 
representative oil red O staining of SGBS adipocytes differentiated for 7 days in the presence of recombi­
nant IL-1P (10ng/ml), IL-1ra (5p.g/ml), Anti-IL-1p antibody (5p.g/ml) or IL-18 (25ng/ml). F, Western blot 
analysis of caspase-1 in total human and mouse white adipose tissue. Protein marker is given in kDalton.
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G, caspase-1 expression in the stromal vascular cells and mature adipocytes fractionated from total white 
adipose tissue. Data are presented as mean ± SEM. Asteriks depict statistically significant differences
between control and experimental groups. * P-value< 0.05, ** P-value< 0.005.
Gene expression analysis of PPARy and adiponectin revealed that knockdown of 
caspase-1 led to a significant increase in expression of 4.01 +/-1.12 fold of PPARy 
and 1.88 +/-0.19 fold of adiponectin compared to mock treated cells (data not shown). 
Silencing of caspase-1 in SGBS adipocytes improved insulin sensitivity as determined 
by pAKT/AKT ratios after short term insulin treatment (mock vs. siRNA Caspase-1: 
0.95 ± 0.14 vs. 2.10 ± 0.16. ^-value < 0.005). Finally, treatment of caspase-1-depleted 
cells with recombinant IL-1p led to a reduction in pAKT levels (Supplemental Figure 
1H).
To examine whether the effects of caspase-1 may be mediated by processing of IL- 
1p or IL-18, we studied the effects of these cytokines on adipocyte differentiation. 
Whereas recombinant IL-ip blocked adipogenesis, as assessed by oil Red O staining, 
recombinant IL-18 had no affect (Figure 1E). Importantly, treatment of differentiat­
ing adipocytes with recombinant IL-1 receptor antagonist to block endogenous IL-1 
signaling mirrored the effects of caspase-1 inhibition (Figure 1E). Moreover, specific 
blockage of IL-1p-signaling pathways in differentiating SGBS adipocytes using an 
anti-IL-1p antibody also resulted in an improvement of adipogenesis (Figure 1E).
{g} Thus, effects of caspase-1 on adipogenesis are likely conveyed via endogenous IL-1p.
In order to confirm that caspase-1 has a functional role in vivo, caspase-1 protein 
levels were assessed in human and mouse white adipose tissue. Both human and 
mouse white adipose tissue displayed total (45kDA) and activated caspase-1 isoforms 
(34kDA) (Figure 1F). Fractioning of total human and mouse white adipose tissue into 
mature adipocytes and stromal vascular cells revealed that caspase-1 is expressed in 
both cell populations (Figure 1G). Taken together, our data show that caspase-1 is up 
regulated during in-vitro adipocyte differentiation and is present in mouse and human 
white adipose tissue in vivo.
Caspase-1 function in experimental models o f obesity
To determine caspase-1 function in adipose tissue during diet-induced obesity,
C57Bl/6 mice were fed a high fat diet (HFD) for 16 weeks. HFD feeding caused obe­
sity as illustrated by increased bodyweight (Figure 2A) and epididymal adipose tissue 
mass (Figure 2B). Importantly, after prolonged HFD, adipose tissue expression of 
caspase-1 was markedly increased (Figure 2C). A similar increase in caspase-1 mRNA 
and protein was observed in obese db/db mice and Ob/Ob mice (Figure 2D). Protein 
levels of the active isoform of caspase-1 (34kDA) were increased in white adipose 
tissue of obese animals (Figure 2E). In line with elevated gene expression and protein 
levels, caspase-1 activity was also increased in total white adipose tissue of HFD and 
Ob/Ob animals compared to lean mice (Figure 2F). The increased caspase-1 activity
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Figure 2 Caspase-1 is activated in adipocytes of diet-and genetically induced obese animals. A,
Bodyweight development in male wild-type C57/bl6 animals (2 months of age at start of intervention) 
fed either a low or high fat diet (n=10 per group). B, % of epidydimal white adipose tissue after 17 weeks 
of high fat diet feeding. C, quantitative PCR analysis of caspase-1 gene expression in white adipose tis­
sue of C57/Bl6 animals during dietary intervention (n=6 per group). D, white adipose tissue of wild-type, 
Db/Db and Ob/Ob animals (4 months of age) is analyzed for caspase-1 gene expression levels using 
quantitative PCR analysis (n=5 per group). E, Western blot analysis of caspase-1 in white adipose tissue 
of wild-type and Db/Db animals. Actin levels are shown as loading control. F, caspase-1 activity levels 
measured in total white adipose tissue of LFD or HFD fed animals and Ob/Ob mice. G,IL-1p and IL-18 
concentrations (pg/ml) measured in total white adipose tissue of wild-type animals fed a LFD or HFD 
and IL-1p concentrations (pg/ml) present in white adipose tissue of wild-type and Db/Db mice (n=5 per 
group). H, Gene expression levels of CD68 and caspase-1 in white adipose tissue of wild-type animals 
(2 months of age at start of intervention) fed a low fat diet or a high fat diet for 16 weeks and a high fat 
diet followed by intraperitoneal injection with clodronate liposomes. Data are presented as mean ± sem. 
Asterisks depict statistically significant difference between control and experimental groups. * P-val- 
ue<0.05, ** P-value<0.005, *** P-value<0.001.
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was accompanied by significantly elevated IL-1p and IL-18 protein levels in adipose 
tissue of diet- and genetically-induced obese mice (Figure 2G). Although IL-1p and 
IL-18 protein levels were elevated, we were unable to detect any significant changes 
in gene expression of IL-1p and IL-18 in total adipose tissue of obese vs. lean ani­
mals.
Previous studies have shown that obesity and adipocyte hypertrophy result in an in­
flux of macrophages into adipose tissue (4;23), and we assessed whether the increased 
expression of caspase-1 in adipose tissue was due to an increase in the infiltrating 
macrophages or the adipocytes themselves. Partial depletion of macrophages from 
adipose tissue of animals fed a HFD decreased the expression of the macrophage 
marker CD68, yet did not alter the expression of caspase-1 (Figure 2H), suggest­
ing that caspase-1 effects on adipose tissue are not only exerted through infiltrating 
macrophages. Together, these data show that both diet-and genetically induced obesity 
result in activation of caspase-1 and increased levels of IL-1p and IL-18 in adipose 
tissue.
Caspase-1 modulates adipocyte function
To assess in more detail the role of caspase-1 in adipocyte function, pre-adipocytes 
from caspase-1-deficient mice and wild-type mice were differentiated towards adipo­
cytes using a standard adipocyte differentiation protocol. In the absence of caspase-1, 
adipogenesis was enhanced, as illustrated by oil red O staining (Figure 3A) and 
increased gene expression levels of GLUT-4, adiponectin and PPARy (Figure 3B). 
Importantly, secretion of adiponectin, a key regulator of insulin sensitivity (24), was 
significantly elevated in caspase-1 deficient adipocytes (Figure 3C). Additionally, in­
sulin signaling in caspase-1-deficient adipocytes was ameliorated, as visualized by an 
increased phosphorylation of Akt (Figure 3D) (Relative pAKT/AKT ratio: wild-type 
10nm insulin vs. Caspase-1-/- 10nm insulin: 1 ± 0.53 vs. 3.09 ± 0.12, P-value<0.05 ; 
wild-type 100nm insulin vs. Caspase-1-/- 100nm insulin: 4.13 ± 1.33 vs. 8.85 ± 1.8, 
P-value<0.05). Importantly, in mature human adipocytes made insulin resistant by 
overnight treatment with 200nM of insulin, caspase-1 inhibition increased insulin 
action as determined by pAKT levels after 20 minutes of insulin treatment (50nM) 
(Figure 3E) (Relative pAKT/AKT ratio: Control vs. inhibitor: 1 ± 0.24 vs. 2.41 ±
0.15, P-value<0.01).
Because NLRP3 is an important component of the inflammasome involved in the 
activation of caspase-1 (9), we investigated whether absence of NLRP3 mimics the 
effects seen in caspase-1 deficient animals. Adipocyte differentiation of pre-adipo­
cytes isolated from NLRP3-deficient animals was similarly enhanced compared to 
caspase-1 deficient cells (Figure 3F and G). Finally, we tested insulin sensitivity of 
total white adipose in wild-type, caspase-1-/- and NLRP3-/- animals. As shown in 
figure 3H, the absence of caspase-1 and NLRP3 in white adipose tissue resulted in 
an increase in adipose tissue insulin sensitivity as determined by phosphorylation of
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AKT (Relative pAKT/AKT ratio: wild-type vs. Caspase-1-/- vs. NALP3-/- , 10nM 
insulin: 4.06 ± 0.54 vs. 11.20 ± 1.66 vs. 12.11 ± 2.19, .P-value<0.05, 100nm insulin: 
5.56 ± 0.43 vs. 14.47 ± 2.88 vs. 29.23 ± 7.28, .P-value<0.05) . In line with the rise in 
insulin sensitivity, IL-1P production of adipose tissue isolated from caspase-1-/- and 
NLRP3-/- animals was significantly reduced as compared to white adipose tissue from 
wild-type mice (Figure 3I). These data establish an important function of caspase-1 
and NLRP3 in adipocyte formation and insulin sensitivity.
Figure 3 Absence of caspase-1 and NLRP3 improves adipogenesis and insulin sensitivity in dif­
ferentiated adipocytes. A, Representative Oil red O staining pictures and quantification of wild-type and 
caspase-1-deficient pre-adipocytes differentiated towards adipocytes for 7 days. B, GLUT4, Adiponectin 
and PPARy gene expression levels as determined by quantitative real-time PCR in pre-adipocytes (Pre)
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or differentiated adipocytes (Induction) from wild-type or caspase-1 deficient animals. C, Adiponectin 
concentrations (pg/ml) measured in medium of pre-adipocytes (Pre) or adipocytes (Induction) differenti­
ated for 7 days from wild-type or caspase-1 deficient animals. D, Western blot analysis of phosphory- 
lated AKT and total AKT levels after insulin treatment for 20 minutes in adipocytes differentiated for 7 
days. E, Western blot analysis of phosphorylated AKT and total AKT levels after 20 minutes of insulin 
treatment in mature SGBS adipocytes pre-treated overnight with 200nM of insulin and/or the caspase-1 
inhibitor pralnacasan (100^M). F, Representative Oil red O staining pictures and quantification of wild­
type and NLRP3-deficient pre-adipocytes differentiated towards adipocytes for 7 days. G, GLUT4, Adi­
ponectin and PPARy gene expression levels in pre-adipocytes (Pre) or differentiated adipocytes (Induc­
tion) from wild-type or NALP3 deficient animals. H, Western blot analysis of phosphorylated AKT and 
total AKT levels in white adipose tissue explants from wild-type, caspase-1-/- and NLRP3-/- animals (2 
months of age) after 20 minutes of insulin treatment. I, IL-1P production of adipose tissue explants from 
wildtype, caspase-1-/- and NLRP3-/- animals after 24 hours of culturing. Data are presented as mean 
± sem. Asterisks depict statistically significant differences between control and experimental groups. * 
P-value< 0.05, ** P-value< 0.005.
Absence o f caspase-1 improves insulin sensitivity in vivo
To unveil the potential role of caspase-1 in vivo, adipose tissue function and morphol­
ogy was analyzed in caspase-1-deficient animals. The absence of caspase-1 led to a 
profound change in adipose tissue morphology (Figure 4A) with markedly smaller 
adipocytes (average adipocyte size: wild-type mice 966,8^M2, Caspase-1-/- mice 
629,16^M2, ^-value < 0.001) (Figure 4A). In addition, although total bodyweight 
was not different between both genotypes (Figure 4B), DEXA scan analysis of cas- 
pase-1-/- animals revealed a profound reduction in total fat mass (Figure 4B). On the 
other hand, bone mineral content was significantly elevated in caspase-1-/- animals 
compared to wildtype mice (Figure 4B).
In line with the beneficial change in adipose tissue morphology, gene expression 
analysis revealed elevated levels of PPARy, adiponectin and GLUT4, consistent with 
increased insulin sensitivity and improved glucose uptake in adipose tissue (Figure 
4C). In addition, adipose PGC1a and PGC1P gene expression levels were highly el­
evated in caspase-1 deficient animals (Figure 4C), implying an increase in mitochon­
drial activity and energy expenditure (25). Indeed, quantification of mitochondrial 
DNA content in WAT of wildtype and caspase-1-/- animals revealed a robust increase 
in mtDNA of white adipose tissue in the absence of caspase-1 (Figure 4D).
Finally, our in vitro observations showing enhanced insulin action in caspase-1 defi­
cient adipocytes were accompanied by an improvement in total insulin sensitivity in 
caspase-1 deficient animals, as illustrated by a decrease in basal plasma insulin levels 
and lower plasma glucose levels during insulin tolerance tests (Figure 4E and F). 
Assessment of whole body insulin resistance by euglycemic hyperinsulinemic clamp 
analysis revealed a significant improvement of insulin sensitivity in caspase-1-/- ani­
mals as compared to wild-type mice (Figure 4G, Supplement Figure 1E, Supplemen­
tary table 1).
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Figure 4 Caspase-1 contributes to adipose tissue formation and function in vivo. A, Representative 
HE-staining of white adipose tissue and quantification of adipocyte size. B, Total bodyweight, percentage 
of fat mass and bone mineral content of wild-type and capase-1-/- mice (6 months of age). C, gene ex­
pression analysis of total white adipose of wildtype and caspase-1 deficient mice using real-time quantita­
tive PCR techniques. D, mtDNA content of total white adipose tissue from wildtype and caspase-1-/- ani­
mals. E, Plasma insulin levels in non-fasted wild-type and caspase-1 deficient animals (n=9 per group).
F, Insulin tolerance test in wild-type and caspase-1-deficient animals (n=9 per group). G, Assessment of 
whole body insulin resistance by euglycemic hyperinsulinemic clamp analysis in wild-type (n=17) and 
caspase-1-/- (n=18) animals at 1 year of age.
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Glucose infusion rates (GIR) during the euglycemic hyperinsulinemic clamp analysis are shown. H, 
Insulin tolerance test in wild-type and IL-1P-deficient animals (n=5 per group). I, Insulin tolerance test 
in wildtype and NALP3-deficient animals (n=5 per group). Data are presented as mean ± sem. Asterisks 
depict statistically significant differences between control and experimental groups.* P-value< 0.05, **P- 
value< 0.005, *** P-value< 0.001
Furthermore, both basal and hyperinsulinemic FFA concentrations were significantly 
lower in caspase1-/- mice compared to control mice (basal: 0.69 ± 0.06 vs.0.89 ±
0.04, P-value=0.001; hyperinsulinemic :0.30 ± 0.02 vs. 0.41 ± 0.04; P-value=0.01), 
consistent with a reduction in lipolytic activity and an increase in insulin sensitivity 
of white adipose tissue in the absence of caspase-1. Other basal plasma lipids includ­
ing triglycerides and cholesterol were not altered in caspase-1 deficient animals (data 
not shown). Since caspase-1 controls IL-1p activity, insulin tolerance was also ana­
lyzed in IL-1p-deficient animals. Insulin sensitivity was improved in IL-1p-deficient 
animals when compared to wild-type mice (Figure 4G). Finally, in line with the 
important role of NLRP3 in the activation of caspase-1, NLRP3-/- animals were more 
insulin sensitive compared to wild-type animals (Figure 4H). Noticeably, adipose tis­
sue morphology in IL-1 and NLRP3-deficient animals was unchanged. Nevertheless, 
mtDNA content tended to be higher in NLRP3-/- animals although differences were 
not statistically significant (supplement Figure 1D).
Caspase-1 inhibition during obesity improves insulin sensitivity 
The involvement of caspase-1 in the modulation of insulin resistance renders it an 
attractive therapeutic target in clinical conditions such as type 2 diabetes. In order to 
provide the proof-of-principle that caspase-1 inhibition can improve insulin sensitiv­
ity, ob/ob mice were treated with a chemical inhibitor of caspase-1 activity. Animals 
received orally 200mg/kg bodyweight caspase-1 inhibitor (Pralnacasan) or vehicle 
daily for two weeks. After two weeks of treatment, insulin tolerance tests were per­
formed. Animals treated with the caspase-1 inhibitor showed a robust improvement 
of insulin sensitivity as compared to animals receiving vehicle only (Figure 5A). The 
effectiveness of caspase-1 inhibition was analyzed by measuring IL-1p protein levels 
in white adipose tissue. As expected, caspase-1 inhibition led to a significant reduc­
tion of IL-1p protein concentration in fat (Figure 5B). Noticeably, treatment of Ob/
Ob animals with pralnacasan did not result in changes in faecal fat content or physical 
activity levels of the animals.
Interestingly, the improvement of insulin sensitivity was accompanied by an attenu­
ated increase in bodyweight in animals receiving the caspase-1 inhibitor (Figure 5C) 
despite a similar daily food intake (Figure 5D). The percentage of epidydimal white 
adipose tissue in ob/ob animals receiving the inhibitor tended to be lower as compared 
to animals receiving vehicle only (P-value=0.06) suggestive for changes in lipid stor­
age and lipogenesis in white adipose tissue (Figure 5E).
Because lipid composition may be involved in the effects of caspase-1 on adipose
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Figure 5 Caspase-1 blockage improves insulin sensitivity. A, Insulin tolerance test in male Ob/Ob ani­
mals (2 months of age at start of intervention) orally treated with a chemical caspase-1 inhibitor (Pralna­
casan) or vehicle for two weeks (n=5 per group). B, IL-1p concentrations (pg/ml) measured in total white 
adipose tissue of Ob/Ob mice receiving vehicle or a caspase-1 inhibitor (n=5 per group). C, Body weight 
change (in %) during oral treatment of Ob/Ob animals with vehicle or a caspase-1 inhibitor (n=5 per 
group). D, Food intake (kcal/day) of Ob/Ob animals orally treated with a chemical caspase-1 inhibitor or 
vehicle for two weeks. E, percentage of epididymal white adipose tissue. F, lipid composition of white 
adipose tissue. G, Desaturation indexes in vehicle or caspase-1 inhibitor treated animals. H, Bodyweight 
development of wild-type or caspase-1-/- animals (2 months of age at start of intervention) fed a low fat 
diet or high fat diet for 10 weeks (n=10 per group). I, Food intake (kcal/day) of wild-type or caspase-1-/- 
fed a LFD or HFD. J, Insulin tolerance test in wild-type and caspase-1-/- animals fed a HFD for 10 weeks 
(n=5 per group). Data are presented as mean ± sem. Asterisks depict statistically significant differences
between control and experimental groups.* P-value<0.05, ** P-value<0.005
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tissue, the general lipid composition of the white adipose tissue was analyzed. As 
shown in figure 5F, the amounts of C16:0 (palmitic acid) and C18:0 (stearic acid) 
present in white adipose tissue were significantly higher in animals receiving the 
inhibitor whereas the concentration of C18:1 (oleic acid) was lower. Finally, the ratios 
of C16:1/C16:0 and C18:1/C18:0, indicative of desaturation through SCD-1 activity, 
were lower in Ob/Ob animals treated with the inhibitor (Figure 5G) suggestive for a 
decrease in lipogenesis.
Inasmuch no changes were observed in the ratios of C18:0/C16:0 and C16:1/C18:1 
(data not shown), elongase activity appeared to be unchanged. Noticeably, fatty acid 
composition and ratios of C18:1/C18:0 and C16:1/C16:0 in plasma samples were 
unchanged. Plasma FFA levels were unchanged in ob/ob animals fed the inhibitor as 
compared to the control animals (0.18mM ± 0.04 vs. 0.18mM ± 0.009).
The effect of caspase-1 on the development of obesity and insulin resistance was 
analyzed using a diet intervention. 10 weeks of HFD feeding led to significantly less 
bodyweight gain in caspase-1-/- mice as compared to HFD fed wild-type animals 
(Figure 5H) despite a similar food intake (Figure 5I). Moreover, insulin sensitivity as 
measured by an ITT test was significantly higher in caspase-1-/- animals compared to 
wild-type mice fed the HFD (Figure 5J).
Absence of caspase-1 increases fat oxidation rate
Inasmuch the inhibition of caspase-1 attenuates bodyweight gain despite a similar 
food intake, caspase 1-/- and C57Bl/6 wild-type mice were subjected to indirect calo­
rimetry analysis using metabolic cages to determine their energy expenditure. Food 
intake and respiratory gas exchange was measured at 7 minute intervals for a period 
of 60 hours. Respiratory gas exchange was calculated from oxygen consumption and 
carbon dioxide production, and analyzed separately for diurnal and nocturnal periods 
to distinguish between periods of low (diurnal) and high (nocturnal) physical activity. 
In line with our previous results, food intake was similar in both groups (wild-type, 
4.99 ± 0.26g/day; caspase-1-/-, 4.62 ± 0.15g/day; P-value=0.3). Fecal output (wild­
type, 1.4 ± 0.07g/day; caspase-1-/-, 1.4 ± 0.07g/day; P-value=0.9) as well as fecal fat 
content (steatocrit %: wild-type, 7.13 ± 0.38; caspase-1-/-, 8.02 ± 0.49; P-value=0.17) 
were not different between both genotypes.
Total energy expenditure did not differ between groups during the nocturnal period 
(wild-type, 0.54 ± 0.03kcal/h; caspase-1-/-, 0.62 ± 0.03kcal/h; P-value=0.06), nor 
the diurnal period (wild-type, 0.45 ± 0.02kcal/h; caspase-1-/-, 0.45 ± 0.02kcal/h; 
P-value=0.9). Interestingly, diurnal RER values were significantly lower in caspase 
1-/- animals (wild-type, 0.919 ± 0.012; caspase-1-/-, 0.885 ± 0.006) (Figure 6A). The 
lower RER values were translated into a higher absolute fat oxidation rate during the 
diurnal part of the day (wild-type, 0.09 ± 0.01kcal/h; caspase-1-/-, 0.13 ± 0.01kcal/h; 
P-value=0.02) (Figure 6B). Nocturnal relative and absolute fat oxidation rates as well 
as total diurnal and nocturnal carbohydrate oxidation rates did not differ between
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groups (Figure 6B and C). Together, these data indicate that caspase-1-/- animals have 
higher fat oxidation rates compared to controls, while food intake and fecal output 
was equal between groups.
Figure 6 Absence of caspase-1 augments fat oxidation rate. A, Respiratory exchange rates, B, fat oxi­
dation and C, carbohydrate oxidation levels in wildtype and caspase 1-/- animals. Black and white bars 
represent mean nocturnal and diurnal data ± SEM, respectively. * indicates P-value<0.05.
Discussion
In the present study we demonstrate that during differentiation and lipid accumulation, 
adipose tissue undergoes important pro-inflammatory changes represented by inflam- 
masome and caspase-1 activation. These changes lead to a higher of IL-ip production 
and contribute to the induction of insulin resistance.
The importance of inflammation and infiltration of macrophages in the modulation 
of adipose tissue function and insulin resistance has been intensively studied over 
the last years (3;4). IL-ip has been previously linked to obesity-induced inflamma­
tion and the development of insulin resistance in adipose tissue (26;27). Our results 
demonstrate that caspase-1 activation in adipose tissue of obese animals takes place 
partly independent of macrophage infiltration, induces the release of IL-ip, and finally 
results in the development of insulin resistance through autocrine and paracrine ef­
fects. In the absence of caspase-1, adipocytes differentiate more efficiently and are 
more sensitive to insulin. We observed similar effects in the absence of the inflamma- 
some component NLRP3 that has been previously demonstrated to mediate caspase-i 
activation (9). In addition to robust changes in adipose tissue morphology, we also 
suggest that the absence of caspase-1 results in an increased mitochondrial energy 
dissipation reflected by an increase in PGC-1a and PGC-ip gene expression and 
enhancement of mtDNA content in white adipose tissue. Expression levels of PGC- 
1a and p in caspase-1 deficient animals are probably increased due to the absence of 
bio-active IL-1p (28). Assessment of additional metabolic parameters of caspase-1-/- 
animals revealed that, although total caloric expenditure as well as food intake and
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fecal output did not differ between groups, absolute fat oxidation rates were higher 
in caspase-1-/- animals. Whereas fat oxidation comprised 20% of the total amount of 
diurnal caloric expenditure in wild-type animals, it contributed up to 30% in the cas- 
pase-1-/- animals. Ultimately, this results in a less positive fat balance and can explain 
the reduction in fat mass observed in caspase-1-/- animals.
In addition to activation of IL-1p, caspase-1 also cleaves pro-IL-18 to its bioactive 
form. In line with activation of caspase-1 in adipose tissue, IL-18 protein levels were 
increased in adipose tissue of HFD fed animals compared to mice fed the LFD. How­
ever, our in vitro data show that the effects of IL-18 on adipocyte differentiation and 
gene expression are minor as compared to IL-ip. In addition, it has been previously 
shown that aging IL-18-/- animals develop obesity and insulin resistance (8). Overall 
this suggests that, although IL-1p and IL-18 both serve as substrates of caspase-1, the 
effects of these cytokines on adipocyte function and insulin sensitivity appear to be 
opposite, and the absence of IL-1p masks the effects of IL-18.
Importantly, we show that caspase-1 deficient animals are more insulin sensitive, 
which strongly supports the concept of the involvement of the inflammasome/cas- 
pase-1 pathway in the development of insulin resistance associated with obesity. 
Additionally, we demonstrate that blockage of caspase-1 in obese and insulin resistant 
animals results in an improvement of insulin sensitivity and a smaller increase in total 
bodyweight. This reduction in weight gain is also reflected by a lower adipose tissue 
mass in animals receiving the caspase-1 inhibitor. The relatively small reduction in 
adipose tissue mass in animals receiving the inhibitor may be partly explained by the 
limited treatment period. Longer treatment of the animals with a caspase-1 inhibitor 
might lead to more pronounced differences in adipose tissue mass. In addition to the 
quantitative changes, we also observed qualitative changes in adipose tissue composi­
tion illustrated by a significantly lower desaturation in white adipose tissue of animals 
treated with the inhibitor. This suggests that SCD-1 activity that catalyzes the synthe­
sis of monounsaturated fatty acids is lower after caspase-1 inhibition. Since SCD-1- 
/- animals have a reduction in adiposity due to enhanced lipid oxidation together with 
an improvement in insulin sensitivity (29), regulation of SCD-1 activity by caspase-1 
in adipose tissue may partly explain our observations. Inasmuch SREBPs, that partly 
control SCD-1 activity, are processed and activated by caspase-1 (30), it may explain 
the reduction in desaturation index in adipose tissue of ob/ob animals after caspase-1 
inhibition.
Hypothetically, the absence of caspase-1 in adipose tissue leads to an enhanced adipo- 
genesis paralleled by an improvement in lipid oxidation due to enhanced mitochondri­
al function. The stimulation of adipogenesis in caspase-1-/- animals might primarily 
prevent lipid accumulation in non-fat tissues. In addition, it is unlikely that caspase-1
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activation in adipose tissue will solely lead to IL-1p and IL-18 production since it has 
been reported that caspase-1 is able to cleave additional substrates (31). Adipocyte- 
specific proteins may also serve as caspase-1 substrates leading to functional changes 
in adipose tissue of obese animals. Interestingly, it has been shown that caspase-1 is 
able to cleave and inactivate PPARy in adipocytes (32) that may also contribute to the 
detrimental effects of caspase-1 activation in adipose tissue of obese animals. Further­
more, adipose tissue-independent effects of caspase-1 may also contribute to the de­
velopment of obesity-induced insulin resistance. Future studies are needed to resolve 
this issue and will shed more light on the mechanisms responsible for the resistance to 
diet-induced obesity in caspase-1-/- animals.
Beneficial effects of IL-1 blockade by the natural antagonist IL-1Ra have been re­
cently reported in type 2 diabetes patients (7), and our data provides the rationale for 
proposing caspase-1 inhibition as a potential novel therapeutic target in conditions 
associated with obesity and/or insulin resistance.
One important question that remains to be answered regards the precise mechanisms 
leading to caspase-1 activation during accumulation of fat in the adipocytes. It is 
still conceivable that the influx of macrophages might influence the activation of 
adipocyte-specific caspase-1, although our in-vitro experiments showing caspase-1 
{g} activation in adipocytes in settings free of inflammatory cells suggest that adipo­
cytes represent an important source of caspase-1. Nevertheless, our results do not 
rule out crosstalk between adipocyte-specific caspase-1 and production of IL-1p by 
macrophages in adipose tissue. Alternatively, lipids themselves or other mediators 
encountered in the obese patient (e.g. adipokines) could induce activation of cas- 
pase-1. Finally, glycemic conditions might induce caspase-1 activation in adipose 
tissue. Interestingly, hyperglycemic conditions have been shown to activate NLRP3 in 
pancreatic cells and a similar mechanism may exist in adipose tissue (33). Unraveling 
these molecular mechanisms is one of the important challenges for the near future.
In conclusion, our data reveal a novel metabolic function of the inflammasome/cas- 
pase-1 in adipose tissue. An increase in fat mass causes up regulation and activation 
of caspase-1 that counteracts the normal metabolic function of adipose tissue leading 
to insulin resistance. Inhibition of caspase-1 in obese and insulin resistant animals 
strongly improves insulin sensitivity together with changes in adipose tissue mass 
and composition. Importantly, the absence of caspase-1 results in an enhancement 
of overall fat oxidation rates. These findings suggest that pharmacological inhibition 
of caspase-1 in obese and/or patients with type 2 diabetes may restore the metabolic 
function of adipose tissue, and subsequently improve insulin sensitivity.
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Supplemental data
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Supplemental figure 1 A, Assessment of the inhibition of caspase-1 by Yvad and Pralnacasan using a 
fluorometric activity assay. B, IL-1P production by human white adipose tissue after 24 hours of culture 
in the presence or absence of caspase-1 inhibitor Pralnacasan (100^M).
Scramble siRNA Casp-1
Supplemental figure 2 A, Protein levels total caspase-1 after 48 hours treatment of SGBS cells with 
scramble or caspase-1 targeted siRNA. B, pAKT levels in SGBS adipocytes after siRNA treatment tar­
geted against caspase-1 and subsequent recombinant IL-ip exposure overnight.
Supplemental figure 3 Western blot analysis of caspase-1 
protein levels in total white adipose tissue of wild-type and 
caspase-1-/- animals
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Supplemental figure 4 A, Glucose values during euglycemic hyperinsulinemic clamp analyisi in wild­
type («=17) and caspase-1-/- animals («=18), mean ± SEM. B, relative mtDNA content of white adipose 
tissue from wild-type and NALP3-/- animals.
Supplemental table 1
Animals Glucose (mM) Insulin (ng/mL)
Basal Hyperinsulinemic Basal Hyperinsulinemic
Wild-type 4.12 ± 0.18 5.07 ± 0.24 0.29 ± 0.06 5.27 ± 0.63
Caspase-1-/- 4.00 ± 0.18 4.31 ± 0.19* 0.14 ± 0.04 5.16 ± 1.00
Plasma parameters under basal or hyperinsulinemic conditions in overnight fasted caspase-1 deficient 
and wild-type mice. Data are the means ± SEM. *, P-value<0.05 vs. wild-type.
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Abstract
Introduction: Obesity is characterized by elevated levels of pro-inflammatory cy­
tokines, including IL-1p, that contribute to the development of insulin resistance. In 
this study, we set out to investigate whether hyperglycemia drives IL-ip production 
and caspase-1 activation in mouse and human adipose tissue, thus inducing insulin 
resistance.
Research design and methods: Ob/Ob animals were used as a model to study obe­
sity and hyperglycemia. Human adipose tissue fragments or adipocytes were cultured 
in medium containing normal or high glucose levels. Additionally, the role of thiore- 
doxin interacting protein (TXNIP) in glucose-induced IL-ip production was assessed.
Results: TXNIP and caspase-1 protein levels were more abundantly expressed in 
adipose tissue of hyperglycemic Ob/Ob animals as compared to Wildtype mice. In 
human adipose tissue, high glucose resulted in a 10-fold up regulation of TXNIP gene 
expression levels (P-value<0.01) and a 10% elevation of caspase-1 activity (P-value 
<0.05), together with induction of IL-1p transcription (2-fold, P-value<0.01) and 
a significant increase in IL-1P secretion. TXNIP suppression in human adipocytes, 
either by an siRNA approach or a PPARy agonist, counteracted the effects of high 
^  glucose on bioactive IL-1 production (P-value<0.01) mainly through a decrease in
transcription levels paralleled by reduced intracellular pro-IL-1p levels.
Conclusions: High glucose activates caspase-1 in human and mouse adipose tissue. 
Glucose-induced activation of TXNIP mediates IL-1p mRNA expression levels and 
intracellular pro-IL-1p accumulation in adipose tissue. The concerted actions lead to 
enhanced secretion of IL-1p in adipose tissue that may contribute to the development 
of insulin resistance.
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Introduction
Obesity is associated with a low-grade systemic inflammation, with elevated levels 
of pro-inflammatory cytokines, such as IL-1p, TNF-a and IL-6, that contribute to 
the development of insulin resistance and progression to type 2 diabetes mellitus 
(T2DM). (1;2). The mechanisms that trigger the development of inflammation are 
currently unknown, although the adipose tissue has been viewed upon as the instiga­
tor of these effects (3;4). Earlier studies have shown that high glucose promotes the 
production of acute phase reactants (5) and pro-inflammatory cytokines by adipocytes 
(6). In addition, several studies have shown that hyperglycemia induces the produc­
tion of IL-1p in different cell types including endothelial cells, monocytes, p-cells 
and other pancreatic islet cells (7-9). Although short time exposure to low concentra­
tions of IL-1p enhances p-cell function, high glucose-induced islet IL-1p secretion 
is known to negatively interfere with insulin signalling and has cytotoxic effects on 
beta-cells leading to impaired insulin secretion (8;10). IL-1p is produced via cleav­
age of pro-IL-1p by caspase-1, a cysteine protease (11) that is activated by a protein 
complex named the inflammasome (12). Until recently, the mechanism by which high 
glucose induces IL-1p remained largely unknown. However, in a recent study Zhou et 
al. demonstrated a crucial role for thioredoxin interacting protein (TXNIP or vitamin 
D3 upregulated protein 1 (VDUP1)) during high glucose-mediated caspase-1 activa-
0  tion in mouse beta-cells, by direct interaction with the nucleotide-binding oligomer­
ization domain (NOD)-like receptor (NLR)-3 (NLRP3)-inflammasome (13). TXNIP 
is expressed in a wide variety of cell types including skeletal myocytes, pancreatic 
beta-cells, endothelial cells and adipocytes, and acts as an endogenous inhibitor of the 
reactive oxygen species (ROS) scavenging protein thioredoxin (14;15). TXNIP levels 
are elevated in subjects with T2DM (15) and its expression is induced by glucose-6- 
phosphate through an intracellular transcriptional complex of MondoA and Max-like 
protein X (16).
Here we investigate whether high glucose levels also drive TXNIP and caspase-1 acti­
vation in human adipocytes and intact adipose tissue and whether this may contribute 
to the production of IL-1p.
Research design and methods
Animal experiments
Blood glucose levels of five 8-week old male Ob/Ob C57/B16 and Wildtype C57/B16 
animals (Jackson Laboratory) were determined after four hours of fasting. A glucose 
tolerance test and insulin tolerance test was performed in five 8-week old male cas- 
pase-1 -/- C57/Bl6 mice (average bodyweight: 23.6grams) and five age- and weight- 
matched wild-type C57/Bl6 animals. Epididymal white adipose tissue was used to
97
thesis def 1.indd 97 »  11-7-2011 10:19:49
Chapter 6
analyze protein levels of caspase-1 and TXNIP.
In-vitro and ex-vivo experiments with human adipose tissue 
Intact adipose tissue fragments and cultured human preadipocytes from subcutaneous 
adipose tissue (n=6), obtained during plastic surgery, and the SGBS cell line were 
used to study the effects of high glucose levels. The protocol was approved by the 
hospital ethics committee and the tissue samples were collected after written informed 
consent. Adipose tissue fragments were directly cultured for 48 hours in DMEM 
supplemented with 10% fetal calf serum containing normal glucose levels (5mM) or 
high glucose levels (25mM). Pre-adipocytes were isolated from the adipose tissue 
according the procedure described by Rodbell et al. (17). Primary or SGBS preadi­
pocytes were differentiated towards mature adipocytes using a standard adipogenic 
protocol (18). After 12 days of differentiation adipocytes were cultured under 5mM 
or 25mM glucose conditions. Mannose was added to cells cultured in the presence of 
5mM glucose.
RNA isolation and PCR analysis
RNA was extracted from total adipose tissue or adipocytes using TRIzol reagent 
(Invitrogen, Carlstad, USA). cDNA synthesis was performed using the iScript™ cDNA 
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). Real-time PCR was done using 
&  Power-SYBR® Green master mix and the 7300 Real-Time PCR system (Applied Bio- ^
system, Warrington, UK). Expression of genes was normalized to P2M or 36B4 gene 
expression levels. Primer sequences are available upon request.
Protein analysis
Protein expression of TXNIP, caspase-1, P-actin and GAPDH were measured by 
western blotting. Antibodies were from Santa Cruz (caspase-1), Zymed (TXNIP),
Abcam (NLRP3), Sigma-Aldrich (P-actin) and Calbiochem (GAPDH). Bioactive IL-1 
secretion was quantified in a bioassay using the murine thymoma cell line EL4/NOB
1 that produces IL-2 in response to bioactive IL-1 (19). IL-2 and intracellular human 
pro-IL-1p levels were measured by Elisa (R&D). In short, medium collected from adi­
pocytes or total adipose tissue cultured in the presence of 5mM or 25mM of glucose 
was added to NOB-1 cells. After 24 hours of incubation, medium was used for IL-2 
measurements. The specificity of the NOB-1 assay to produce IL-2 in response to IL- 
1P was confirmed in this study (Supplemental figure 1).
Caspase-1 activity assay
Caspase-1 activity in adipocyte lysates was determined with a caspase-1 fluorometric 
kit (Biovision) following the cleavage of 50^M peptide YVAD-AFC. The fluores­
cence of the cleaved substrate was measured every 90 seconds using a fluorometer 
(Polarstar BMG, fluostar galaxy).
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Small interference (si) RNA
To specifically suppress TXNIP expression in differentiated adipocytes, cells were 
transfected (X-tremeGENE siRNA Transfection Reagent, Roche) with siRNA against 
TXNIP (Thermo Scientific). As a non-specific control, scrambled siRNA (Thermo 
Scientific) was used.
Statistical analysis
Variables are expressed as means ± SD. One-way ANOVA , the Wilcoxon rank test 
and Student’s paired t-test were used to analyze statistical significance. Two-tailed 
P-value<0.05 was considered significant. All statistic analysis were performed using 
SPSS software (version 16.0; SPSS Inc.,Chicago, IL).
Results
To determine whether hyperglycemic conditions induce caspase-1 and TXNIP in 
adipose tissue in-vivo, we used the Ob/Ob animal model which is characterized by, 
obesity, insulin resistance and hyperglycemia (Figure 1A). Both the inactive pro-cas- 
pase-1 (p45) and the active caspase-1 (p35) protein levels were up-regulated in Ob/Ob 
mice compared to the normoglycemic Wildtype animals (Figure 1B). In parallel with 
caspase-1 activation, TXNIP protein levels were elevated in adipose tissue of Ob/Ob 
animals. Interestingly, the absence of caspase-1 led to an improvement of glucose tol­
erance (Figure 1C) and insulin sensitivity (Figure 1D). Supported by the observation 
that TXNIP-/- animals are more insulin sensitive (20), these in-vivo results strongly 
suggest a link between TXNIP and caspase-1 activation during hyperglycemic condi­
tions in adipose tissue that contributes to the development of insulin resistance.
Next, we studied the effects of high glucose on caspase-1 activation and the pro­
duction of IL-1p in human adipose tissue. Treatment of adipose tissue with 25mM 
glucose increased the gene expression levels of pro-inflammatory mediators includ­
ing IL-6 and IL-8 (P-value<0.01) together with a significant 4-fold reduction in 
PPARy expression levels (Figure 2A). Moreover, IL-ip gene expression levels were 
also elevated upon short- or long term stimulation of adipose tissue and adipocytes 
with 25mM of glucose (7.5 fold; P-value<0.01, 4 fold; P-value<0.06, respectively), 
whereas IL-18 levels were unaffected (Figure 2B and 2C). In line with activation of 
IL-ip transcription levels, both the intracellular content of pro-IL-ip and secretion of 
bioactive IL-1 were significantly elevated after exposure of adipocytes or intact adi­
pose tissue to 25mM of glucose (Figure 2D and 2E). Since IL-1 production depends 
on caspase-1 activation, we determined caspase-1 activity levels in adipocytes treated 
with 5mM or 25mM of glucose. As shown in figure 2F, a significant increase in 
caspase-1 activity was observed in primary human adipocytes treated with 25mM of
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glucose for 48h, compared to adipocytes treated with 5mM of glucose. In line with the 
enhanced caspase-1 activity, high glucose levels led to an increase in NLRP3 protein 
levels in primary human adipocytes (Figure 2G). Although only a trend was observed 
(P-value=0.07), our results imply that NLRP3 is one of the signaling molecules that 
translate high glucose levels into caspase-1 activation. Noticeably, similar results were 
obtained using human adipose tissue explants (data not shown). Overall, these results 
suggest that high glucose induces IL-1 J3 transcription, activation of caspase-1 and 
secretion of IL-1 in human adipose tissue.
A B
W ild ty p e  O b /O b
C D
Minutes Minutes
Figure 1. TXNIP and caspase-1 protein levels are increased in the adipose tissue of Ob/Ob mice.
A. Plasma glucose levels in fasted wild-type mice and Ob/Ob mice (n=5 per group). B. Western blot 
images and quantification of TXNIP, pro-caspase-1 (p45) and active caspase-1 (p35) protein levels in the 
epididymal adipose tissue of wild-type mice and Ob/Ob mice (n=5 per group). C. A glucose tolerance 
test was done using fasted wild-type and caspase-1-/- animals (n=5 animals per group). D. An insulin 
tolerance test was performed in fasted wild-type and caspase-1-/- animals (n=5 animals per group). * = 
p-value < 0.05, ** = p-value < 0.01 using a Student’s T-test.
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Figure 2. Hyperglycemia induces pro-inflammatory gene expression and results in an increased 
production of IL-1 by intact adipose tissue and adipocytes. A. IL-6, IL-8 and PPARy gene expression 
levels in human intact adipose tissue (n=3) after 6h or 48h of glucose treatment. B. IL-1P gene expres­
sion levels in human adipose tissue (n=3) treated with glucose for 6h or 48h. C. IL-1P and IL-18 gene 
expression levels in human primary adipocytes (n=3) treated with various concentrations of glucose.
D,E. Intracellular pro-IL-1P levels measured in lysates from intact human adipose tissue (D) or human 
primary adipocytes (E) treated with 5mM or 25mM glucose for 48 hours (n=4) and IL-2 production from 
NOB-1 cells after exposure to medium from intact human subcutaneous adipose tissue of three differ­
ent donors treated with 5mM or 25mM of glucose for 48 hours. F. Caspase-1 activity assay in primary 
human adipocytes treated with 5mM, 25mM of glucose or LPS (10ng/ml) for 48 hours. The left graph 
displays the results of one representative experiment. The right graph displays the average results of 
n=6 experiments. G. NLRP3 protein expression levels in human primary adipocytes treated with 5mM 
or 25mM of glucose for 48 hours. A representative western blot and quantification of the results (n=3) 
are shown. * = p-value<0.05, ** = p-value<0.01 using an one-way ANOVA test (Figures A, B and C), 
Student’s T-test (figures D and E) or a Wilcoxon rank test (Figure F; right graph).
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To assess whether high glucose induces TXNIP in human adipose tissue and adipo­
cytes to a similar extent as observed in Ob/Ob animals, we first studied the regulation 
of TXNIP during the differentiation of human preadipocytes towards fully mature 
adipocytes. Whereas TXNIP is expressed in human preadipocytes, expression levels 
rapidly increased during differentiation towards mature adipocytes both at gene and 
protein expression levels (Figure 3A).
In addition to caspase-1, TXNIP protein levels were detectable in total human sub­
cutaneous adipose tissue and tended to increase in parallel with BMI (Figure 3B).
As adipose tissue is composed of both adipocytes and non-adipocyte cells, including 
inflammatory cells, we determined gene expression levels in both fractions. Purity 
of the different fractions was confirmed with the markers adiponectin (adipocyte- 
specific) and F4/80+ (macrophage-specific) (Supplemental Figure 2). Whereas TXNIP 
is expressed in the stromal vascular fraction (SVF), expression levels were 2.5 times 
higher in adipocytes (Figure 3C). As shown in figure 3D and E, glucose was a potent 
regulator of TXNIP mRNA expression in both isolated adipocytes and adipose tissue 
explants. Further, treatment of adipocytes with 5mM 2-deoxyglucose leading to a 
chronic activation of the MondoA:Mlx, resulted in a more pronounced activation of 
TXNIP gene expression (Figure 3D and 3E). In line with these transcriptional chang­
es, protein levels of TXNIP varied in response to different glucose concentrations 
added to adipocytes or intact adipose tissue (Figure 3F and G).
#  #  
Since high glucose potently activates TXNIP expression in adipocytes (Figure 3) 
and TXNIP has been shown to induce IL-1p secretion from mouse pancreatic islets 
cells in response to elevated glucose via activation of caspase-1 (13), we investigated 
whether TXNIP mediates high glucose-induced IL-1 production in human adipocytes 
using siRNA targeted against TXNIP. In adipocytes exposed to 25mM of glucose, suc­
cessful knockdown of TXNIP by siRNA (Figure 4A) led to a significant reduction in 
bioactive IL-1 production towards basal IL-1 levels induced by 5mM glucose (Figure 
4B). Additionally, IL-1p transcription and intracellular levels of pro-IL-1p were re­
duced upon siRNA-mediated depletion of TXNIP (Figure 4C). Whereas high glucose 
treatment increased caspase-1 activity levels in adipocytes (Figure 2F), siRNA medi­
ated knockdown of TXNIP had no effect on caspase-1 activation (Figure 4D). Inter­
estingly, reducing TXNIP gene expression with the PPARy agonist Rosiglitazone in 
adipocytes and adipose tissue explants exposed to 25mM glucose for 48 hours (Figure 
4E), also led to a significant decrease in intracellular pro-IL-1p and bioactive IL-1 
production (Figure 4F and 4G). These results demonstrate that TXNIP contributes to 
high glucose-induced IL-1 release by modulating the transcription of IL-1p and the 
intracellular pool of pro-IL-1p.
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Figure 3. TXNIP is present in human adipose tissue and adipocytes and is regulated by glucose. A.
TXNIP gene and protein expression levels during adipocyte differentiation of human primary adipo­
cytes or human SGBS adipocytes. B. Western blot images of caspase-1 and TXNIP protein levels in 
total human subcutaneous adipose tissue (n=2). C. Relative gene expression levels of TXNIP in mature 
adipocytes or the stromal vascular fraction (SVF) isolated from human adipose tissue (n=3). D. Gene 
expression levels of TXNIP in intact adipose tissue treated with various concentrations of glucose (n=3). 
E. Gene expression levels of TXNIP in human primary adipocytes treated with various concentrations of 
glucose (n=3). F. Protein levels of TXNIP in human adipose tissue after 5mM glucose, 25mM glucose or 
5mM deoxyglucose treatment for 48 hours (n=2). G. Protein levels of TXNIP after glucose starvation (no 
glucose), 5mM glucose and 25mM glucose for 48 hours in human primary adipocytes. * = p-value<0.05, 
** = p-value<0.01 using an one-way ANOVA test (Figures D and E) or a Student’s T-test (Figure C).
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Figure 4. TXNIP reduction results in a decline of high glucose-induced IL-1 production by modu­
lating IL -ip  gene expression. A. Gene and protein expression levels of TXNIP after siRNA treatment 
against TXNIP in human primary adipocytes («=6). B. IL-2 production from NOB-1 cells after expo­
sure to medium from human primary adipocytes transfected with TXNIP siRNA and treated with 5mM 
or 25mM glucose for 48 hours (n=6). C. IL-1p mRNA expression and intracellular pro-IL-1p levels in 
TXNIP siRNA treated adipocytes exposed to 5mM or 25mM glucose for 48 hours (n=4). D. Caspase-1 
activity assay in TXNIP siRNA treated human primary adipocytes exposed to 5mM or 25mM glucose for 
48 hours (n=3). E. TXNIP gene expression levels in intact human adipose tissue and primary adipocytes 
exposed to 25mM glucose for 48 hours with or without Rosiglitazone (10^M) treatment for 24 hours 
(n=3). F. Intracellular pro-IL-1p levels measured in lysates of intact human adipose tissue and primary 
adipocytes exposed to 25mM glucose for 48 hours with or without Rosiglitazone (10^M) treatment for 
10 hours (n=3). G. IL-2 production from NOB-1 cells after exposure to medium from intact adipose 
tissue and human primary adipocytes treated with 25mM glucose for 48 hours with or without Rosigli­
tazone (10^M) stimulation for 10 hours (n=4). H. Role of TXNIP in hyperglycemia-induced release of 
IL-1p from adipose tissue. * = P-value < 0.05, ** = P-value < 0.01 using an one-way ANOVA test (Fig­
ures B and C) or a Student’s T-test (Figure D, E, F, G).
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Discussion
Several studies show that IL-1p deteriorates peripheral insulin sensitivity and inhibits 
insulin production by the pancreas (8;10). The notion that IL-ip is relevant in human 
(patho)physiology is supported by the finding that blocking of IL-1 signaling path­
ways in T2DM patients by treatment with IL-1 receptor antagonist Anakinra improves 
glycemic control (21). However, the precise mechanisms leading to an enhanced pro­
duction of IL-1p in the “inflamed” adipose tissue over the course of development of 
insulin resistance have remained obscure. The importance of hyperglycemia-induced 
insulin resistance in T2DM patients is well accepted, although no current explanation 
is available for this process. The stimulatory role of hyperglycemia on IL-1p produc­
tion is however known for several years (7-9). The combination of this knowledge 
with the recent discovery of the important effect of IL-1p on the induction of insulin 
resistance (22) directed us to the hypothesis that hyperglycemia induces insulin resis­
tance in adipose tissue through activation of caspase-1 and IL-1p secretion. Moreover, 
Zhou et al have recently uncovered TXNIP as an essential mediator of hyperglyce­
mia-induced caspase-1-dependent IL-1p production in the mouse pancreatic p-cell 
(13), and we explored whether TXNIP could mediate a similar effect in human and 
mouse adipocytes. Our data clearly show that adipose tissue-resident caspase-1 and 
TXNIP are activated in both hyperglycemic Ob/Ob animals and in human adipose 
^  tissue treated with 25mM of glucose, resulting in an increased IL-1p production. Both
the absence of caspase-1 and TXNIP (20) significantly improved insulin sensitivity 
and resulted in lower plasma glucose levels. Together, these findings strengthen the 
concept that aberrant IL-1p production via caspase-1 underlies the pathophysiology of 
T2DM in different cellular sources, linking this disease to auto-inflammatory syn­
dromes.
The glucose-responsive TXNIP gene has been previously linked to diabetes and 
insulin resistance, since diabetic patients expressed consistently higher TXNIP 
mRNA gene levels in skeletal muscles (15), while animals lacking TXNIP displayed 
a hypoglycemic, hypoinsulinemic phenotype (23). Furthermore, it has been shown 
that PPARy negatively regulates TXNIP expression in adipose tissue (24). In agree­
ment, we showed that activation of PPARy by its agonist Rosiglitazone led to reduced 
TXNIP levels together with a decline in IL-1p. The elucidation of the exact molecular 
mechanisms through which TXNIP contributes to enhanced IL-1p production by the 
adipose tissue will need further study. Whereas TXNIP has been shown to directly 
controls caspase-1 activation in pancreatic beta cells (13), our results suggest that, at 
least in adipocytes, TXNIP mainly regulates IL-1p mRNA transcription levels and 
intracellular pro-IL-1p pools and does not directly affect caspase-1 activity levels. 
This discrepancy may largely be explained by cell-specific differences in adipocytes 
vs. pancreatic beta cells. In line with our results, Masters et al. reported no changes in
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caspase-1 activation upon TXNIP depletion in macrophages. However, these authors 
also failed to detect differences in IL-ip production upon stimulation with ATP and 
uric crystals in Wildtype vs. TXNIP-/- macrophages (25). This could be explained 
by the constitutive large expression of TXNIP in macrophages that is not influenced 
by high levels of glucose. In contrast, TXNIP does play a role in adipocyte glucose 
homeostasis and elevated levels of glucose potently induce TXNIP expression in 
adipocytes (15).
Since excessive production of reactive oxygen species (ROS) has been found to 
increase IL-p activity and may contribute to the toxic effect of high glucose on p-cells 
(26), future studies will need to reveal a possible role of TXNIP- induced oxidative 
stress induced by high glucose in mediating the release of IL-1p by adipose tissue. In 
addition, it would be interesting to investigate whether other metabolic stress signals 
that are elevated during the development of insulin resistance bear the potential to 
induce caspase-1.
In conclusion, adipocyte-specific TXNIP up regulation induced by hyperglycemia 
may contribute to a sustained pro-inflammatory state and hyperglycemia-associated 
insulin resistance partly through inducing IL-ip transcription. Furthermore, elevated 
levels of glucose increased the activation of caspase-1 in adipocytes. Although more 
efforts are needed, the high glucose-induced increase in NLRP3 protein levels in 
primary human adipocytes suggests involvement of the NLRP3-inflammasome in me­
diating caspase-1 activation during hyperglycemic conditions. Therefore, we suggest 
that, at least in adipose tissue, both activation of TXNIP and caspase-1 during hyper­
glycemic conditions lead to an enhanced production of IL-ip (Figure 4H). In this way, 
TXNIP links hyperglycemia to increased IL-ip production that may result in insulin 
resistance at the level of the adipose tissue. As a consequence, inhibition of TXNIP 
may represent a novel therapeutic target in the treatment of insulin resistance that will 
ameliorate adipose tissue functioning.
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Supplemental Figure 1. Specificity of the NOB-1 bioassay. The specificity of the NOB-1 bioassay was 
tested by incubation of NOB-1 cells with recombinant IL-ip (10ng/ml), TNFa (10ng/ml), IL-10 (10ng/ 
ml) and IL-IRa (15ug/ml).
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Supplemental Figure 2. Purity of adipose tissue fractioning. Analysis of adiponectin and F4/80+ gene 
expression levels in the SVF and mature adipocyte fraction of subcutaneous adipose tissue. ** = p-val- 
ue<0.01 using a Student’s T-test.
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Abstract
The immune competent abdominal adipose tissue, either stored viscerally (VAT) or 
subcutaneously (SAT), has been identified as a source of IL-1p and IL-18. To become 
active, the pro-forms of these cytokines require processing by caspase-1, which itself 
is mediated by the inflammasome. In this descriptive study, we investigate the expres­
sion of inflammasome components and caspase-1 in human fat and determine whether 
caspase-1 activity contributes to the enhanced inflammatory status of VAT.
Paired SAT and VAT biopsies from ten overweight subjects (BMI: 25-28 kg/m2) were 
used to study the cellular composition and the intrinsic inflammatory capacity of both 
adipose tissue depots.
The percentage of CD8+ T-cells within the lymphocyte fraction was significantly 
higher in VAT compared to SAT (41.6% vs. 30.4%; .P-value<0.05). Adipose tissue 
cultures showed a higher release of IL-ip (10-fold; .P-value<0.05), IL-18 (3-fold;
.P-value<0.05), IL-6 and IL-8 (3-fold; .P-value<0.05 and 4-fold; .P-value<0.05, re­
spectively) from VAT compared to SAT that was significantly reduced by inhibiting 
caspase-1 activity. In addition, caspase-1 activity was 3-fold (P-value<0.05) higher in 
VAT compared to SAT, together with an increase in the protein levels of the inflamma­
some members ASC (2-fold; .P-value<0.05) and NLRP3 (2-fold; ns). Finally, cas- 
pase-1 activity levels were positively correlated with the percentage of CD8+ T-cells 
^  present in adipose tissue. Our results show that caspase-1 and NLRP3 inflammasome ^
members are abundantly present in human VAT. The increased intrinsic caspase-1 
activity in VAT represents a novel and specific inflammatory pathway that may deter­
mine the pro-inflammatory character of this specific depot.
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Introduction
Chronic low-grade inflammation has now been recognized as one of the key steps in 
the pathogenesis of obesity-induced insulin resistance and type 2 diabetes mellitus.
The metabolically active abdominal adipose tissue secretes a wide variety of cyto­
kines, that may promote the development of peripheral insulin resistance (1). Obesity- 
induced enlargement of adipose tissue is accompanied by elevated plasma levels of 
cytokines, including IL-6, IL-8, IL-1p, IL-18 and TNFa that affect insulin sensitivity 
in peripheral tissues (2-6). It has been suggested that especially visceral adipose tis­
sue (VAT), rather than subcutaneous adipose tissue (SAT), contributes to the elevated 
circulating levels of inflammatory cytokines in obese individuals (7;8) that may be 
attributed to enhanced influx of immune cells including macrophages, monocytes, and 
B- and T-cells (9;10). However, efforts to identify possible mechanisms underlying 
the enhanced inflammatory capacity of VAT compared to SAT are scarce.
Recently, it was shown that the Toll-like receptor (TLR)-4 inflammatory pathway 
is activated in the adipose tissue during obesity and affects insulin responsiveness 
(11). The expression levels of multiple TLR family members were enhanced in VAT 
compared to SAT, suggesting that the TLR signaling pathway may contribute to an 
enhanced inflammatory capacity of VAT (12). IL-1p and IL-18 have been linked to the 
^  development of obesity and insulin resistance, and they partly originate from adipose ^
tissue (4;13). In order to become active, the pro-form of IL-1p and IL-18 are pro­
cessed by a cysteine protease named caspase-1. Activation of caspase-1 itself is medi­
ated by a multiprotein complex entitled the inflammasome (14;15). Upon stimulation 
by exogenous (bacterial products) or endogenous (uric acids crystals, hyperglycemia, 
or cholesterol crystals) signals, formation of the inflammasome complex consisting of 
a NOD-like receptor (NLR) family member and the adaptor protein apoptosis-associ- 
ated speck-like protein containing a CARD (ASC) occurs (16-20). To date, activation 
and function of the NLRP3-inflammasome composed of NLRP3, the adaptor mole­
cule ASC and caspase-1, is most fully characterized and responsible for recognition of 
invading pathogens and non-microbial molecules that eventuates into IL-1p and IL-18 
production (21;22).
Inasmuch adipose tissue has been identified as a significant source of IL-18 and IL-1p, 
this suggests the presence of the NLRP-3 inflammasome machinery at the tissue level.
Indeed, we have recently described that caspase-1 is well expressed in adipose tissue 
of obese animals and in human SAT (23;24), yet nothing is known about the NLRP3 
inflammasome expression in human VAT compared to SAT. Therefore, we set out to 
study the presence of the NLRP3-inflammasome components and caspase-1 in human 
fat and to determine whether caspase-1 activity contributes to the enhanced inflamma­
tory status of VAT versus SAT.
113
thesis def 1.indd 113 11-7-2011 10:20:10
Chapter 7
Methods
Subjects
Paired SAT and VAT (omentum) samples were obtained according a standardized 
procedure from ten patients (five females and five males) undergoing a cholecystec­
tomy or an inguinal hernia surgery. Inclusion criteria were age between 40-60 years 
and body mass index (BMI) 25-28 kg/m2. Subjects were normoglycemic and had a 
mean waist to hip ratio (WHR) of 0.90 (Supplementary table 1). Metabolic diseases, 
endocrine diseases and chronic and/or acute inflammatory diseases (high sensitivity 
C-reactive protein (hsCRP) above 1mg/L) were excluded. The tissue samples were 
collected after written informed consent and the protocol was approved by the ethical 
committee of the Radboud University Nijmegen Medical Centre.
Ex-vivo stimulation experiments with human adipose tissue 
Intact human adipose tissue fragments from paired SAT and VAT were used to study 
the presence of the NLRP3 inflammasome components and the intrinsic caspase-1 
activity as well as the cytokine release of IL-1p and IL-18 during a 24 hours culture 
using standard conditions (DMEM supplemented with 10% fetal calf serum contain­
ing 5mM glucose) with or without the addition of the caspase-1 inhibitor pralnacasan 
(100pM) (25).
Part of the freshly collected SAT and VAT samples were disaggregated using collage­
nase digestion to isolate mature adipocytes and the stromal vascular fraction (SVF). 
Purity of the two different fractions was confirmed with the markers adiponectin, 
leptin (adipocyte-specific) and CD45 (hematopoietic cell line marker (Supplementary 
figure 1). The separate cellular fractions were subsequently used for cell culture using 
standard conditions for 24 hours, FACS analysis and RNA isolation, followed by real­
time PCR analysis.
RNA isolation and PCR analysis
RNA was extracted from total SAT and VAT or different adipose tissue cell fractions 
using TRIzol reagent (Invitrogen, Carlstad, USA). RNA concentration was determined 
using a NanoDrop™ (NanoDrop Technologies, Wilmington, USA) and cDNA synthe­
sis was performed using the iScript ™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA). Real-time PCR was done using Power-SYBR® Green master mix and 
the 7300 Real-Time PCR system (Applied Biosystem, Warrington, UK). Expression 
of genes was normalized to p2M gene expression levels. Primer sequences are avail­
able upon request.
Protein analysis
Protein lysates from total adipose tissue of both depots were prepared to determine the 
presence of caspase-1 (Santa Cruz), NLRP3 (Abcam) and ASC (Abcam) by western
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blotting. Secretion of IL-1p, IL-6, IL-8, IL-18, TNFa and adiponectin was analyzed 
by ELISA (R&D). Bioactive IL-1 secretion was quantified in a bioassay using the mu­
rine thymoma cell line EL4/NOB 1 that produces IL-2 in response to bioactive IL-1 
(26). IL-2 levels were measured by ELISA (R&D).
Caspase-1 activity assay
Caspase-1 activity in total SAT and VAT protein lysates was determined with a cas- 
pase-1 fluorometric kit (Biovision) by measuring the cleavage of 50^l of the caspase-1 
substrate YVAD-AFC. The fluorescence of the cleaved substrate was measured every
90 seconds using a fluorometer (Polarstar BMG, fluostar galaxy).
FACS analysis
SVFs of both SAT and VAT were analyzed by flow cytometry (FC500, Beckman 
Coulter). To this purpose, 100000 cells/100^l PBS + 1% BSA were incubated in three 
separate cocktails with the following conjugated monoclonal antibodies: anti-CD14 
(Ph imm27074)-ECD, anti-CD45 (A 07785)-PCy5, anti-CD3 (A 07747)-PE, anti-CD8 
(737659)-ECD, anti-CD4 (6604727)-ECD (Beckman Coulter), anti-F4/80 (ab60343- 
50)-FITC (Abcam). Blood contamination of the samples was prevented by treating the 
SVFs with an erythrocyte lysis buffer.
^  Statistical analysis ^
Data are presented as mean ± SEM. Comparisons between SAT and VAT parameters 
were calculated using the non-parametric Wilcoxon rank test. Correlations were de­
termined using a Spearman correlation test. The cut-off for statistical significance was 
set at a P-value of 0.05 or below. All statistics were performed using SPSS software 
(version 16.0; SPSS Inc., Chicago, IL).
Results
Cellular composition o f SAT and VAT
Since adipose tissue-resident macrophages represent potent inflammatory cytokine 
producers during obesity (27;28), we set out to study the macrophage content in the 
SVF of both SAT and VAT obtained by flow cytometry (Table 1). Our study revealed 
that the numbers of macrophages were equally distributed throughout SAT and VAT. 
Subsequent FACS analysis of the SVF of the adipose tissue to determine the cellular 
immune cell composition including monocytes and granulocytes, did not show signifi­
cant differences between both fat depots. However, the percentage of CD8+ (cytotox­
ic) T- lymphocytes was significantly increased in VAT compared to SAT, whereas the 
CD4+ cell number was not different in both depots (Table 1). Supplementary figures 
2A and B show representative dot plots of flow cytometry data of the different im­
mune cells within the SVF of SAT and VAT, respectively.
115
thesis def l.indd 115 »  11-7-2011 10:20:10
■ ■ ■ #  1 ■  ■  ■
Chapter 7
Table 1
Immune cell composition of subcutaneous and visceral adipose tissue from seven
subjects
Immune cells in SVF SAT (%) VAT (%)
Granulocytes (% of CD45+ cells) 29.0 ± 5.6 31.0 ± 6.5
Monocytes (% of CD45+ cells) 3.7 ± 0.8 2.8 ± 0.7
Macrophages (% of CD45+ cells) 5.7 ± 1.5 3.6 ± 1.3
Lymphocytes (% of CD45+ cells) 39.4 ± 6.0 47.3 ± 6.0§
T-cells (% of CD45+ cells) 29.2 ± 4.6 38.6 ± 5.4§
CD4 T-cells (% of CD45+ cells) 14.7 ± 3.0 16.4 ± 3.2
CD8 T-cells (% of CD45+ cells) 10.8 ± 2.0 16.6 ± 2.4t
Number of immune cells (percent) part of the innate immune system (granulocytes, monocytes, and 
macrophages) or adaptive immune system (total lymphocytes and T (CD4+ or CD8+) lymphocytes) in 
the SVF of SAT and VAT. Data are presented as mean ± SEM (n=7). §, P-value<0.05; t, P -value<0.01
Enhanced release o f bioactive IL-1fi and IL-18 from VAT compared to SAT 
To examine the production capacity of IL-1P, IL-18 and other cytokines by VAT and 
SAT, total adipose tissue was brought into culture and cytokine production was mea­
sured after 24 hours. Interestingly, secretion of both total IL-ip and bioactive IL-1, as 
determined by ELISA and the NOB-1 bioassay, respectively, was significantly higher 
(P-value<0.05) in VAT compared to SAT. In addition, IL-18 production from VAT was 
also significantly enhanced (Figure 1A). The production of other pro-inflammatory 
cytokines including IL-6, IL-8 and IL-1Ra was also elevated in VAT compared to 
SAT explants (3-fold; .P-value<0.05, 4-fold; .P-value<0.05, and 2-fold; .P-value<0.05. 
respectively) and secretion of adiponectin, a protein known for its insulin-sensitizing 
action (29), was reduced by VAT compared to SAT (P-value<0.05) (Figure 1B). 
Noticeably, secretion levels of the pro-inflammatory cytokine TNFa were comparable 
between VAT and SAT (Figure 1B).
To determine gene expression levels of different cytokines in VAT and SAT, qPCR 
analysis was performed. Whereas IL-1P gene expression levels were similar in both 
depots, IL-18 mRNA levels were significantly upregulated in VAT (Figure 2A). Gene 
expression levels of IL-6, IL-8 and adiponectin did not differ between both fat depots 
(data not shown). Fractioning of VAT into mature adipocytes and the SVF component 
revealed that IL-1p and IL-18 mRNA were significantly more expressed in the SVF 
(Figure 2B). In accordance with the gene expression profile, IL-1P production was 
elevated in the SVF compared to the mature adipocyte fraction in both fat depots. 
However, the production of IL-1P by mature adipocytes and SVF was higher in VAT 
compared to the correspondence fractions isolated from SAT (Figure 2C).
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Figure 1. Enhanced production of IL-ip, IL-18, IL-6, IL-8 yet not TNFa from VAT. A. Secretion of 
IL-ip, bioactive IL-1 (# measured as IL-2 production from NOB-1 cells in response to bioactive IL-1), 
and IL-18 in intact SAT and VAT fragments cultured for 24hrs («=5; BMI range 25-28). B. Secretion 
levels of IL-6, IL-8, IL-IRa, adiponectin, and TNFa by VAT and SAT after 24hrs of culturing (n=5). * = 
/'-value«!05, / ,-value<0.01 using a Wilcoxon rank test.
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Figure 2. Expression profile of IL -ip  and IL-18 in VAT and SAT. A. Relative IL-1p and IL-18 gene 
expression levels in total SAT and VAT (n=8). B. Relative IL-1p and IL-18 gene expression in mature 
adipocytes (MAT) and the SVF isolated from VAT (n=7; BMI range 25-28). C. IL-1p production by 
MAT and SVF isolated from one gram of SAT and VAT cultured for 24 hours (n=4). * = P-value<0.05, 
P-value<0.01 using a Wilcoxon rank test.
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Inflammasome expression and caspase-1 activation are increased in VAT 
compared to SAT
Inasmuch the adipose tissue is able to secrete IL-1|3 and IL-18 (Figure 1A), it suggests 
the presence o f active caspase-1 in human adipose tissue. Indeed, the active form of 
caspase-1 was detectable in both fat depots (Figure 3A and 3B). Although caspase-1 
gene expression was similar in both fat depots (data not shown), a 3-fold increase in 
caspase-1 protein levels was observed in the VAT samples from the ten study subjects 
as determined by Westem-blot analysis (Figure 3A (western blot image from one 
subjects) and figure 3B (all subjects)). In addition, caspase-1 activity was enhanced 
in VAT compared to SAT as determined by a functional caspase-1 activity assay in 
freshly isolated adipose tissue from two patients (Figure 3C).
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Figure 3. Protein levels of ASC, NLRP3 and caspase-1 in VAT and SAT. A. Caspase-1, ASC and 
NLRP3 protein levels in paired total SAT and VAT samples. Western blot images are shown for one 
subject. Several bands observed for NLRP3 represents the difference in length of the leucine-rich 
repeats, which forms a part of NLRP3 (53). B. Mean caspase-1, ASC and NLRP3 protein expression in 
paired SAT and VAT samples from ten subjects quantified by densitometry relative to actin protein levels. 
C. Functional caspase-1 activity assay in paired SAT and VAT of two different subjects. D. Relative 
caspase-1, ASC and NLRP3 gene expression in MAT and the SVF isolated from VAT (n=7) * = P-val- 
ue<0.05, ** P-value<0.01 using a Wilcoxon rank test.
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The abundant activity of caspase-1 in VAT (Figure 3A, B and C), implies the pres­
ence of the inflammasome machinery in human adipose tissue. Therefore, we tested 
whether the inflammasome components NLRP3 and ASC were present in the ten 
human VAT and SAT samples. Similar to caspase-1, ASC protein was detected in both 
depots, yet significantly upregulated in VAT (Figure 3A (western blot image from 
one subjects) and figure 3B (all subjects)). Due to a large inter-individual variation 
in NLRP3 protein levels between SAT and VAT, the expression levels of this protein 
only tended to be higher in VAT without reaching statistical significance. (Figure 3A 
and B). To investigate the cellular origin of the inflammasome components in hu­
man adipose tissue, qPCR analysis of fractionated VAT revealed that caspase-1 gene 
expression mainly originated from mature adipocytes, while ASC mRNA expression 
levels were higher in the SVF (Figure 3D). NLRP3 transcription levels were equally 
distributed between the two fractions of VAT (Figure 3D).
Blocking o f caspase-1 inhibits cytokine release o f VAT
To determine the potential of caspase-1 blockage to reduce the inflammatory trait of 
VAT, caspase-1 activity was blocked by the specific inhibitor pralnacasan. In figure 
4A, the enhanced release of both IL-1|3 and IL-18 in VAT was significantly reduced 
when caspase-1 was blocked.
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Figure 4. Caspase-1 inhibition reduces production of IL-1ß, IL-18, IL-6, IL-8 yet not TNFa from 
VAT. A. Secretion of IL-1ß, bioactive IL-1 (# measured as IL-2 production from NOB-1 cells in response 
to bioactive IL-1), and IL-18 by intact VAT («=5) cultured for 24 hours in the presence or absence of 
pralnacasan (100^M). B. IL-1ß production by MAT and SVF isolated from one gram of SAT and VAT 
(«=4) cultured for 24 hours in the presence or absence of pralnacasan (100^M). C. Secretion of IL-6, 
IL-8, TNFa and adiponectin by intact VAT («=5) cultured for 24 hours in the presence or absence of 
pralnacasan (100^M). * = P-value<0.05, ** P-value<0.01 using a Wilcoxon rank test.
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The diminished IL-1P production in VAT was observed in both adipocytes and SVF 
cells, illustrating that caspase-1 is functionally active in both cellular fractions (Figure 
4B). Interestingly, inhibition of caspase-1 activity also limited the boosted production 
of IL-6 (P-value=0.06) and IL-8 (P-value<0.05) by VAT, yet no effect was observed 
on adiponectin and TNFa secretion levels (Figure 4C). These results demonstrate 
that caspase-1 activity is mainly responsible for the production of IL-ip and IL-18 by 
VAT.
The percentage o f CD8+ T-cells in adipose tissue positively correlates with 
caspase-1 activity levels
Adipose tissue inflammation is partly caused by the influx of immune cells includ­
ing macrophages, monocytes, and T-cells (30-33). To examine whether the intrinsic 
activity of caspase-1 in adipose tissue is associated with the immune cell composition, 
we studied correlations between caspase-1 activity levels and the number of immune 
cells present in both adipose tissue depots as determined by FACS analysis (Table 1).
As shown in figure 5, a significant positive correlation was observed between cas- 
pase-1 activity levels and the percentage of CD8+ T-cells present in adipose tissue.
Noticeably, none of the other cells measured by FACS analysis (Table 1) correlated 
significantly with caspase-1 activity levels (data not shown). Interestingly, CD8+ T- 
cells have been shown to serve as a major contributor to adipose tissue inflammation 
^  (34). In line with the differences in caspase-1 activity levels between VAT and SAT, ^
the number of CD8+ T-cells was significantly lower in SAT (Table 1). Moreover, both 
in SAT and VAT separately, a positive correlation was observed between caspase-1 
activity levels and the CD8+ T-cells present in adipose tissue (data not shown). These 
results suggest that caspase-1 activity in adipose tissue is associated with the influx of 
CD8+ T-cells.
Caspase-1 activity 
(p35/actin)
Figure 5. Caspase-1 activity levels correlates 
positively with CD8+ T-cell num ber present 
in both SAT and VAT. Caspase-1 activity 
is represented by the density of the active 
caspase-1 band (p35). Percentage of CD8+ 
T-lymphocytes in the SVF from both SAT and 
VAT were obtained by FACS analysis (ft=7) 
P-value<0.01 using Spearman’s rank correla­
tion.
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Discussion
In this descriptive study, we demonstrate that in paired human adipose tissue biopsies 
the innate immune system represented by the NLRP3 inflammasome is abundantly 
present in VAT compared to SAT. In addition, intrinsic caspase-1 activity is elevated 
in VAT contributing to the production of IL-1p and IL-18 as well as IL-6 and IL-8.
Moreover, caspase-1 activity levels positively correlated with CD8+ T-cells present in 
the adipose tissue.
In addition to the storage of excessive amounts of energy, adipose tissue has been 
identified as a source of many inflammatory mediators (1). Interestingly, obesity- 
induced low-grade inflammation originating from expanding adipose tissue, exploits 
similar pathways initiated by host defense mechanisms suggestive of an important 
function of the innate immune system in fat (5;35). Circulating levels of IL-ip and 
IL-18, both part of the innate immune response, are increased in obese and insulin 
resistant individuals and have robust effects on atherosclerosis and insulin resistance 
(36;37). Several reports have identified adipose tissue as a potent source of IL-18 and 
IL-ip (4;23;38). Human adipose tissue depots have unique inflammatory character­
istics exemplified by enhanced production of IL-6, IL-8, TNF-a, and CRP by VAT 
compared to SAT, that contribute to key features of the metabolic syndrome (7;8;39-
0  41). In line with these studies, we showed an increased production of IL-6, IL-8 and ^
IL-iRa, together with lower secretion levels of adiponectin in VAT explants.
In this study, we extended the pro-inflammatory properties of VAT by demonstrating 
that the protein levels of the inflammasome members NLRP3 and ASC were more 
expressed in this specific depot and that caspase-1 activation is severely increased in 
VAT compared to SAT resulting in a higher production of IL-1p and IL-18. In ad­
dition, secretion levels of the anti-inflammatory cytokine IL-1Ra by VAT were also 
enhanced and may be the result of a compensatory protective response aimed at 
counteracting the excessive IL-1p secretion by VAT. Caspase-1 dependent production 
of IL-1p and IL-18 is supported by the observation that blocking caspase-1 activity 
in VAT by pralnacasan reduces the secretion of both cytokines. Furthermore, IL-1p 
release was reduced in both adipocytes and SVF after inhibiting caspase-1, indicat­
ing that this enzyme is involved in the IL-1p production in both fractions of VAT.
The caspase-1 dependent release of IL-6 and IL-8 by VAT fits with the well-known 
capacity of IL-1p to enhance the production of IL-6 and IL-8 by adipose tissue 
(42;43). Our results show that activation of caspase-1 controls the production of these 
pro-inflammatory proteins by VAT. However, secretion levels of TNFa from both fat 
depots were comparable suggesting that the enhanced release of IL-1p and IL-18 is 
conveyed by a specific mechanism and does not involve a general increase in inflam­
matory status of VAT.
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Although our study clearly demonstrated that IL-ip production was mainly derived 
from the SVF within VAT, mature adipocytes were also capable to release IL-ip. We 
hypothesize that in-vivo, an interaction between adipocytes and various cells from the 
SVF determine the caspase-1 dependent cytokine-secreting capacity of the adipose 
tissue, hence explaining the high levels of caspase-1 gene expression in adipocytes. 
Additionally, these high mRNA expression levels in adipocytes may also indicate 
IL-ip independent effects. Caspase-1 has been shown to regulate insulin sensitivity 
and to suppress PPAR-y activity in adipocytes (23;44). Despite the enhanced IL-ip 
production in VAT compared to SAT and elevated protein levels of caspase-1 and ASC 
analyzed by western blot, we would like to emphasize that these outcomes can only be 
used as indirect measurements of inflammasome-dependent caspase-1 activation since 
the inflammasome depends on protein-protein interactions to activate caspase-1.
Even though it has been clearly established that VAT displays enhanced inflamma­
tory properties compared to SAT, much less is known about the underlying molecular 
mechanisms. Macrophage infiltration is known to contribute to the inflammatory 
status of a tissue (28). In the present study, FACS analysis revealed no differences in 
macrophage content in both fat depots, although we did not differentiate between the 
resident macrophage populations and the infiltrating macrophages that may repre­
sent the primary pro-inflammatory cells (45). The percentage of adipose tissue mac­
rophages in this study was relatively low compared subjects suffering from severe 
obesity (46). This could be explained by inclusion of solely (healthy) overweight 
subjects (average BMI: 26.1 kg/m2 ± SD 2.7). In addition to macrophages, the per­
centage of other immune cells that are part of the innate immune system (monocytes 
and granulocytes) present in the SVF of VAT and SAT did not differ. These results 
rule out differences in caspase-1 activity in VAT compared to SAT due to the influx of 
innate immune cells. However, in this study caspase-1 activity was associated with the 
infiltration of cytotoxic T-lymphocytes into adipose tissue. A robust positive correla­
tion was observed between caspase-1 activity levels and the number of CD8+ T-cells 
present in adipose tissue. Moreover, differences in the percentage of CD8+ T-cells in 
VAT compared to SAT were mirrored by similar changes in caspase-1 activity levels. 
Although we did not study the direct effect of caspase-1 on CD8+ T-cell influx in the 
adipose tissue, caspase-1 itself or by its activation of IL-1p and IL-18 might control 
the activation and number of CD8+ T-cells present in human adipose tissue. Inasmuch 
a recent study has demonstrated an important role for CD8+ T-cells in determining 
adipose tissue inflammation, the influx of these T-cells may represent an important 
mechanism by which caspase-1 controls adipose tissue inflammation (34). However, 
further studies will be needed to reveal the possible role of caspase-1 in controlling 
the influx of CD8+ T-cells into adipose tissue.
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Future research should be aimed at identifying possible signals that trigger caspase-1 
activation specifically in VAT. The enhanced rate of lipolysis and resistance to insulin 
action in VAT (47;48) may contribute to elevated activity levels of caspase-1. Hyper­
glycemia may also be one of the stimulators of caspase-1 in VAT (19), although it re­
mains to be determined why high glucose levels would specifically activate caspase-1 
in VAT and not in SAT. In addition to NLRP3, other members of the NLR family that 
can activate caspase-1, including NLRP1, NLRC4 (IPAF), should be studied in human 
adipose tissue.
Irrespective of the cellular origin or activators of caspase-1, we demonstrate that the 
differences in IL-1p and IL-18 release in VAT are mediated by caspase-1. Previously, 
it has been suggested that expression and regulation of IL-1p are not solely dependent 
on inflammasome-mediated caspase-1 processing (49;50). Several studies have identi­
fied other enzymes that can process pro-IL-1p and pro-IL-18 into their active forms 
including the neutrophil-derived proteinase-3 under circumstances when neutrophils 
infiltrate sites of infection (51). Interestingly, it has been reported that neutrophils are 
activated to a greater extend in obese subjects (52), suggesting that these cells may 
also contribute to processing of bioactive IL-1p and IL-18. However, FACS analysis 
revealed no difference in granulocyte infiltration in both fat depots, making it less 
likely that IL-1p and IL-18 production by VAT occurred independently of caspase-1.
#  #  
Whereas our study population was composed of a relatively small number of over­
weight subjects, future studies should be aimed at comparing caspase-1 levels in 
severely obese and non-obese individuals with or without type 2 diabetes mellitus in 
larger study populations. Hypothetically, enhanced caspase-1 activation in VAT of 
severely obese individuals may explain why an increase in this fat depot is associated 
with an enhanced pro-inflammatory status that may contribute to the progression of 
cardiovascular disease and type 2 diabetes mellitus.
In conclusion, we demonstrate that the inflammasome components NLRP3, ASC and 
caspase-1 are present in human abdominal adipose tissue and are highly activated in 
VAT compared to SAT. Caspase-1 activation leads to an increased release of IL-1p 
and IL-18, regulates the production of other pro-inflammatory cytokines including 
IL-6 and IL-8 and appears to be associated with the number of CD8+ T-cells present 
in adipose tissue. These findings give new insight into the important function of cas- 
pase-1 activation in determining the inflammatory characteristics of human adipose
tissue.
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Supplemental data
Supplemental table 1
Characteristics of the study population
Characteristics All
N  (male/female) 10 (5/5)
Age (years) 50.5 (8.33)
BMI (kg/m2) 26.1 (2.73)
WHR 0.90 (0.06)
Glucose (mmol/L) 5.1 (0.65)
hsCRP (mg/L) 0.29 (0.24)
Data are presented as means ± SD. BMI, body mass index; WHR, waist- 
to-hip ratio; Glucose; fasting levels of plasma glucose hsCRP, plasma 
levels of high sensitivity C-reactive protein.
Leptin Adiponectin CD45
Supplementary figure 1. Purity of adipose tissue fractioning. Analysis of adiponectin, leptin, and CD45 
gene expression levels in the SVF and MAT fraction from VAT. ** = ,P-value<0.01 using a Student’s T- 
test.
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Supplementary figure 2. Immune cell composition of the SVF of human SAT and VAT. Representative dot plots o f flow cytometry data showing 
immune cells that are part o f the innate immune system (granulocytes (CD45+; CD67+), monocytes (CD45+; CD14+; F4/80) and macrophages (CD45+; 
CD14+; F4/80+)) and adaptive immune system (total lymphocytes (CD45+ cells plotted against side-scatter area), CD4+ T-cells (CD3+; CD4+ within the 
lymphocyte population) and CD8+ T-cells (CD8+ plotted against side-scatter area within the lymphocyte population)) within the SVF cells o f SAT (A) 
and VAT (B).
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Inflammatory Adipose (T)issue: Central Role for IL-ip
Obesity-induced insulin resistance is associated with elevated serum levels of pro- 
inflammatory mediators including the IL-1 family members IL-ip and IL-18 (1-3).
Despite a lot of research during the past years, the underlying mechanism which 
trigger the development of insulin resistance and type 2 diabetes mellitus remain 
largely unknown. However, results of numerous animal studies, in-vitro experiments 
and clinical trials have generated evidence that IL-ip-driven inflammation in pancre­
atic beta-cells plays an important role in the pathogenesis of type 2 diabetes mellitus 
(2;4-6). Additionally, inflammation originating from adipose tissue has been shown to 
drive the development of metabolic abnormalities including insulin resistance (7;8).
However, the central role of the IL-ip-driven inflammatory response in adipose tissue 
has not been clearly described.
Inflammation is a physiological mechanism necessary to defend the host from external 
and internal “danger” signals, such as pathogens, DNA damage and metabolic stress 
(9). Continuous presence of these “danger” signals, which may occur during the de­
velopment of obesity, could eventually result in an immunogenic reaction in adipose 
tissue. The inflammatory response in adipose tissue which promotes the development 
of insulin resistance needs several components that include: 1) a trigger to induce an 
inflammatory response, 2) a sensor recognizing the trigger, 3) inflammatory mediators 
^  that regulate the immune response and 4) influx of immune cells which contribute to ^
the inflammatory response.
Deciphering the inflammatory cascade in obesity-induced insulin resistance will ulti­
mately lead to more effective and specific anti-inflammatory interventions. Based on 
these four inflammatory components, we will postulate a concept in which the inflam- 
masome-mediated caspase-1 activation plays an important role in controlling adipose 
tissue inflammation during the development of obesity and insulin resistance through 
its control of IL-ip release. This results in a vicious circle of pro-inflammatory media­
tors secreted by dysfunctional adipose tissue preserving the chronic inflammatory 
environment, which could eventually lead to insulin resistance.
Metabolic signals triggering adipose tissue inflammation
Several metabolic triggers including excessive amounts of nutrients, have been found 
to initiate and maintain obesity-induced inflammation (10-12). Hyperglycemia has 
been linked to a pro-inflammatory environment in different tissues including blood 
vessels, pancreas and adipose tissue. High levels of glucose increase the ability of 
circulating monocytes for endothelial cell attachment and induce the expression of 
IL-ip, IL-6, IL-8 and MCP-1 in adipocytes, endothelial cells and pancreatic beta-cells 
(13-18). Similar to glucose, elevated levels of free fatty acids (FFAs) induce inflam-
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matory cytokine production including IL-ip, IL-6 and TNF-a in pancreatic islets, 
macrophages and adipocytes (i9-2i).
Research using pancreatic beta-cells and macrophages gave important clues about 
which nutrient-derived triggers are involved in the secretion of IL-ip. Nutrient-de­
rived triggers including elevated levels of glucose, FFAs, leptin, oxidized low density 
lipoprotein (oxLDL), gut microbiota-derived lipoploysaccharide (LPS), cholesterol 
crystals, and islet amyloid polypeptide have been found to induce the release of 
bioactive IL-ip (i9;22-28). In addition, IL-ip itself is able to increase the levels of 
pro-IL-ip in an autocrine fashion (5). Our results demonstrated that elevated levels of 
glucose also increase the secretion of IL-ip in adipose tissue (chapter 6).
Toxicity by elevated levels of glucose and FFAs is mediated, at least to a significant 
extend, by an increased production of reactive oxygen species (ROS) which lead to 
oxidative stress in pancreatic beta-cells, macrophages and adipose tissue (i6;i8;29). 
Recent evidence suggest that ROS stimulate the secretion of IL-ip in pancreatic beta- 
cells and macrophages (30). Thus ROS may also play an important role in adipose 
tissue inflammation during obesity. However, more research is necessary to unravel 
the involvement of ROS in adipose tissue release of IL-ip upon stimulation with high 
levels of glucose or free fatty acids.
^  Cellular sensor mechanism recognizing metabolic triggers: ^  
Role of the inflammasome
How does adipose tissue sense these triggers which arise during the development 
of obesity? Recently, a mechanism has been uncovered in pancreatic beta-cells and 
macrophages, which involves NLRP3 inflammasome-mediated caspase-i activation 
upon stimulation with nutrition-derived ligands (3i;32). These results suggest that 
NLRP3 inflammasome-dependent release of IL-ip contributes to the pathogenesis of 
type 2 diabetes mellitus. We demonstrated for the first time the presence of NLRP3 
inflammasome components in adipose tissue, together with increased levels of cas- 
pase-i activity and IL-ip in adipose tissue of obese mice models, which supports the 
concept that a similar sensing mechanism exists in adipose tissue (chapter 5 and 6).
Indeed, caspase-i-/- mice show a decrease in adipose tissue-derived IL-ip and reveal 
an improvement of insulin sensitivity as compared to wild-type mice. Thus, caspase-i 
is an important link between obesity-induced inflammation in adipose tissue medi­
ated by IL-ip and the development of insulin resistance. Interestingly, we showed that 
the intrinsic levels of the NLRP3 inflammasome components are significantly higher 
expressed in visceral adipose tissue (VAT) compared to subcutaneous adipose tissue 
(SAT), which corresponds with the elevated basal IL-ip production in this specific 
depot (chapter 7).
As previously mentioned, NLRP3 inflammasome serves as an intracellular sensor
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of metabolic stress in mouse pancreatic beta-cells and macrophages resulting in an 
enhanced release of IL-ip. A crucial role for ROS as a potential activator for NLRP3 
has been described (33). The mechanism whereby ROS lead to NLRP3 inflammasome 
activation upon stimulation with high concentrations of glucose in mouse pancreatic 
beta-cells has been described by Zhou et al (34). In this model, thioredoxin interact­
ing protein (TXNIP) has a prominent role since it dissociates from the ROS scavenger 
thioredoxin after oxidative stress and activates the inflammasome by binding NLRP3. 
Interestingly, TXNIP is also involved in glucose uptake in adipocytes (35). We 
showed for the first time that TXNIP regulates high glucose-induced IL-ip transcrip­
tion in adipocytes, without affecting caspase-i activation (chapter 6). Additionally, 
hyperglycemia tended to elevate protein levels of NLRP3 in adipocytes (chapter 6), 
which fits with the concept that NLRP3 inflammasome-dependent IL-ip release could 
also be controlled by the expression level of NLRP3 itself (36). All together, these 
findings indicate that in adipose tissue NLRP3 inflammasome could indeed act as an 
intracellular sensor detecting nutrient-derived triggers like elevated levels of glucose. 
However, the pathway which leads to hyperglycemia-induced IL-ip secretion in adi­
pocytes seems to differ from what is observed in pancreatic beta-cells. In contrast to 
the study of Zhou et al, we did not detect a direct role for TXNIP in caspase-i activa­
tion.
#  #  
Role of IL-1 family members in adipose tissue inflammation
The IL-1 family members IL-1p and IL-18 are strongly associated with inflammation 
and partially secreted by adipose tissue from subjects with obesity and insulin resis­
tance (37-39). Whereas increased levels of IL-p are linked to the development of insu­
lin resistance (2;40;41), IL-18 appears to suppress insulin resistance as a consequence 
of reducing obesity caused by inhibition of food and energy intake, as observed in 
IL-18 -/- mice (42;43) (chapter 4). Paradoxically, obese subjects are often character­
ized by increased levels of circulating IL-18. This observation may be explained by 
the development of a lower cellular response to IL-18 in obese subjects, which is sub­
sequently compensated by a higher production of IL-18 similar to hyperinsulinemia 
and hyperleptinemia (44). These data suggest that IL-1p and IL-18 oppositely affect 
systemic insulin sensitivity. In chapter 5 we showed that the absence of caspase-1, has 
a beneficial effect on insulin sensitivity. This suggests that the absence of the adverse 
effects of IL-1p dominate the increased insulin resistance associated with the lack of 
IL-18.
In this thesis we demonstrated the central role of IL-1p in adipose tissue inflammation 
in different ways. First, IL-1p secretion by adipose tissue is higher in animal models 
associated with obesity and insulin resistance (chapter 5). Secondly, hyperglycemia 
induce the release of IL-1p in adipocytes (chapter 6) and finally, VAT secretes higher
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levels of IL-1p compared to SAT (chapter 7). The hazardous effects of IL-1p in 
adipose tissue which contribute to the pathophysiology of insulin resistance have been 
partially unravelled in different human and rodent studies. Elevated levels of IL-1p 
reduce adipocyte differentiation, stimulate lipolysis and inhibit the insulin signalling 
pathway in adipocytes (40;45-47) (chapter 5).
Impaired adipocyte differentiation could indirectly lead to hypertrophy of the remain­
ing adipocytes. Besides a decrease in adiponectin production, enlarged adipocytes 
secrete higher levels of the pro-inflammatory mediators leptin, MCP-1, TNF-a, IL-6 
and FFAs which promote insulin resistance (48;49). This could induce the infiltration 
of macrophages into adipose tissue, which contribute to the inflammatory response by 
inducing the secretion of pro-inflammatory cytokines. Indeed, the number of mac­
rophages in adipose tissue have been shown to correlate directly with adipocyte size 
(50). Decreased levels of adiponectin are associated with enhanced expression of pro- 
inflammatory genes including hsCRP, TNF-a and IL-6 (51-53), whereas the produc­
tion of the anti-inflammatory cytokines IL-1Ra and IL-10 are reduced in macrophages 
(54;55).
Interestingly, in pancreatic islets IL-1p is capable to potentiate its own secretion by 
auto-stimulation mediated by NF-kB, which is a known activator of the IL-1p pro­
moter (5;56). This auto-stimulation process has not been described in adipose tissue 
so far. However, it is possible that this mechanism is present in adipose tissue ampli­
fying the immune response, yet more research is needed to verify this hypothesis. In 
addition, IL-1p is a potent inducer of IL-6 and IL-8 in adipose tissue and blocking the 
effects of endogenous IL-1p in an adipose tissue explant culture with a neutralizing 
antibody results in a decrease of both IL-6 and IL-8 (57).
All together, IL-1p-induced inflammation creates a disturbed balance between pro- 
inflammatory and anti-inflammatory mediators in adipose tissue, which may lead to 
an increased risk to develop type 2 diabetes and CVD.
Cells contributing to the IL-ip-mediated inflammatory re­
sponse within the adipose tissue
Initially, it was thought that IL-ip was primarily produced by cells of the innate im­
mune system (58;59). However, it became clear that cells outside the immune system 
secrete IL-ip including pancreatic beta-cells and adipocytes (15;60). Adipose tissue 
of subjects suffering from obesity and insulin resistance is characterized by an in­
flux of macrophages (50;61). Together, these cells may contribute to increased IL-ip 
production due to coherence and create an inflammatory environment in the adipose 
tissue. This is in line with the IL-ip transcription levels observed in the different cel­
lular fractions of adipose tissue. Although IL-ip is expressed by isolated adipocytes, 
IL-ip transcription levels are significantly higher in stromal vascular fraction (SVF)
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derived from adipose tissue (chapter 7). Comparison of the expression levels of the 
inflammasome members in the different adipose tissue fractions revealed that NLRP3 
is equally distributed among the different adipose tissue fractions, caspase-i is sig­
nificantly elevated in mature adipocytes, whereas the expression of adapter protein 
apoptosis-associated specklike protein (ASC) is higher in the SVF fraction. This dis­
crepancy in inflammasome expression could suggest a crosstalk between adipocytes 
and immune cells in the adipose tissue regulating and amplifying IL-ip production. 
However, additional studies are needed to single out the contribution of each adipose 
tissue fraction to produce IL-ip.
Interestingly, we reported a strong positive correlation between caspase-i activation 
and the presence of CD8+ T-lymphocytes (cytotoxic T-cells) in both VAT and SAT 
of overweight subjects (chapter 7). The contribution of this pro-inflammatory T-cell 
subset in adipose tissue inflammation has been revealed in a study by Nishimura et al., 
who described that cytotoxic T-cells precede the invasion of macrophages into adipose 
tissue during the onset of obesity (62). Although more studies will be needed to deter­
mine the exact underlying cause of the association between caspase-i and cytotoxic 
T-cells, caspase-i itself or via IL-ip activation may control the number of cytotoxic 
T-cells present in human adipose tissue. This concept is supported by a study demon­
strating that IL-ip induces the secretion of the chemokine IP-i0 in mature adipocytes 
which regulates the migration of T-cells into adipose tissue (63).
All together, we demonstrated that both the adipocyte fraction and the immune cells 
in the SVF fraction may contribute to the caspase-i-dependent production of IL-ip. 
Furthermore, increased caspase-i activation in adipose tissue is associated with an 
increased number of cytotoxic T-cells, which may contribute to the progression of the 
inflammatory response.
Therapeutic and lifestyle interventions to inhibit obesity- 
induced inflammation
Normally, the acute immune response is terminated when the initial trigger has been 
eliminated. However, during obesity, adipose tissue is continuously exposed to nutri­
ent-derived triggers, which results in persistent low-grade inflammation. Suppressing 
the inflammatory response by modulating one of the four critical components of the 
inflammatory cascade within adipose tissue inflammation, will lead to beneficial ef­
fects on insulin sensitivity. First of all, there have been some experiments with ROS 
inhibitors which target oxidative stress in cells resulting in a restoration of insulin 
sensitivity (18;64). This might also be a promising intervention in reducing adipose 
tissue inflammation. Other targets that could suppress the inflammatory response in 
adipose tissue include inhibitors of the inflammasome sensing mechanism. In line 
with this, we clearly demonstrated that treatment of Ob/Ob mice, characterized by
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insulin resistance, display a reduction in weight gain and improvement of insulin sen­
sitivity after oral treatment with a caspase-i inhibitor. This could be explained by the 
loss of the direct deleterious metabolic effects of IL-ip on adipogenesis and improved 
adipose tissue insulin sensitivity. Additionally, metabolic cage analysis reveals that 
caspase-i-/- animals are characterized by an enhancement in fat oxidation rate, which 
may contribute to the beneficial effects on adiposity compared to wild-type animals 
(chapter 5). Recent data have also revealed that the absence of caspase-i prevents the 
influx of macrophages into adipose tissue during high fat diet-feeding (unpublished 
data). Furthermore, blocking caspase-i results in a diminished pro-inflammatory 
secretion profile in VAT by reducing the IL-p-induced production of IL-6 and IL-8. 
Specifically targeting NLRP3 would also be an interesting probability to suppress 
the release of IL-ip, since this inflammasome component has mainly been ascribed 
to sense metabolic abnormalities associated with obesity. Moreover, inflammasomes 
consisting of other cytoplasmic sensors would not be affected in this way, which pre­
vents the lack of a decent immune response during infection.
Until now, several animal experiments and clinical trials have been performed to 
study the effects of IL-ip neutralization (antibody against IL-ip) or IL-i receptor 
blockade (IL-iRa treatment) on glycemic control. Blocking the effects of IL-ip in 
patients with type 2 diabetes mellitus and in insulin resistant animal models, revealed 
an improvement of glycemic control and pancreatic beta-cell function (4;65). Until 
now, the beneficial effects of these treatments have not been studied in adipose tissue, 
yet in-vitro experiments with VAT explants suggests that blocking endogenous IL-ip 
results in a decreased production of pro-inflammatory cytokines (57). Furthermore, 
blocking IL-ip release from adipocytes prevents hepatic insulin resistance, which 
suggest that IL-ip could mediate a specific cross talk between adipose tissue and liver
(4i).
Another approach to disrupt the pro-inflammatory status of adipose tissue, is to reduce 
adipocyte hypertrophy by treatment with thiazolidinediones (TZDs) or to lose weight. 
Indeed, a decrease in adipocyte cell surface observed after weight loss and treatment 
with TZDs normalizes the release of FFAs and TNF-a, which ameliorating insulin 
sensitivity (66;67). TZDs also increase the expression of adiponectin and stimulate 
visceral adipocyte differentiation promoting the development of small insulin sensi­
tive adipocytes (68;69). Interestingly, we found that the TZD pioglitazone results in 
subcutaneous adipocyte enlargement with a reduction in inflammation and improve­
ment of insulin sensitivity (chapter 3). This could be explained by redistribution of 
visceral fat storage towards the SAT depot, leading to smaller, more insulin sensitive 
visceral adipocytes. Furthermore, it has been found that inducing macrophage-specific 
PPAR-y activity promotes differentiation towards macrophages with anti-inflamma­
tory characteristics (70;7i). Interestingly, we observed that the TZD rosiglitazone in­
hibits high glucose-induced IL-ip possibly by down-regulating TXNIP in adipocytes 
(chapter 5). These findings result in a reduction of pro-inflammatory mediators in the
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adipose tissue that may contribute to the pathogenesis of insulin resistance.
Other promising research against obesity and metabolic disease has focused on spe­
cific nutrients that may have anti-inflammatory potential, the polyunsaturated FFAs. 
High fat diet-fed mouse treated with additional polyunsaturated FFAs show a de­
creased expression of pro-inflammatory cytokines, a reduction in macrophage infiltra­
tion into adipose tissue and an improvement of systemic insulin sensitivity (72). In 
contrast to saturated FFAs, polyunsaturated FFAs may exert their anti-inflammatory 
effects through inhibiting TLR4 signaling, thereby reducing the release of pro-inflam­
matory mediators (73). In this context it would be interesting to study potential inhibi­
tory effects on inflammasome/caspase-1 activation by polyunsatured FFAs.
Conclusion
In conclusion, elevated levels of glucose accompanied with obesity create an in­
flammatory environment in adipose tissue by inducing caspase-1-dependent IL-ip 
production in adipocytes through the NLRP3 inflammasome. During the onset of 
obesity, IL-ip contributes to the progression of adipocyte hypertrophy by inhibit­
ing differentiation of newly formed adipocytes resulting in adipocyte dysfunction 
characterized by an increased pro-inflammatory cytokine and chemokine secretion 
profile. This contributes to the recruitment of immune cells including cytotoxic T-cells 
and macrophages into the adipose tissue, which further potentiates the inflammatory 
response. This inflammatory cascade, induced by caspase-1 activation, seems to be 
more pronounced VAT as compared to SAT which may explain why accumulation of 
the visceral fat depot contributes to the increased risk to develop insulin resistance or 
CVD (74). Therefore, we would like to propose a central role for caspase-1-mediated 
IL-ip activation in adipose tissue inflammation during obesity (Figure 1).
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Figure 1. IL-ip-mediated inflammation in adipose tissue during obesity. Metabolic triggers like hy­
perglycemia, and perhaps free fatty acids (FFAs), promote IL-ip in hypertrophic adipocytes by activating 
two separate pathways. 1). inducing IL-ip mRNA transcription via up-regulating o f TXNIP expression 
2). increasing (NLRP3 inflammasome-dependent) caspase-1 activation. This leads to the release o f active 
IL-ip by the adipose tissue. IL-ip inhibits adipocyte differentiation and induce expression o f pro-inflam­
matory mediators (IL-6, IL-8 TNF-a, IP-10 and MCP-1), which recruit cytotoxic T-cells and macro­
phages into the adipose tissue. The immune cells contribute to a broad immune response and infiltrated 
macrophages further promote the release o f IL-ip and other cytokines (IL-18 and TNF-a).
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Future perspectives
Since the discovery that obesity-induced insulin resistance is accompanied by a 
systemic low-grade inflammation originating from adipose tissue, many efforts have 
been made to unravel the triggers of the inflammatory response and the subsequently 
activated mechanisms which finally result in the development of systemic insulin 
resistance. Although our data suggests an important role for caspase-1 in regulating 
adipose tissue inflammation by mediating IL-ip activity, some unanswered questions 
still remain.
Like discussed in chapter 8, most of the research that aims at identification of 
obesity-induced triggers and its sensors has been performed in pancreatic beta-cells 
and macrophages. Except the role of hyperglycemia studied in this thesis, it is un­
known whether triggers like oxidized LDL, FFAs and cholesterol crystals also lead to 
caspase-1 mediated IL-ip release in adipose tissue.
Apart from the NLRP3 inflammasome, other inflammasomes have been 
described based upon the NLRs cytoplasmic sensor component including NLRP1 and 
NLRC4. Recently, the protein absent in melanoma 2 (AIM2) has also been reported 
to have the capacity to assemble an inflammasome. Therefore, future research should 
focus on the identification of the specific inflammasomes that may contribute to the 
obesity-induced adipose tissue inflammation.
^  In chapter 7 we observed an increase in caspase-1 activation in VAT com­
pared to SAT, which may partly explain the pro-inflammatory character of this fat 
depot. However, the paired adipose tissue biopsies were obtained from mildly over­
weight subjects only. Therefore, it would be interesting to study caspase-1 activation 
in fat depots from both lean and obese subjects or from patients suffering from type 
2 diabetes and familial combined hyperlipidemia (FCH). This will give valuable 
insights into the role of caspase-1-mediated inflammation in SAT and VAT and the 
pathogenesis of insulin resistance and type 2 diabetes mellitus.
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Summary
Obesity is characterized by excessive adipose tissue accumulation, caused by an inac­
tive lifestyle, increased food intake and genetic factors that may predispose to exces­
sive weight gain. Obesity is associated with an increased risk to develop metabolic 
disorders that include insulin resistance, type 2 diabetes mellitus and cardiovascular 
diseases (CVD). Alterations in the endocrine characteristics of the adipose tissue play 
a major role in mediating these metabolic abnormalities including a disturbed secre­
tion of various adipokines that leads to changes in energy homeostasis, lipid- and 
glucose metabolism. These mostly adverse metabolic alterations are associated with 
profound changes in adipose tissue morphology that include an increased number of 
large dysfunctional adipocytes.
Research has singled out inflammation as one of the most important links between 
obesity and the development of metabolic abnormalities. Elevated levels of circulating 
cytokines are observed in insulin resistant subjects and closely correlate with an in­
crease in adipose tissue mass. More specifically, it has been shown that the enhanced 
inflammatory status observed in obese subjects primarily originates from expanding 
visceral adipose tissue (VAT) whereas the enlargement of the subcutaneous adipose 
tissue (SAT) depot is relatively harmless.
Only since the early 90’s, our view of the adipose tissue as solely an organ to store 
^  excessive amounts of energy has dramatically changed as several studies revealed ^
that the adipose tissue is a prominent source of pro-inflammatory mediators in obese 
individuals. TNF-a, MCP-1, IL-6, IL-8, IL-ip and IL-18 are among a rapidly growing 
list of pro-inflammatory mediators secreted by the adipose tissue during the develop­
ment of obesity. Most importantly, inflammation of the adipose tissue is accompanied 
by an influx of a variety of immune cells including macrophages, neutrophils, and 
T-lymphocytes. These pro-inflammatory characteristics are more closely linked to ex­
panding VAT as compared to SAT. However, the exact mechanisms by which obesity 
contributes to the development of metabolic abnormalities via propagation of adipose 
tissue inflammation are still unknown.
Pathogenic role of adipose tissue in metabolic disorders
Disturbed adipose tissue function: altered adiponectin secretion 
We demonstrated that total plasma levels of the anti-inflammatory and insulin-sen­
sitizing protein adiponectin were reduced in subjects diagnosed with familial com­
bined hyperlipidemia (FCH), who are characterized by elevated levels of cholesterol, 
triglycerides, apo-lipoprotein B and insulin resistance. Adiponectin circulates in 
various multimeric isoforms: low molecular weight (LMW), middle molecular weight 
(MMW) and high molecular weight (HMW) isoform. Additional studies have shown
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that the favourable metabolic and anti-inflammatory effects of adiponectin are mainly 
mediated by the HMW isoform of adiponectin. Therefore the beneficial circulating ad- 
iponectin profile is often expressed as the ratio between HMW and total adiponectin, 
whereas a more unfavourable adiponectin profile is expressed as the LMW to HMW 
ratio. Therefore, we investigated whether a reduced plasma level of total adiponectin 
in subjects with FCH was accompanied by a change in adiponectin multimer distribu­
tion. In addition, we studied the association between the circulating concentrations 
of the different adiponectin multimeric isoforms and the presence of CVD in patients 
suffering from FCH (chapter 2).
The decreased systemic levels of total adiponectin found in subjects with FCH com­
pared to healthy controls was mainly attributed to a reduction in both the LMW and 
HMW isoforms of adiponectin. However, the ratio between the HMW isoform and 
total adiponectin and the LMW/HMW adiponectin ratio did not differ between FCH 
and control subjects. The adiponectin multimer distribution differed significantly 
between male and female subjects in both study populations and the more favour­
able distribution was observed in females. Interestingly, within the group of females 
diagnosed with FCH, the presence of CVD correlated with a reduction of the HMW 
form of adiponectin compared to women without CVD (HMW/total adiponectin: 34.2 
± 10% vs. 46.0 ± 7.1% for FCH females with and without CVD, respectively; LMW/ 
HMW adiponectin ratio: 1.3 ± 0.8 and 0.9 ± 0.7 for FCH females with and without 
CVD, respectively). Inasmuch adiponectin has been attributed with anti-inflammatory 
properties including the reduction of NF-kB activity, the adverse multimer secretion 
profile originating from adipose tissue might promote a more pro-inflammatory envi­
ronment that increases the risk to develop CVD.
Adipocyte hypertrophy in relation to adipocyte dysfunction 
Obesity is associated with hypertrophic adipocytes, which are characterized by pro- 
inflammatory properties promoting the infiltration of macrophages into adipose tissue 
that lead to the development of insulin insensitivity. Thiazolidinediones (TZDs) are an 
insulin-sensitizing class of pharmaceutical compounds used for the treatment of type 
2 diabetes mellitus that directly affect adipose tissue by improvement of adipocyte 
differentiation and glucose homeostasis through activation of PPARy. In a study with 
congenital adrenal hyperplasia (CAH) subjects who suffer from insulin resistance, 
we investigated the effects of the TZD pioglitazone on insulin sensitivity, subcuta­
neous adipocyte surface, and adipose tissue-specific gene expression (chapter 3). 
Before treatment, mean subcutaneous adipocyte surface showed clear inter-individual 
differences and was positively correlated with the percentage of trunk fat (r=0.73; 
^-value=0.01), plasma leptin (r=0.70; ^-value=0.01) and MCP-1 gene expression 
levels in adipose tissue (r=0.57; ^-value=0.05). Adipocyte cell surface was negatively 
correlated with systemic insulin sensitivity (r= -0.60; ^-value=0.04) and adipose tis­
sue expression of the glucose uptake transporter (GLUT)-4 (r=-0.65; ^-value=0.03).
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Treatment with pioglitazone resulted in an improvement of systemic insulin sensitiv­
ity, accompanied by an increase in BMI (by 7 ± 1.1 kg/m2; .P-value= 0.06) and subcu­
taneous adipocyte cell surface (by 497 ± 625 ^m2; .P-value< 0.05). Furthermore, gene 
expression levels of insulin sensitivity markers adiponectin and GLUT-4 were up- 
regulated, whereas expression of the pro-inflammatory gene MCP-1 was decreased. 
Interestingly, the percentage of trunk fat, plasma leptin levels and MCP-1 gene 
expression were no longer positively correlated with subcutaneous adipocyte surface. 
This implies that the impaired metabolic characteristics of hypertrophic adipocytes are 
diminished after treatment with pioglitazone, while the mean subcutaneous adipocyte 
cell surface was even further increased. We hypothesize that the pioglitazone-induced 
enlargement of adipocyte cell surface results from redistribution fat from VAT depots 
towards storage in SAT. This redistribution may alleviate the pro-inflammatory trait 
of VAT by reducing the number of large adipocytes and enhancing the percentage of 
insulin sensitive smaller visceral adipocytes.
Inflammasome-mediated caspase-1 activation in adipose tissue
IL-18 protects against the development o f obesity-induced insulin resistance 
Obesity-induced inflammation and insulin resistance are characterized by elevated 
circulating cytokine levels. It is generally believed that obesity-induced inflammatory 
mediators originate from expanding adipose tissue. However, fat may also accumulate 
in other tissues including the liver during the development of obesity and may pro­
mote hepatic inflammation.
Cytokines have divergent effects on insulin sensitivity. While TNF-a, IL-6, IL-8 and 
IL-1p promote obesity-induced insulin resistance others appear to promote insulin 
sensitivity. Plasma levels of the prominent IL-1 family members IL-ip and IL-18 are 
increased during obesity and associated with insulin resistance. However, IL-18 has 
been shown to improve insulin sensitivity and prevent the development of obesity 
partly by controlling food intake, yet the underlying molecular mechanisms remain 
unknown. Therefore, we set out to determine the contribution of IL-18 to the develop­
ment of obesity-induced inflammation and insulin resistance by feeding both wild­
type and IL-18-/- animals a high fat diet (HFD) to promote obesity (chapter 4). To 
our surprise, HFD-induced weight gain was similar in both IL-18-/- and wild-type 
animals. However, IL-18 knockout animals were more insulin resistant compared to 
wild-type mice fed the HFD. Furthermore, HFD-fed IL-18-/- mice displayed meta­
bolic abnormalities including higher levels of circulating VLDL triglycerides and 
lower plasma adiponectin levels compared to wild-type animals fed the HFD. Since 
IL-18 is highly expressed in adipose tissue and liver, it suggests that these tissues 
play a prominent role in translating the insulin-sensitizing effects of IL-18. Interest­
ingly, treatment of IL-18-/- mice with recombinant IL-18 resulted in an improvement
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of hepatic insulin sensitivity. Detailed analysis of the liver-specific effects of IL-18 
during the development of obesity revealed no difference in the degree of hepatic 
steatosis between both genotypes fed the HFD. However, plasma ALT levels were 
clearly elevated in IL-18-/- fed the HFD compared to the wild-type controls, sugges­
tive of liver damage. Adipose tissue morphology did not differ between wild-type and 
IL-18-/- animals. Surprisingly, influx of macrophages into adipose tissue revealed a 
reduction in HFD-fed IL-18-/- animals in conjunction with lower levels of MCP-1, 
yet gene expression levels in adipose tissue of the pro-inflammatory cytokine IL-6 
were increased, whereas levels of anti-inflammatory cytokine IL-1Ra were decreased. 
All together, these findings imply that IL-18 controls insulin sensitivity independently 
of hepatic steatosis and adipose tissue macrophage influx. IL-18 seems to directly im­
prove hepatic insulin sensitivity, and a lack of IL-18 is accompanied by lower adipo- 
nectin secretion levels that may promote insulin resistance.
Inflammasome/caspase-1 controlling adipose tissue insulin sensitivity 
In order to become active, the precursors of IL-ip and IL-18 are processed into their 
active forms by a cysteine protease called caspase-1. Activation of caspase-1 itself 
involves cleavage by an intracellular protein complex called the inflammasome, con­
sisting of the (NOD)-like receptor (NLR) family member NLRP3 and adapter protein 
apoptosis-associated specklike protein (ASC). Because IL-1p and IL-18 influence 
metabolic homeostasis and due to the essential role of inflammasome-mediated cas- 
pase-1 to activate these two cytokines, we determined the role of caspase-1 in adipose 
tissue function (chapter 5). Obese insulin resistant mouse models were character­
ized by an increased activation of caspase-1 in adipose tissue together with elevated 
levels of IL-1p and IL-18 in adipose tissue. Depletion of caspase-1 in adipocytes 
improved adipogenesis (increased gene expression of PPAR-y, adiponectin, GLUT-4) 
and insulin sensitivity as determined by an increased phosphorylation of AKT (mock 
vs. caspase-1 siRNA, 0.95 ± 0.14 vs. 2.10 ± 0.16; .P-value<0.005). These effects of 
caspase-1 were likely conveyed by processing of IL-1p. Whereas treatment of adipo­
cytes with an anti-IL-1p antibody mirrored the effects of caspase-1 inhibition, recom­
binant IL-18 treatment had no effect on adipogenesis. Absence of NLRP3 mimics the 
effects seen in caspase-1-/- animals, with an enhanced adipocyte differentiation and 
improved adipose tissue insulin sensitivity. In line with the increased adipose tissue- 
specific insulin sensitivity, IL-1p release from adipose tissue was reduced in caspase-1 
and NLRP3 deficient animals. In-vivo experiments with caspase-1-/- animals revealed 
an improvement of systemic insulin sensitivity compared to wild-type littermates. In 
parallel, treatment of Ob/Ob mice, characterized by an excessive bodyweight and the 
presence of insulin resistance, with a caspase-1 inhibitor improved insulin sensitivity 
and led to a reduction in bodyweight gain. The absence of caspase-1 led to a reduction 
in fat mass and smaller adipocytes (mean adipocyte cell surface, wild-type mice 966.8 
^M2, caspase-1-/- mice 629.16 ^M2; .P-value<0.001). Furthermore, indirect calorimet-
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ric analysis revealed higher fat oxidation rates in caspase-1-/- animals. These results 
demonstrated that inflammasome-mediated caspase-1 activation in adipose tissue 
during obesity leads to increased IL-1p production and contributes to the induction of 
tissue-specific and systemic insulin resistance, whereas the absence or inhibition of 
caspase-1 improved insulin sensitivity and adipose tissue function. These results im­
ply that pharmaceutical inhibition of caspase-1 could be a potential therapeutic target 
in the treatment of obesity and type 2 diabetes mellitus.
Hyperglycemia-mediated caspase-1 activation and IL-1fi secretion in adipose 
tissue
The importance of IL-ip in obesity-induced inflammation and the development of 
insulin resistance in adipose tissue have been well documented in several studies. In 
addition, we demonstrated that inflammasome/caspase-1 affects adipose tissue func­
tion during the development of obesity (chapter 5), yet the exact triggers leading to 
caspase-1 activation in adipose tissue remain unknown. Interestingly, a recent study 
demonstrated that hyperglycemia induces an interaction between thioredoxin interact­
ing protein (TXNIP) and NLRP3 that subsequently leads to caspase-1 activation and 
IL-1p production by mouse pancreatic beta-cells. We determined whether a similar 
mechanism may exist in human adipocytes and intact adipose tissue (chapter 6).
Treatment of human intact adipose tissue and primary adipocytes with high levels of 
^  glucose led to an increase in IL-1p transcription levels (7.5-fold; .P-value<0.01, 1.7- ^
fold; .P-value<0.05, respectively), intracellular protein levels of pro-IL-1p (2.0-fold;
.P-value<0.01, 1.5-fold; .P-value<0.05, respectively) and secretion of bioactive IL-1 
(2.0-fold; .P-value<0.01, 3.0-fold; .P-value<0.05, respectively). Additionally, caspase-1 
activity levels were elevated by 10% (P-value<0.05) and NLRP3 protein levels were 
increased in human adipocytes treated with high levels of glucose. In addition to 
caspase-1 and NLRP3, TXNIP protein levels increased in response to elevated levels 
of glucose in both human adipocytes and intact adipose tissue (2-fold; .P-value<0.05.
5-fold; .P-value<0.01, respectively). High glucose-induced bioactive IL-1 secretion 
was reduced in adipocytes targeted with siRNA against TXNIP. This was accompa­
nied by a significant 2-fold decrease in IL-1p transcription levels and intracellular 
levels of pro-IL-1p. However, depletion of TXNIP had no effect on caspase-1 activa­
tion when adipocytes were stimulated with high levels of glucose.
These results demonstrated that hyperglycemia could serve as a trigger for NLRP3 
inflammasome mediated-caspase-1 activation. Furthermore, elevated levels of glucose 
induced adipocyte-specific TXNIP expression that subsequently led to increased IL- 
1p transcription. However, in adipose tissue TXNIP did not appear to directly stimu­
late caspase-1 activation. In conclusion, hyperglycemia independently induces both 
TXNIP-mediated IL-1p transcription and caspase-1 activation that together lead to 
enhanced production of IL-1p that may promote insulin resistance.
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Inflammasome and caspase-1 activation in VAT
It has been suggested that VAT, rather than SAT, contributes to the elevated circulating 
levels of pro-inflammatory cytokines in obese subjects. The enhanced inflammatory 
properties of VAT compared to SAT may be attributed to an augmented influx of dif­
ferent immune cells that promote the production of a variety of inflammatory media­
tors. Although the inflammasome-mediated IL-ip and IL-18 have also been linked 
to obesity and insulin resistance and they partly originate from adipose tissue, it is 
currently unknown whether inflammasome/caspase-1 activity contributes to the en­
hanced pro-inflammatory status of VAT versus SAT. Therefore, we set out to study the 
expression profile of the NLRP3 inflammasome components in paired VAT and SAT 
biopsies from overweight subjects both by using mRNA expression and protein analy­
sis (chapter 7). In this study, the cellular composition of the stromal vascular fraction 
of VAT was characterized by an increased number of CD8+ T-lymphocytes compared 
to SAT (30.4% vs. 41.6%; .P-value<0.05). No differences in macrophage number or 
in adipocyte cell size surface were observed between VAT and SAT. However, ex­
vivo adipose tissue cultures demonstrated enhanced intrinsic inflammatory properties 
of VAT illustrated by a boosted release of IL-6, IL-8, IL-IRa (3-fold; .P-value<0.05. 
4-fold; .P-value<0.05, and 2-fold; .P-value<0.05, respectively) and decrease in adi- 
ponectin secretion levels. Importantly, total IL-ip (pro-form of IL-ip + active form 
of IL-ip), bioactive IL-1 (10-fold; .P-value<0.05) and IL-18 (3-fold; .P-value<0.05) 
secretion from VAT were enhanced as compared to SAT.
In line with the elevated secretion levels of IL-ip and IL-18, VAT showed a 3-fold 
(P-value<0.05) increase in caspase-1 activation compared to SAT, together with an 
up regulation of the inflammasome components NLRP3 (2-fold; ns) and ASC (2-fold; 
.P-value<0.05) protein levels. The caspase-1 dependent cytokine production by human 
white adipose tissue was further supported by treatment of VAT explants with pralna- 
casan, a specific inhibitor of caspase-1, which led to a reduced release of IL-ip and 
IL-18, yet also diminished the production of IL-6 and IL-8. However, TNFa secretion 
levels were unaffected by caspase-1 inhibition. Finally, a significant positive cor­
relation was observed between caspase-1 activity levels and the percentage of CD8+ 
T-lymphocytes present in adipose tissue (r=0.77; .P-value<0.01). These results suggest 
that caspase-1 serves as an important contributor to the intrinsic pro-inflammatory 
trait of VAT via increased production of IL-ip and IL-18, but also by regulating the 
secretion of IL-6 and IL-8. Furthermore, caspase-1 activity was positively associated 
with the number of CD8+ T-lymphocytes present in adipose tissue, which are known 
to contribute to adipose tissue inflammation. Controlling the influx of CD8+ T-lym- 
phocytes may be an additional pathway by which caspase-1 governs adipose tissue 
inflammation.
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Conclusions
1. Reduced circulating levels of total adiponectin in subjects with FCH are not 
associated with a disturbed adiponectin multimer profile. However, in females 
diagnosed with FCH, the presence of CVD is accompanied by a more 
atherogenic adiponectin multimer secretion profile originating from adipose 
tissue.
2. Enlarged subcutaneous adipocyte cell surface is associated with inflammation 
and insulin resistance. Pioglitazone treatment uncouples this association 
illustrated by subcutaneous adipocyte surface enlargement together with a 
reduction in inflammation and an improvement of systemic insulin sensitivity.
3. The IL-1 family member IL-18 regulates insulin sensitivity independently of 
the development of obesity and without affecting hepatic steatosis and 
macrophage infiltration into adipose tissue during high fat diet feeding.
4. Increased inflammasome-mediated caspase-1 activation in adipose tissue 
during obesity leads to elevated IL-ip production and contributes to the 
induction of insulin resistance. Absence or inhibition of caspase-1 improves 
insulin sensitivity and restores normal adipocyte function. These data 
suggest that the inflammasome-mediated caspase-1 is an important regulator 
of adipocyte function and insulin sensitivity.
5. Hyperglycemia triggers activation of NLRP3 inflammasome-mediated 
caspase-1 and induces TXNIP-dependant IL-ip transcription in adipocytes. 
Accordingly, TXNIP links hyperglycemia to increased IL-ip production by 
the adipose tissue.
6. The inflammasome members NLRP3, ASC and caspase-1 are more 
abundantly present in human VAT as compared to SAT. Increased caspase-1 
activity leads to elevated IL-p and IL-18 secretion levels and regulates the 
release of IL-6 and IL-8 by VAT. Furthermore, caspase-1 activation strongly 
correlates with the number of CD8+ T-Lymphocytes present in adipose tissue. 
These data unravel caspase-1 as a novel and specific inflammatory mediator 
that may partly determine the pro-inflammatory character of human VAT.
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Samenvatting
Obesitas wordt gekenmerkt door een overmatige ophoping van het vetweefsel, vero­
orzaakt door een inactieve levenstijl, toename van de voedelinname en genetische 
factoren die de aanleg van overgewicht bevorderen. Obesitas is geassocieerd met een 
verhoogd risico op het ontwikkelen van metabole aandoeningen zoals insulineresis- 
tentie, diabetes mellitus type 2 (T2DM) en hart- en vaatziekten (HVZ). Afwijkingen 
in de endocriene functie van het vetweefsel spelen een belangrijke rol bij het ont­
staan van deze metabole aandoeningen. Zo kan een verstoorde secretie van diverse 
adipokines leiden tot veranderingen in de energiehuishouding en in het lipide- en 
glucosemetabolisme. Deze schadelijke metabole veranderingen gaan gepaard met een 
metamorfose van de vetweefselmorfologie, waaronder een toename van het aantal 
grote disfunctionele adipocyten.
Uit onderzoek is gebleken dat inflammatie een van de belangrijkste schakels is tussen 
obesitas en het ontwikkelen van metabole aandoeningen. Insulineresistente individuën 
hebben verhoogde spiegels van circulerende cytokines die sterk gecorreleerd zijn met 
een toename van het vetweefsel. Met name een toename van het viscerale vetweef- 
sel draagt bij aan de verhoogde inflammatoire status in obese individuën, terwijl een 
uitbreiding van het subcutane vetweefsel niet schadelijk lijkt.
Pas in de begin jaren 90 van de vorige eeuw is de algehele opvatting over vetweef- 
^  sel, als zijnde een orgaan dat uitsluitend betrokken is bij de opslag van overmatige ^
hoeveelheden energie, drastisch veranderd. Verschillende studies brachten in deze 
periode aan het licht dat het vetweefsel van obese individuën een belangrijke bron is 
van pro-inflammatoire mediatoren zoals TNF-a, MCP-1, IL-6, IL-8, IL-ip en IL-18.
Deze lokale onsteking van het vetweefsel gaat gepaard met de infiltratie van verschil­
lende soorten immuuncellen zoals macrofagen, neutrofielen en T-cell lymfocyten.
Een toename van het viscerale vetweefsel vertoond meer van deze pro-inflammatoire 
eigenschappen vergeleken met het subcutane vetweefsel. De exacte mechanismen op 
welke manier obesitas bijdraagt aan het ontstaan van metabole verstoringen, middels 
aanhoudende inflammatie van het vetweefsel, zijn echter nog steeds onbekend.
Pathogene rol van het vetweefsel in metabole aandoeningen
Verstoorde vetweefselfunctie: afwijkende adiponectinesecretie 
We hebben aangetoond dat de totale plasmaspiegels van de anti-inflammatoire en 
insuline-gevoeligheidseiwit adiponectine verlaagd zijn in patiënten met familiaire 
gecombineerde hyperlipidemie (FCH). Deze personen worden gekenmerkt door 
verhoogde spiegels van cholesterol, triglyceriden, apolipoproteine B en insulinere- 
sistentie. Adiponectine circuleert in diverse multimere isovormen: laag-moleculair 
gewicht (LMW), middel-moleculair gewicht (MMW) en hoog-moleculair gewicht
156
thesis def 1.indd 156 »  11-7-2011 10:21:04
Chapter 10
(HMW). Aanvullende studies hebben aangetoond dat de gunstige metabole en anti­
inflammatoire effecten van adiponectine voornamelijk gereguleerd worden door de 
HMW-isovorm van adiponectine. Vandaar dat een beschermende adiponectineprofiel 
in de circulatie vaak wordt uitgedrukt als de verhouding tussen HMW en de totale 
adiponectinespiegel, terwijl een ongunstige adiponectinespiegel wordt uitgedrukt 
als de verhouding tussen de LMW- en HMW-isovorm van adiponectine. Wij hebben 
onderzocht of een verlaagd plasmaniveau van de totale adiponectinespiegel in per­
sonen met FCH gepaard ging met een verandering van de adiponectine-multimeerdis- 
tributie. Daarnaast werd de associatie bestudeerd tussen de plasmaconcentraties van 
de verschillende adiponectine-isovormmultimeren en de aanwezigheid van HVZ bij 
patiënten met FCH (hoofdstuk 2).
De verminderde plasmaniveaus van de totale adiponectinegehalte in patiënten met 
FCH ten opzichte van gezonde controles waren voornamelijk toe te wijzen aan een 
afname van zowel de LMW- als de HMW-isovormen van adiponectine. Echter, de 
verhouding tussen de HMW-isovorm en de totale adiponectine en de LMW/HMW 
adiponectine-verhouding verschilden niet tussen FCH en controle proefpersonen. De 
verdeling van de adiponectine-isovormen verschilde significant tussen mannelijke en 
vrouwelijke proefpersonen in beide studie-populaties, waar een gunstigere verdel­
ing werd waargenomen bij de vrouwen. Een interessante observatie was dat binnen 
de groep vrouwen met de diagnose FCH, de aanwezigheid van HVZ gecorreleerd 
was met een vermindering van de HMW-isovorm van adiponectine in vergelijking 
met vrouwen zonder HVZ (HMW/totaal adiponectin: 34.2 ± 10% vs. 46.0 ± 7.1% 
voor respectievelijk FCH-vrouwen met en zonder HVZ; LMW/HMW adiponectine- 
verhouding: 1.3 ± 0.8 en 0.9 ± 0.7 voor respectievelijk FCH-vrouwen met en zonder 
HVZ). Vanwege de anti-inflammatoire eigenschappen die zijn toegeschreven aan 
adiponectine zoals de vermindering van de NF-kB activiteit, kan een nadelige adipo- 
nectine-isovorm secretieprofiel vanuit het vetweefsel een pro-inflammatoire omgeving 
bevorderen die het risico op het ontwikkelen van HVZ vergroot.
Vetcelhypertrofie in relatie tot vetceldisfunctie
Obesitas is geassocieerd met hypertrofische vetcellen die gekenmerkt worden door 
pro-inflammatoire eigenschappen. Dit bevordert de infiltratie van macrofagen in het 
vetweefsel wat uiteindelijk kan leiden tot de ontwikkeling van insulineresistentie.
De thiazolidinediones (TZDs) vormen een klasse van farmacologische verbindingen 
die gebruikt worden voor de behandeling van T2DM. Deze behandeling heeft direct 
invloed op het vetweefsel door verbetering van de vetceldifferentiatie en glucose- 
homeostase veroorzaakt door PPARy-activatie. In een studie met congenitale bijnier- 
hyperplasie (CAH) patiënten die leiden aan insulineresistentie, onderzochten we 
de effecten van de TZD pioglitazone op insulinegevoeligheid, subcutane vetcelop- 
pervlak en vetweefsel-specifieke genexpressie profielen (hoofdstuk 3). Voorafgaand 
aan de behandeling vertoonde de gemiddelde subcutane vetceloppervlak duidelijke
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inter-individuele verschillen en een postitieve correlatie met het percentage rompvet 
(r=0.73; .P-waarde=0.01), plasmaleptinegehalte (r=0.70; .P-waarde=0.01) en MCP-1 
genexpressieniveaus in het vetweefsel (r=0.57; .P-waarde=0.05). Verder was de vetce- 
loppervlak negatief gecorreleerd met de systemische insulinegevoeligheid (r=-0.60; 
.P-waarde=0.04) en met de genexpressie van de glucose-opname transporter (GLUT)- 
4 in het vetweefsel (r= -0.65; .P-waarde=0.03). Behandeling met pioglitazone heeft 
geresulteerd in een verbetering van de systemische insulinegevoeligheid wat gepaard 
ging met een toename van de BMI (met 7 ± 1.1 kg/m2; .P-waarde=0.06) en de sub- 
cutane vetceloppervlak (met 497 ± 625 ^m2; .P-waarde<0.05). Bovendien waren de 
genexpressie niveaus van de insulinegevoeligheids markers adiponectine en GLUT-4 
toegenomen, terwijl de expressie van het pro-inflammatoire gen MCP-1 was verlaagd. 
Interessant is dat het percentage rompvet, plasmaleptinespiegels en MCP-1 genex­
pressie niet langer postief waren gecorreleerd met de subcutane vetceloppervlak. Dit 
suggereert dat de verslechterde metabole kenmerken van de hypertrofische vetcel- 
len verminderd zijn na behandeling met pioglitazone, ondanks een toename van de 
gemiddelde vetceloppervlak. Wij veronderstellen dat de vergroting van de vetcelop- 
pervlak onder invloed van pioglitazone veroorzaakt wordt door een herverdeling van 
het vet vanuit het viscerale naar het subcutane opslagdepot. Deze herverdeling kan het 
pro-inflammatoire karakter van het viscerale vet verminderen door een afname van 
het aantal grote vetcellen en een toename van het percentage kleine insulinegevoelige 
{g} vetcellen in dit specifieke vetdepot.
Inflammasoom-gemedieerde caspase-1 activatie in het 
vetweefsel
IL-18 beschermt tegen de ontwikkeling van insulineresistentie veroorzaakt 
door obesitas
Inflammatie en insulineresistentie veroorzaakt door obesitas wordt gekenmerkt 
door verhoogde cytokinespiegels in de circulatie. Het wordt algemeen aangenomen 
dat deze, door obesitas geïnduceerde, ontstekingsmediatoren afkomstig zijn uit de 
toegenomen hoeveelheid vetweefsel. Echter, tijdens obesitas kan het vet zich ook 
ophopen in andere weefsels zoals de lever waar het ook een onstekingsreactie kan 
veroorzaken.
Cytokinen kunnen tegengestelde effecten hebben op de insulinegevoeligheid. Waar 
TNF-a, IL-6, IL-8 en IL-ip insulineresistentie bevorderen, daar lijken andere cytoki- 
nen dit proces te remmen. Plasmaspiegels van de belangrijke IL-1-familieleden IL-ip 
en IL-18, zijn verhoogd tijdens obesitas en geassocieerd met insulineresistentie. Van 
IL-18 is echter aangetoond dat het de insulinegevoeligheid verbetert en de ontwik­
keling van obesitas tegen gaat mede door het beheersen van de voedselinname, maar 
de onderliggende moleculaire mechanismen hiervan zijn nog onbekend. Daarom is
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besloten om de bijdrage van IL-18 aan de door obesitas veroorzaakte inflammatie en 
insulineresistentie te bepalen, middels het voeren van een hoog-vetdieet aan zowel 
wild-type als IL-18-deficiënte dieren. (hoofdstuk 4). Tot onze verbazing was de 
gewichtstoename na het voeren van een hoog-vetdieet gelijk in zowel de IL-18-/- en 
de wild-type dieren. Wel waren deze IL-18-deficiënte muizen meer insulineresistent 
vergeleken met de wild-type muizen. Bovendien vertoonden de IL-18-deficiënte 
muizen na het eten van een hoog-vetdieet meer metabole afwijkingen zoals hogere 
spiegels van VLDL-triglyceriden in de circulatie en lagere plasmaniveaus van adipo- 
nectine, vergeleken met de wild-type controle muizen. Aangezien IL-18 hoog tot ex­
pressie kwam in zowel het vetweefsel als in de lever, was er het vermoeden dat deze 
weefsels een belangrijke rol konden spelen in de IL-18-afhankelijke effecten op de in- 
sulinegevoeligheid. Een interessante observatie was dat als de IL-18-/- muizen werden 
behandeld met het recombinant IL-18-eiwit, dit resulteerde in een verbetering van de 
hepatische insulinegevoeligheid. Een gedetailleerde analyse van de lever-specifieke 
effecten van IL-18 tijdens de ontwikkeling van hoog-vet geïnduceerde obesitas, leidde 
niet tot een verschil in de mate van leversteatose tussen beide genotypes. Echter, de 
plasma ALT-waarden waren duidelijk verhoogd in deze IL-18-/- muizen vergeleken 
met de wild-type muizen, wat wijst op leverschade. Ook de vetweefselmorfologie was 
niet verschillend tussen beide muismodellen. Verder was er sprake van een verras­
sende afname van de macrofaaginfiltratie en MCP-1-waarden in het vetweefsel van de 
IL-18-/- muizen gevoed met een hoog-vetdieet. Toch waren de genexpressieniveaus 
van het pro-inflammatoire cytokine IL-6 verhoogd en van de anti-inflammatoire 
cytokine IL-1Ra verlaagd in het vetweefsel van deze dieren. Alles bij elkaar sugger­
eren deze bevindingen dat IL-18 de insulinegevoeligheid reguleert, onafhankelijk van 
leversteatose en macrofaaginfiltratie in het vetweefsel. IL-18 lijkt direct de hepatische 
insulinegevoeligheid te verbeteren en een tekort aan IL-18 gaat gepaard met een la­
gere adiponectinesecretie dat insulineresistentie kan bevorderen.
Inflammasoom/caspase-1 reguleren insulinegevoeligheid in het vetweefsel 
De voorlopers van IL-1P en IL-18 worden verwerkt tot hun actieve vorm door een 
cysteïne protease genaamd caspase-1. Caspase-1 raakt zelf geactiveerd als het wordt 
gesplitst door een intracellulair eiwitcomplex dat het inflammasoom wordt genoemd. 
Dit complex bestaat uit een (NOD)-like-receptor (NLR) familielid NLRP3 en een 
eiwit genaamd ASC. Aangezien IL-1P en IL-18 beide invloed hebben op de metabole 
homeostase en vanwege de essentiële rol van inflammasoom-gemedieerde caspase-1 
bij de activatie van deze twee cytokinen, bepaalden wij de rol van caspase-1 in de 
vetweefselfunctie (hoofdstuk 5). Obese muismodellen met insulineresistentie werden 
gekenmerkt door een verhoogde activatie van caspase-1 in het vetweefsel samen 
met toegenomen niveaus van IL-1P en IL-18 in het vetweefsel. Een vermindering 
van caspase-1 in vetcellen resulteerde in een verbetering van de adipogenese (ver­
hoogde genexpressie van PPAR-y, adiponectine en GLUT-4) en de insulinegevoe-
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ligheid, bepaald door een verhoging van de fosforylering van het eiwit AKT (mock 
vs. caspase-1 siRNA, 0.95 ± 0.14 vs. 2.10 ± 0.16; ^-waarde<0.005). Deze effecten 
van caspase-1 werden waarschijnlijk veroorzaakt door de rol van dit enzyme in IL- 
1P-activatie. Dit werd ondersteund doordat behandeling van de vetcellen met een 
antilichaam tegen IL-1P dezelfde effecten op insulinegevoeligheids teweeg brachten 
als die werden gezien ten gevolge van caspase-1-remming. Aan de andere kant werd 
er geen effect op de adipogenese waargenomen na behandeling van de vetcellen met 
recombinant IL-18. De afwezigheid van NLRP3 reproduceerde dezelfde resultaten 
als die werden waargenomen in de caspase-1-/- dieren zoals een verbeterde vetceldif- 
ferentiatie en vetweefselinsulinegevoeligheid. Overeenkomstig met de toegenomen 
insulinegevoeligheid in het vetweefsel was de IL-1p-secretie vanuit het vetweefsel in 
caspase-1-deficiënte en NLRP3- deficiënte dieren afgenomen. In-vivo experimenten 
met caspase-1-/- muizen bracht een verbetering van de systemische insulinegevoe- 
ligheid aan het licht vergeleken met wild-type muizen. Gelijksoortige bevindingen 
werden gedaan in Ob/Ob muizen, die gekenmerkt worden door overgewicht en insuli- 
neresistentie, na behandeling met een caspase-1-inhibitor zoals een verbeterde insuli­
negevoeligheid en een afname van het lichaamsgewicht. Het ontbreken van caspase-1 
heeft geleid tot een vermindering van de vetmassa en kleinere adipocyten (gemid­
delde vetceloppervlak van wild-type muizen 966.8 ^M2, caspase-1-/- muizen 629.16 
^M2; ^-waarde<0.001). Bovendien bleek uit een indirecte calorimetrische analyse dat 
de caspase-1-/- dieren een hogere vetverbranding vertoonden. Deze resultaten tonen 
aan dat de inflammasoom-gemedieerde caspase-1-activering in het vetweefsel tijdens 
obesitas leidt tot een verhoogde IL-1p-productie en bijdraagt aan het ontstaan van 
vetweefsel-specifieke en systemische insulineresistentie. Aan de andere kant zorgt de 
afwezigheid of remming van caspase-1 voor een verbetering van de insulinegevoe­
ligheid en vetweefselfunctie, wat zou kunnen betekenen dat dit als een therapeutisch 
doelwit kan dienen voor de behandeling van obesitas en T2DM.
Hyperglycemie-gemedieerde caspase-1-activatie en IL-1fi-secretie in het 
vetweefsel
Het belang van IL-1P in, de door obesitas opgewekte, ontsteking en in de ontwik­
keling van insulineresistentie in het vetweefsel zijn reeds goed gedocumenteerd in 
verschillende studies. Daarnaast hebben wij aangetoond dat de inflammasoom/cas- 
pase-1 de functie van het vetweefsel beïnvloedt tijdens de ontwikkeling van obesitas 
(hoofdstuk 5). Echter, de signalen die leiden tot caspase-1-activering in het vetweef­
sel zijn nog niet bekend. Een recente studie heeft aangetoond dat hyperglycemie een 
interactie induceerde tussen thioredoxin-interacting protein (TXNIP) en NLRP3, wat 
uiteindelijk leidde tot caspase-1-activering en IL-1p-productie door beta-cellen in de 
pancreas van de muis. Vervolgens hebben wij gekeken of er een soortgelijk mecha­
nisme bestaat in humane vetcellen en intact vetweefsel (hoofdstuk 6). Behandeling 
van humaan intact vetweefsel en primaire vetcellen met hoge concentraties glucose,
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resulteerde in een toename van de IL-1p-transcriptieniveaus (respectievelijk 7.5*; 
^-waarde<0.01 en 1.7*; ^-waarde<0.05), intracellulaire eiwitniveaus van pro-IL-1p 
(respectievelijk 2.0*; .P-waarde<0.01 en 1.5* ^-waarde<0.05) en de secretie van bio- 
actief IL-1 (respectievelijk 2.0*; ^-waarde<0.01 en 3.0*; ^-waarde<0.05). Bovendien 
nam de caspase-1-activiteit toe met 10% (P-waarde<0.05) en waren de NLRP3-eiwit- 
niveaus verhoogd in humane adipocyten die behandeld werden met hoge concentra­
ties glucose. Naast caspase-1 en NLRP3, waren ook de TXNIP-eiwitniveaus gestegen 
in zowel humaan intact vetweefsel als in vetcellen als reactie op het hoge glucosege­
halte (respectievelijk 2*; ^-waarde<0.05 en 5*; ^-waarde<0.01). De verhoogde 
secretie van bioactief IL-1 in vetcellen geïnduceerd door een hoog glucosegehalte, 
verminderde wanneer deze cellen behandeld werden met siRNA tegen TXNIP. Dit 
ging gepaard met een significante 2-voudige afname in IL-1p-transcriptieniveaus en 
intracellulaire niveaus van pro-IL-1p. Echter, de uitschakeling van TXNIP had geen 
effect op de caspase-1-activering wanneer de vetcellen gestimuleerd werden met hoge 
concentraties glucose.
Deze resultaten tonen aan dat hyperglycemie zou kunnen dienen als een signaal voor 
NLRP3-inflammasoom-gemedieerde caspase-1-activering. Bovendien zorgen de hoge 
concentraties glucose voor de inductie van vetcel-specifieke TXNIP-expressie, dat 
vervolgens leidt tot een verhoging van de IL-1p-transcriptie. TXNIP lijkt echter niet 
direct caspase-1-activering te stimuleren in het vetweefsel. Concluderend, hyperglyce- 
{g} mie induceert zelfstandig zowel TXNIP-gereguleerde IL-1p-transcriptie als-caspase-
1-activering, die samen leiden tot een verhoogde productie van IL-1p dat insulinere- 
sistentie kan bevorderen.
Inflammasoom en caspase-1-activering in het viscerale vetdepot 
Er wordt beweerd dat het viscerale vetweefsel meer bijdraagt aan de verhoogde pro­
inflammatoire cytokinen in de circulatie van obese personen dan subcutaan vetweef­
sel. Deze pro-inflammatoire eigenschappen van het viscerale vetweefsel kunnen 
vooral worden toegeschreven aan de toegenomen infiltratie van verschillende ontstek- 
ingscellen die de productie van diverse ontstekingmediatoren bevorderen. Hoewel de 
door het inflammasoom-gereguleerde IL-ip en IL-18 ook in verband worden gebracht 
met obesitas en insulineresistentie, en ze deels afkomstig zijn uit het vetweefsel, is 
het momenteel niet bekend of de inflammasoom/caspase-1-activiteit bijdraagt aan de 
pro-inflammatoire status van het viscerale vetweefsel ten opzichte van het subcutane 
vetweefsel. Daarom hebben wij het expressieprofiel van de NLRP3-inflammasoom- 
componenten te bestudeerd, door middel van mRNA- en eiwitanalyses in gepaarde 
viscerale en subcutane vetweefselbiopten afkomstig van personen met overgewicht 
(hoofdstuk 7). In deze studie werd de cellulaire samenstelling van de stromale vascu­
laire fractie in het viscerale vetweefsel gekenmerkt door een toename van het aantal 
CD8+ T-lymfocyten vergeleken met het subcutane vetweefsel (30.4% vs. 41.6%; 
^-waarde<0.05). Verder werden er geen verschillen waargenomen in het aantal
161
thesis def 1.indd 161 »  11-7-2011 10:21:04
Chapter 10
macrofagen en vetceloppervlak tussen beide vetdepots. De ex-vivo vetweefselkweken 
toonden echter aan dat de toegenomen intrinsieke inflammatoire eigenschappen van 
het viscerale vetweefsel geïllustreerd werden door een versterkte afgifte van IL-6, 
IL-8, IL-1Ra (respectievelijk 3*; P-waarde<0.05, 4*; P-waarde<0.05, en 2*; P- 
waarde<0.05) en een afname in adiponectinesecretieniveaus. Ook van belang is dat de 
totale secretie van IL-1p (pro-IL-1p + actieve vorm van IL-ip, 10*; P-waarde<0.05), 
bioactief IL-1 (10*; P-waarde<0.05) en IL-18 (3*; P-waarde<0.05) hoger was in het 
viscerale vetweefsel vergeleken met het subcutane vetweefsel.
Overeenkomstig de verhoogde secretieniveaus van IL-1p en IL-18, liet het viscerale 
vetweefsel een 3-voudige (P-waarde<0.05) toename zien in caspase-1-activiteit en 
een verhoogd eiwitgehalte van de inflammasoom-componenten NLRP3 (2*; ns) en 
ASC (2*; P-waarde<0.05) vergeleken met het subcutane vetweefsel. De caspase-1-af- 
hankelijke cytokineproductie door humaan vetweefsel werd verder ondersteund door 
de behandeling van stukjes visceraal vetweefsel met de specifieke caspase-1-remmer 
pralnacasan. Dit leidde tot een verminderde afgifte van IL-1p en IL-18, maar ook van 
de productie van IL-6 en IL-8. De TNFa-secretieniveaus werden echter niet beïnvloed 
door het remmen van caspase-1. Ten slotte werd een significante positieve correlatie 
waargenomen tussen de caspase-1-activiteitniveaus en het percentage CD8+ T-lymfo- 
cyten aanwezig in het vetweefsel (r=0.77; P-waarde<0.01). Deze resultaten sugger­
eren dat caspase-1 een belangrijke bijdrage levert aan het intrinsieke pro-inflamma- 
toire karakter van het viscerale vetweefsel via de verhoogde productie van IL-1p en 
IL-18, maar ook door het reguleren van de productie van IL-6 en IL-8. Bovendien is 
caspase-1 positief gecorreleerd met het aantal CD8+ T-lymfocyten in het vetweefsel, 
waarvan bekend is dat ze bijdragen aan de ontsteking in het vetweefsel. Het reguleren 
van de infiltratie van CD8+ T-lymfocyten kan een extra route zijn waarlangs caspase-1 
de vetweefselontsteking beïnvloedt.
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Conclusies
1. Verlaagde totale adiponectinespiegels in de circulatie van FCH-patiënten 
zijn niet geassocieerd met een verstoorde adiponectine-multimeer-profiel. 
Echter, bij vrouwen met de diagnose FCH gaat de aanwezigheid van HVZ 
gepaard met een meer atherogene adiponectine-multimeer-secretieprofiel 
vanuit het vetweefsel.
2. Een toename van de subcutane vetceloppervlak is geassocieerd met 
inflammatie en insulineresistentie. Deze associatie is verdwenen na 
pioglitazone-behandeling wat geïllustreerd wordt door een vergroting van 
de subcutane vetceloppervlak samen met een vermindering van de 
inflammatie en een verbetering van de systemische insulinegevoeligheid.
3. Het IL-1-familielid IL-18 reguleert insulinegevoeligheid zonder de 
ontwikkeling van obesitas te beïnvloeden en zonder dat het een postief effect 
heeft op de mate van lever-steatose en macrofaaginfiltratie in het vetweefsel 
tijdens een hoog-vetdieet.
4. Een toegenomen inflammasoom-gemedieerde caspase-1-activering in het 
vetweefsel tijdens obesitas leidt tot een verhoogde IL-1p-productie en draagt 
bij aan het ontstaan van insulineresistentie. De afwezigheid of remming van 
caspase-1 verbetert de insulinegevoeligheid en herstelt de normale vetcel 
functie. Deze gegevens suggeren dat de inflammasoom-gemedieerde 
caspase-1 een belangrijke regulator is van de vetcelfunctie en 
insulinegevoeligheid.
5. Hyperglycemie brengt een activatie teweeg van de NLRP3 inflammasoom- 
gemedieerde caspase-1 en induceert een TXNIP-afhankelijke IL-ip- 
transcriptie in de vetcellen. Op deze manier koppelt TXNIP hyperglycemie 
aan een verhoogde IL-ip-productie door het vetweefsel.
6. De inflammasoom-componenten NLRP3, ASC and caspase-1 komen meer tot 
expressie in humaan visceraal vetweefsel vergeleken met subcutaan 
vetweefsel. Een toename in caspase-1-activiteit leidt tot verhoogde
IL-p and IL-18 secretieniveaus en reguleert de afgifte van IL-6 en IL-8 in 
het viscerale vetweefsel. Bovendien is caspase-1-activering sterk gecorreleerd 
aan het aantal CD8+ T-lymfocyten die aanwezig zijn in het vetweefsel. Deze 
gegevens ontrafelen caspase-1 als een nieuwe en specifieke ontstekings- 
mediator die deels het pro-inflammatoire karakter bepaalt van het 
humane viscerale vetweefsel.
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Dankwoord
Het klinkt heel erg cliché, maar het doen van promotieonderzoek gaat met pieken en 
dalen. Gedurende deze vier jaar mag ik wel zeggen dat dit ook op mij van toepass­
ing was. Maar de dalen die je in het ondezoek tegenkomt, hebben ook voordelen. Zo 
heb ik gemerkt dat je er eigenlijk altijd sterker uitkomt en deze ervaring neem je weer 
mee in het verdere verloop van je onderzoek. Een ander voordeel is dat wanneer je 
een piek bereikt in je onderzoek, je hier extra van geniet. Deze zogenaamde pieken 
uiten zich in dingen als een mooie paper, het houden van een goede presentatie, het 
vinden van leuke resultaten, of gewoon een simpel schouderklopje die je krijgt voor 
het harde werken. Het behalen van deze pieken daar doe je het allemaal voor en dit 
kan je uiteraard nooit alleen bereiken. Zoals met de meeste dingen in het leven bereik 
je samen altijd veel meer dan in je eentje. Zo’n team van mensen op wie je altijd even 
terug kan vallen, die je raad geven en die je net het duwtje in de juiste richting geven, 
zijn echt goud waard. Dit kunnen mensen zijn in het laboratorium die je praktisch 
ondersteunen, leidinggevenden die je inhoudelijk de weg wijzen, maar ook de mensen 
van het thuisfront die altijd achter je staan. Gelukkig heb ik tijdens mijn onderzoek 
ook te maken gehad met zo’n gouden team, zonder wie dit proefschrift nooit tot stand 
zou zijn gekomen. Enkele personen wil ik graag in het bijzonder bedanken.
Allereerst mijn co-promotor Dr. Rinke Stienstra. Beste Rinke, het is niet overdreven 
door te zeggen dat zonder jou ik hier niet had gestaan. Jij hebt mij na een moeilijk 
eerste jaar kennis laten maken met het onderzoek gericht op het vetweefsel en ontstek­
ing. Onder jouw begeleiding heb ik mij kunnen ontwikkelen tot de onderzoeker die ik 
nu ben. Jij kan als de beste kennis overdragen en mensen enthousiast maken voor het 
onderzoek. Het is mij wel duidelijk dat jij echt een top-onderzoeker wordt, als je het 
al niet bent.
Mijn co-promotor Prof. dr. Jacqueline de Graaf. Beste Jacqueline, jij kunt als de beste 
mensen motiveren voor het doen van onderzoek en het schrijven van artikelen. Als ik 
even compleet vast zat in het onderzoek of tijdens het schrijven van mijn proefschrift, 
was één gesprek met jou voldoende om weer met een frisse en verstandige blik tegen 
de werkzaamheden aan te kijken. Op persoonlijk vlak heb ik mij in deze vier jaar 
sterk kunnen ontwikkelen, ook daarbij was jij van grote waarde. Voor dit alles ben ik 
je veel dank verschuldigd.
Mijn promotor Prof. dr Anton Stalenhoef. Beste Anton, ik wil je bedanken voor de 
kans die jij mij hebt gegeven om dit promotietraject te volgen en de inzichten die je 
mij hebt meegeven wat het doen van wetenschappelijk onderzoek inhoudt.
Prof. dr Cees Tack, Prof. dr Mihai Netea en Dr. Leo Joosten, ook jullie ben ik bij­
zonder veel dank verschuldigd. Door mij direct bij jullie onderzoek te betrekken, heb 
ik een paar mooie publicaties op mijn naam gekregen. Bovenal zijn jullie alle drie
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zeer inspirerend voor mij geweest op zowel het gebied van wetenschappelijk onder­
zoek, maar zeker ook daarbuiten.
Beste Berry, ook jij hebt altijd voor mij klaar gestaan en mij wegwijs gemaakt in de 
wetenschappelijke wereld gedurende de eerste drie jaren van mijn promotietraject. Zo 
vergeet ik nooit jouw enorme betrokkenheid bij de voorbereidingen van mijn eerste 
publicatie. Als kamergenoten konden wij ook dingen bespreken buiten het onderzoek 
om. Ik ben je zeer dankbaar voor dit alles en wens je al het succes toe in je verdere 
leven.
Beste Suzanne, jammer dat we maar zo kort kamergenoten waren. Tijdens de laatste 
fase van mijn promotieonderzoek, heb ik veel gehad aan jou ervaring als pas gepro­
moveerde onderzoeker. Jij bent een van de meest sociale personen die ik ken en wens 
je veel succes in je verdere leven en carrière.
Anneke, Heidi, Helga en Magda. Jullie zijn van onschatbare waarden voor mij gewe­
est op het lab. Een vraag of verzoek van mijn kant was nooit teveel voor jullie. Ik 
ben blij dat ik van jullie kennis gebruik heb mogen maken en zelf ook veel van jullie 
geleerd heb. Ik zal jullie nooit vergeten.
Pleun, Pieter, Henry, Edwin, Duby en Peter, wij hebben toch de meeste raakvlak­
ken gehad op het onderzoeksgebied van obesitas en diabetes. Behalve het delen van 
kennis, hebben we ook leuke momenten gedeeld tijdens de diabetescongressen. Hier 
werden serieuzere zaken op de juiste momenten afgewisseld met de nodige ontspan­
ning in een café of restaurant. Henry en Edwin, ik ben trots en blij dat jullie hier naast 
mij staan als paranimfen. Ik wens jullie allen veel succes met het verdere onderzoek 
en hopelijk zullen we de contacten blijven onderhouden.
Trees, Liesbeth, Johanna, Ineke en Cor, ondanks dat wij qua werkzaamheden niet veel 
samengewerkt hebben wil ik jullie toch bedanken. Ook bij jullie kon ik altijd terecht 
voor een vraag of advies. En het is wel duidelijk dat jullie samen met Anneke, Heidi, 
Helga en Magda het fundament van het onderzoekslab zijn.
Natuurlijk wil ook alle PhDs, AIO’s en junior onderzoekers die op ons lab werken of 
er de afgelopen jaren gewerkt hebben bedanken. Bart, Frank, Matthew, Sanne, Mark 
(1), Theo, Evertine, Everlien, Louis, Monique, Marije, James, Diana, Johanneke, 
Jessica, Nico, Daniela, Mark (2), Suzanne, Teske, Gosia, bedankt voor alle adviezen, 
gesprekken en de broodnodige ontspanning op zijn tijd.
Rene, Henny en Wilbert van de afdeling Maag-, Darm- en Leverziekten. Jullie verdi­
enen een aparte vermelding in mijn dankwoord. Altijd stonden jullie klaar als ik, of
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andere mensen van onze afdeling, weer eens gebruik wilde maken van jullie laborato- 
riumuitrusting. Daarvoor ben ik jullie zeer veel dank verschuldigd.
Jeroen van Velzen en Jeroen van der Laak, ik wil jullie bedanken voor het mede mo­
gelijk maken van mijn studies. Jeroen van Velzen, met jou heb ik met succes gewerkt 
aan een methode om ontstekingscellen in het vetweefsel te kwantificeren. Jeroen van 
der laak, jij hebt een prachtig programma geschreven om de vetcelgrootte te bepalen. 
Beide bepalingen vormen nu een belangrijk deel van onze vetweefselanalyses binnen 
onze afdeling. Met jullie samenwerken heb ik als zeer prettig ervaren.
Beste Hilde de Haan, Dr. Wout Barendregt en alle andere medewerkers van het Ca- 
nisius Wilhelmina ziekenhuis in Nijmegen die hebben meegeholpen aan de vetweef- 
sel biobank. Ik vond het erg prettig om met jullie samen te werken. Door jullie 
medewerking beschikt onze afdeling nu over zeer mooi materiaal om onderzoek mee 
te verrichten. Hopelijk vormen de contacten die wij hebben gelegd een basis voor een 
mooie samenwerking in de toekomst tussen de afdelingen van beide ziekenhuizen.
De medewerkers van de afdeling Plastische Chirurgie en Vasculaire en Transplantatie 
Chirurgie van het UMC St. Radboud, bedankt voor de medewerking die jullie verleent 
hebben om alle vetweefselstudies op te zetten. Zonder jullie hulp waren deze studies 
{g} nooit mogelijk geweest.
Mijn trouwe vriendengroep van de Wippers. Ook jullie hebben, misschien zonder dat 
jullie het weten, een bijdrage geleverd aan dit proefschrift. Ons gezellig samenzijn 
tijdens de weekenden en op het voetbalveld heeft ervoor gezorgd dat ik mijn gedachte 
goed kon verzetten en dat ik weer ontspannen met het onderzoek verder kon gaan. Ik 
ben trots dat ik jullie mijn vrienden mag noemen.
Mijn schoonfamilie. Toon, Engelien, Luuk, Joost, Kelly, Avra en Martijn. Jullie waren 
altijd weer even belangstellend over het wel en wee in het lab. Na mijn moeilijke 
eerste jaar wist onder andere jij, Toon, mij toch te motiveren door te gaan. Jullie 
humor en liefde zijn echt uniek en ik kan mij geen betere en hechtere schoonfamilie 
wensen.
Mijn zusje Susan, meer nog dan een lieve zus ben je echt een vriendin voor mij. He­
laas zit het er niet in om samen een praktijk te beginnen, maar het is al leuk om samen 
in het medische wereldje actief te zijn. Rene, ook jij bedankt voor de interesse die je 
altijd getoond hebt. En hopelijk kan jij de droom van mijn zus verwezenlijken om sa­
men een eigen praktijk te beginnen.
Pap en mam, bedankt voor de onbezorgde jeugd die ik heb gehad en de kans die
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jullie mij hebben geboden om te gaan studeren. Behalve de kennis die ik daar heb 
opgedaan, heb ik ook van jullie ontzettend veel geleerd. Altijd staan jullie klaar voor 
je kinderen en de rest van de familie. Jullie goedkeuring en onvoorwaardelijke steun 
betekenen meer voor mij dan wat voor mooie titel dan ook.
Lonneke, het slot van dit proefschrift heb ik uiteraard bewaard voor jou. Jouw steun 
en liefde zijn onbeschrijfelijk geweest afgelopen vier jaar en zonder jou was er nu ze­
ker geen proefschrift. Jij bent de drijvende kracht en stabiele factor achter dit succes. 
Het valt niet eens in woorden uit te drukken hoe belangrijk jij voor mij bent. Ik kan 
mij nu al verheugen om weer meer tijd met elkaar door te brengen.
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Curriculum Vitae
Tim Bemardus Koenen werd geboren op 24 september 1982 te zevenaar. Na het be­
halen van het VWO diploma aan het Candea College in Duiven begon hij in 2001 met 
de studie Biomedische Wetenschappen aan de Radboud Univeristeit Nijmegen met als 
hoofdvak Pathobiologie. Tijdens zijn studie heeft hij onderzoekservaring opgedaan 
bij de afdeling Orthodontie en craniofaciale Biologie (onder begeleiding van Dr. Hans 
Von den Hoff), bij de afdeling nierziekten (onder begeleiding van Dr. Mabel van den 
Hoven en Dr. Johan van der Vlag) en bij de afdeling Research and Development van 
Organon (onder begeleiding van Dr. Han Gerrits). In November 2006 heeft hij zijn 
studie met goed gevolg afgerond en behaalde hij zijn Master of Science graad. Van 
januari 2007 tot en met januari 2011 was hij verbonden als junior onderzoeker aan 
de afdeling Algemeen Interne Geneeskunde van de Radboud Universiteit Nijmegen 
Medisch Centrum, alwaar dit proefschrift tot stand is gekomen. In de maanden januari 
tot en met april van 2011 heeft hij in samenwerking met de afdeling Chirurgie van het 
Canisius Wilhelimina Ziekenhuis een vetweefsel bio-bank tot stand gebracht die in de 
toekomst gebruikt kan worden voor het onderzoek. Na deze mooi ervaring binnen de 
academie, wil hij zijn carrière vervolgen in de farmaceutische industrie.
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